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ABSTRACT
MODELING BREAST CANCER DORMANCY AND
RECURRENCE FOLLOWING ONCOGENIC PATHWAY INHIBITION
Jason R. Ruth
Lewis A. Chodosh, MD, PhD
Breast cancer recurrence is the primary cause of mortality in breast cancer, and although
advances have been made in the treatment of primary breast cancer, recurrent breast cancer
remains uncurable. Targeted therapy has had a major impact on survival across multiple cancer
types, including breast cancer, however patients who respond to targeted therapy ultimately
relapse. Residual disease, the tumor cells that survive initial therapy, represent an attractive
therapeutic target, however little is known about the biology of these cells. We use mouse
models of breast cancer to investigate the phenotype of residual disease that survives targeted
therapy, and to explore approaches to inhibit tumor recurrence. Residual disease exhibits cellular
dormancy in models driven by distinct oncogenic pathways. Gene expression profiling reveals
that residual tumor cells are enriched for a phenotype associated with normal and neoplastic
stem-like cells, but are not enriched for tumor initiative cells. Interventions that inhibit
inflammatory signaling inhibit tumor recurrence, however increasing inflammation promotes tumor
recurrence. Inflammatory macrophages may be leukocytes that promote inflammation and drive
recurrence in these models. Together, our findings present a more comprehensive picture of
residual tumor cells surviving targeted therapy, and suggest possible therapeutic strategies for
targeting residual disease that gives rise to cancer recurrence.

v

TABLE OF CONTENTS

ACKNOWLEDGMENT ................................................................................................... IV
ABSTRACT....................................................................................................................... V
LIST OF TABLES .......................................................................................................... VII
LIST OF ILLUSTRATIONS ......................................................................................... VIII
CHAPTER 1: Breast Cancer Dormancy and Recurrence Following Oncogenic
Pathway Inhibition ............................................................................................................ 1
CHAPTER 2: Modeling Cancer in Mice ..................................................................... 19
CHAPTER 3: Modeling Dormant Residual Disease and Breast Cancer
Recurrence ...................................................................................................................... 24
CHAPTER 4: Modeling the Impact of Immune Modulation on Breast Cancer
Recurrence .................................................................................................................... 123
CHAPTER 5: Summary and Future Directions ....................................................... 160

vi

LIST OF TABLES

Table 3.1. Agilent Bioanalyzer Analysis Results of RNA from FACS-isolated Tumor Cells from
Residual Lesions in vivo
Table 3.2. Gene Sets Down-regulated in Dormant Residual Tumor Cells in HER2/neu-Prim1 and
Wnt1-Prim1 Models
Table 3.3. Gene Sets Up-regulated in Dormant Residual Tumor Cells in HER2/neu-Prim1 and
Wnt1-Prim1 Models
Table 3.4. Copy Number Variation (CNV) Analysis of Gene Sets Up-regulated in Dormant
Residual Tumor Cells
Table 3.5. Gene Sets Differentially Regulated in Dormant Residual Tumor Cells
Table 3.6. TIC Frequency Calculation for All Tumor Cells in Intact MTB/TAN/TTC/rYFP Primary
Tumors or Residual Lesions
Table 3.7. TIC Frequency Calculation for All Tumor Cells in Syngeneic Orthotopic
MTB/TAN/TTC/rYFP Primary Tumors or Residual Lesions
Table 3.8. TIC Frequency Calculation for EpCAM+CD49e- Tumor Cells in Intact
MTB/TAN/TTC/rYFP Primary Tumors or Residual Lesions
Table 3.9. TIC Frequency Calculation for All Tumor Cells in Intact MTB/TWNT/TTC/rYFP Primary
Tumors or Residual Lesions
Table 3.10. TIC Frequency Calculation for All Tumor Cells in Syngeneic Orthotopic
MTB/TWNT/TTC/rYFP Primary Tumors or Residual Lesions
Table 3.11. TIC Frequency Calculation for All Tumor Cells from H2B-eGFP-labeled Orthotopic
HER2/neu-Prim1 Primary Tumors or Residual Lesions

vii

LIST OF ILLUSTRATIONS

Figure 1.1. Cumulative Number of Targeted Therapy New Medical Entity (NME) Approvals by
the FDA
Figure 3.1. Kinetics of Tumor Recurrence Suggest a Latent Phase
Figure 3.2. Identification of Residual Tumor Cells Following Oncogenic Pathway Inhibition
Figure 3.3. Systemic Metastases with Intracardiac Injection of HER2/neu-Prim1 Tumor Cells
Figure 3.4. Systemic Metastases in Cre-driven YFP and tdTomato Fluorescent Reporter Mice
Figure 3.5. Peripheral Blood Leukocytes in MTB/TAN/TTC/rYFP Model Express YFP
Figure 3.6. CTCs and DTCs in Orthotopic HER2/neu-Prim1 Model
Figure 3.7. Residual Tumor Cells are Quiescent
Figure 3.8. Minimal Residual Lesions are Well-Vascularized and Not Hypoxic
Figure 3.9. CD31 Co-localizes with Intravenously Injected Lectin-AF647
Figure 3.10. Residual Metastases Exhibit Cellular Dormancy
Figure 3.11. Human Breast Cancer Xenografts Develop Micrometastases in Lung
Figure 3.12. Human Breast Cancer Xenografts Exhibit Quiescence Following Targeted Therapy
Figure 3.13. Proliferative Residual Tumor Cells are Juxtaposed with Normal Mouse Mammary
Duct in HER2/neu-Prim1 Model)
Figure 3.14. Proliferative Residual Tumor Cells are Juxtaposed with Normal Mouse Mammary
Duct in HER2/neu-Prim1 Model
Figure 3.15. Analysis of RNA Isolated from MTB/TAN/TTC/rYFP No Culture Orthotopic Residual
Lesions
Figure 3.16. Residual Tumor Cells Express Genes Associated with Dormancy
Figure 3.17. Dormant Residual Disease Resides in Desmoplastic Stroma
Figure 3.18. Comparison of Intact Donors to No Culture Orthotopic Tumors with Array
Comparative Genomic Hybridization (aCGH) and Whole Exome Sequencing (WES) on Bulk
Tumor Tissue and RNA-Seq on FACS-isolated Tumor Cells
Figure 3.19. Expression of HER2/neu and Epithelial Markers in Some No Culture Orthotopic
Recurrent Tumors
Figure 3.20. Pathway Scores for No Culture Orthotopic MTB/TAN/TTC/rYFP Donor and
Orthotopic Primary Tumor, Residual Lesion, and Recurrent Tumor
Figure 3.21. Residual Tumor Cells from HER2/neu but not Wnt1 Models Express Genes
Associated with EMT
Figure 3.22. HER2/neu-Prim1 but not Wnt1-Prim1 Residual Disease is Enriched for
Mesenchymal Tumor Cells

viii

Figure 3.23. Distribution of Mesenchymal Tumor Cells in HER2/neu-Prim1 Residual Lesion
Figure 3.24. Flow Cytometry Analysis of EMT in HER2/neu-Prim1 cells in vitro and in vivo
Figure 3.25. Identification of Residual Tumor Cells Lacking Epithelial Markers in Intact Mice
Figure 3.26. Residual Disease is Enriched for Rare Tumor Cell Subpopulations Present in
Primary Tumors
Figure 3.27. Mesenchymal Markers Identified in HER2/neu Residual Disease are Prognostic for
Poor Recurrence-Free Survival in HER2+ Breast Cancer
Figure 3.28. Genes Associated with Stem-like Cells are Up-regulated in Residual Lesion Tumor
Cells in HER2/neu and Wnt1 models
Figure 3.29. Residual Tumor Cells from MTB/TWNT/TTC/rYFP No Culture Orthotopic Tumors
Give Rise to Mammary Epithelial Trees
Figure 3.30. Immunohistochemistry (IHC) for Proteins Identified by Up-regulation of Genes in
Analysis of Residual Disease
Figure 4.1. Distribution of Leukocyte Populations Relative to Mesenchymal Residual Tumor
Cells
Figure 4.2. Association Between Macrophage-related Transcripts and Recurrence-free Survival
(RFS) for Breast Cancer Patients
Figure 4.3. Evidence Supporting a Role for Macrophages in Tumor Progression in Transgenic
Mouse Models of Breast Cancer
Figure 4.4. Residual Lesion Leukocytes but not Tumor Cells Express CD40
Figure 4.5. Macrophages are Activated by anti-CD40 Antibody FGK45
Figure 4.6. Impact of Treatment with FGK45 on ECM Protein Expression and Recurrence
Latency
Figure 4.7. Evidence Supporting a Role for COX Signaling in Tumor Progression in Transgenic
Mouse Models of Breast Cancer
Figure 4.8. Dexamethasone Inhibits Tumor Recurrence at Doses that Ablate Macrophages
within Residual Lesions
Figure 4.9. Impact of Clodronate Liposomes or anti-GR1 antibody on RFS
Figure 4.10. Spleen Size is Increased by anti-GR1 Treatment and Decreased by
Dexamethasone
Figure 4.11. c-fms-dependent Macrophage Ablation Results in a Small Delay in Tumor
Recurrence

ix

CHAPTER 1
Breast Cancer Dormancy and Recurrence Following Oncogenic Pathway Inhibition
Breast cancer
Breast cancer is the most prevalent cancer among women worldwide [1]. Almost 40,000 women
in the United States will succumb to this disease in 2013, and it is the second most frequent
cause of cancer-related deaths among women in the developed world [1, 2]. Improvements in
diagnosis and treatment of breast cancer have led to a dramatic increase in the survival of breast
cancer patients since the 1970s [2], however these gains have primarily come from successful
resection of early stage breast cancers that have not spread [3]. As a result of improved
treatment of early breast cancer, nearly three million women in the United States are breast
cancer survivors, and these women are at risk of breast cancer recurrence [4]. In contrast to
primary breast cancer, recurrent breast cancer is incurable, and consequently represents the
primary cause of mortality among breast cancer patients.
A broad understanding of breast cancer can be achieved by identifying epidemiological and
clinical parameters that impact incidence and survival. Disease incidence and outcome are each
functions of a large number of parameters. Various epidemiological factors impact both breast
cancer risk and clinical prognosis, including sex, age, and genetic background, among many
others [2, 5-8]. Females have a greater than 100-fold higher risk of developing breast cancer
than men [5]. Age also has a major impact, as the probability of developing breast cancer before
the age of 40 years old is almost one eighth of the risk of developing breast cancer between the
ages 60-69 years old [2]. Genetic background may impact breast cancer risk as the combination
of many germline variations with a small impact on cancer incidence [9], or the presence of
germline mutations that confer a major increase in the risk of developing breast cancer, such as
mutations in BRCA1 or BRCA2 [10].
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Additionally, certain clinical, histopathological, and molecular qualities of the cancer itself are
major determinants of a patient’s prognosis. For example, tumor grade is a number given by a
pathologist analyzing a hematoxylin and eosin-stained section, which incorporates tubule
formation, nuclear grade, and mitotic rate, in order to provide prognostic information about a
patients’ particular tumor [11]. Tumor stage is determined by the TNM staging system, wherein
tumor size and local invasion (T), lymph node involvement (N), and presence of metastatic
disease (M) are synthesized to evaluate tumor stage [12]. Higher tumor grade or tumor stage are
each associated with a poor prognosis. Both grade and stage are critical components to
determining the proper clinical management for a particular breast cancer patient.
Beyond the use of epidemiological and clinical parameters, stratifying breast cancer by its
molecular etiology provides an indispensable approach for understanding and treating this
malignancy. Like all cancers, breast cancer is driven by alterations in several key cellular
processes, resulting from genomic alterations that activate oncogenic pathways driving
tumorigenesis [13]. Whereas qualities such as tumor size and extent of dissemination are
determined largely by the length of time a tumor has developed within a patient prior to
presentation, tumor subtypes largely reflect the oncogenic pathways driving the tumor. One can
broadly define breast cancer using either histopathological subtypes, molecular subtypes defined
through gene expression profiling, or genomic subtypes using genomic mutation data.
Histopathological subtype is broadly defined by expression of the hormone receptors estrogen
receptor (ER) and progesterone receptor (PR), and expression of the human epidermal growth
factor receptor 2 (HER2). Using expression of these receptors, breast cancer can be classified
into three major types, hormone receptor positive, HER2 positive, or triple negative breast cancer
(TNBC), wherein a tumor does not express sufficient levels of either hormone receptor or HER2
in order to qualify as one of those subtypes. Targeted therapy against hormone receptor positive
tumors includes selective estrogen receptor modulators and aromatase inhibitors, both of which
ultimately decrease signaling through the estrogen receptor in order to treat cancer. Analogously,
patients with HER2-positive breast cancer receive treatments that block signaling through HER2,
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such as the tyrosine kinase inhibitor (TKI) lapatinib, or a combination of the anti-HER2 antibodies
trastuzumab and pertuzumab.
In the early 2000s, recurrent molecular subtypes of breast cancer were identified in a landmark
study that used unsupervised hierarchical clustering to identify breast cancer subtypes based on
gene expression profiles [14]. Tumors in these subtypes respond differently to chemotherapy
[15]. A general role for gene expression profiles in clinical management manifests through a
gene expression profile that is used as a predictive test to drive treatment decisions in early stage
ER-positive breast cancer [16].
An alternative method of identifying molecular drivers behind breast cancer has recently emerged
in profiling genomic alterations in tumors. Early profiling efforts revealed that breast cancer has a
greater degree of heterogeneity than may have been expected prior to genomic profiling [17].
Recent studies across multiple cancer types indicate that genetic heterogeneity may underlie
resistance, and genomic profiling is a critical component in the identification of therapies suitable
for specifically targeting a patient’s cancer, generally referred to as targeted therapies. Wide
recognition for the potentially transformative role of genomic profiling and targeted therapy is
evidenced by the success of Foundation Medicine, a company whose primary product platform is
targeted deep sequencing of a panel of cancer-related genes. Less than two years after raising
Series A funding, Foundation Medicine went public with a one billion dollar initial public offering in
September 2013.
Oncogenic pathway inhibition – Clinical impact and disease resistance
Cancer researchers have long sought to develop anti-cancer compounds with progressively
greater specificity and sensitivity, in hopes of prolonging both survival and quality of life in cancer
patients. This tenet was present even in Sydney Farber’s use of anti-folates to treat acute
lymphoblastic leukemia (ALL) in 1948 [18], however chemotherapies such as anti-folates
generally have broader side effect profiles than targeted therapies. Recent years have seen a
dramatic shift away from the development of novel chemotherapeutics in favor of targeted
therapies developed against specific molecular targets critical to oncogenic pathway activity.
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Reflecting this shift towards an increased use of targeted therapies, the number of new molecular
entity (NME) approvals by the FDA for targeted therapies has increased dramatically in recent
years. Whereas only three targeted therapies (rituximab, trastuzumab, and imatinib) were given
the NME designation over the span of 1997 – 2002, a total of seventeen targeted therapies were
approved as NMEs from 2011 – 2013 (Figure 1.1). These targeted therapies have a major
positive impact on overall survival (OS) for cancer patients. The anti-HER2 antibody trastuzumab
can result in greater than 30% improvement in five year OS compared to chemotherapy alone
[19]. Despite the significant gains to recurrence-free survival (RFS) and OS afforded by the first
targeted therapies, many patients ultimately developed recurrent disease [20, 21]. Unfortunately,
recurrent disease is frequently refractory to previous therapies that had been used in a particular
patient, and thereby is frequently fatal.
As a consequence of the frequency of recurrent disease, the increase in NME approvals from
2011 – 2013 reflects in part the development of drugs intended to be administered in conjunction
with, or after treatment failure of, the targeted therapies that first appeared over a decade ago.
Examples of these new drugs include pertuzumab and ponatinib. Trastuzumab works in part
through inhibition of HER2:HER2 homodimers [22]. In contrast, pertuzumab inhibits HER2:HER3
heterodimerization, and administration of pertuzumab in combination with trastuzumab and
docetaxel in the neoadjuvant setting improved median progression-free survival (PFS) by 6.1
months vs trastuzumab-docetaxel alone (12.4 months PFS with trastuzumab-docetaxel vs. 18.5
months PFS with pertuzumab-trastuzumab-docetaxel, p<0.001) [23]. While pertuzumab is
intended to be administered in conjunction with trastuzumab to inhibit HER2 signaling in patients
with breast cancer, ponatinib is intended to be given as a single agent after treatment failure with
a tyrosine kinase inhibitor, such as imatinib, in order to block signaling through the Philadelphia
chromosome in patients with Philadelphia chromosome-positive ALL [24]. Administration of
ponatinib resulted in a 54 percent major hematologic response when administered to patients
with Philadelphia chromosome-positive chronic phase-ALL who were previously intolerant or
resistant to treatment with imatinib [24]. Despite the improvement in survival that these newer
targeted therapies provide, many patients develop recurrent disease.
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To develop therapies that can prevent disease relapse, researchers have investigated both the
biology of recurrent tumors, as well as the biology of residual disease.
A major challenge in treating recurrent disease is the diversity of mechanisms that can underlie
treatment resistance, suggesting that although targeted therapies inhibiting single pathways may
be sufficient to treat a specific molecular subtype of cancer, many different strategies will be
required to treat the address the many molecular subtypes associated with resistance. Examples
of mechanisms that recurrent tumors exploit to resume growth following targeted therapy include
mutation or amplification of the drug target, increasing signaling through bypass pathways,
defects in growth arrest or survival, or cell state alterations such as an epithelial-to-mesenchymal
transition (EMT) [25]. p95-HER2, a truncated 95kDa isoform of HER2 that lacks the trastuzumab
binding region, is associated with resistance to trastuzumab therapy, but remains susceptible to
treatment with the anti-HER2 TKI lapatinib [27, 28]. Other mutations to HER2 exist as well [25].
Bypass signaling has been reported in the setting of trastuzumab resistance, by receptor tyrosine
kinases (RTKs) signaling through EGFR, HER3, IGF-1R, or MET, and by mutations in
downstream signaling components such as PI3K/AKT or loss of PTEN [29-32]. Alternatively,
alterations that promote cell cycle entry, such as Cyclin E amplification and down-regulation of
cyclin-dependent kinase inhibitor p27 may also underlie trastuzumab resistance [33-34]. Reports
in non-small cell lung cancer (NSCLC) reveal that recurrent tumors may also exhibit tumor cells
with an alteration in cell state, such as EMT, or alternatively NSCLC may also recur as small cell
lung cancer [35].
Given the pleiotropic mechanisms underlying tumor recurrence, it would be desirable to define a
single biological phenotype that generally describes all tumor cells responsible for resistance,
such that inhibition of this phenotype or state may have a broad impact on cancer progression.
One such general endpoint is represented by the idea of ‘cancer stem cells’ a broad term
generally used to describe a rare subpopulation of tumor cells that both give rise to other tumor
cells, and are more resistant to therapy than the bulk population of tumor cells. Perhaps because
the idea of a single cell type that underlies all resistance is such an appealing Achilles’ heel of
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cancer, a plurality of studies assume residual breast cancer is likely comprised of tumor cells with
stem cell-like properties [36], whereas it actually remains unclear whether residual disease in
breast cancer is maintained by such a population. In the case of breast cancer patients treated
with neoadjuvant therapy targeted against the estrogen receptor, residual tumor cells have been
identified locally within breast tissue upon surgical resection [37]. These residual tumor cells are
identified by expression of CK8, and express phenotypic markers correlated with both a
mesenchymal and a stem cell phenotype. While this study supports a role for a stem cell-like
population in disease resistance, a recent study using alternative methodology of isolating
residual tumor cells arrives at a different conclusion. Microfluidic chips coated with antibodies to
capture cells in the blood expressing EpCAM, EGFR, and HER2, were used to identify circulating
tumor cells in patients undergoing therapy, and assessed epithelial or mesenchymal phenotype of
captured cells from mRNA in situ immunohistochemistry [38]. In this study, the authors they find
that residual breast cancer cells may either be enriched for an epithelial phenotype, or a
mesenchymal phenotype. Consequently, it is clear that residual disease can’t generally be
described as consistently either mesenchymal or epithelial, but instead that the result may be
context dependent.
Taken together, these reports reveal that the use of targeted therapies has dramatically improved
outcomes in cancer patients, and newer generation therapies will continue to strengthen these
gains. In spite of this progress, patients frequently relapse. Analysis of tumor recurrence reveals
a breadth of resistance mechanisms, posing a challenge for the development of therapeutic
strategies that will impact large percentages of patients. However, it is possible that residual
disease across different cancer types may harbor unifying characteristics, although residual
disease is challenging to identify and isolate in vivo. Thus, targeting residual disease is an
attractive strategy to prevent tumor recurrence, but more investigation is required to describe the
phenotype of residual disease.
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Immunity and inflammation in recurrence
A role for the immune system and inflammation in cancer progression is well established, and
several clinical studies have demonstrated that therapeutically targeting either specific
components of the immune system, or inflammation in general, can improve survival for cancer
patients. Clinical trials using checkpoint blockade inhibitors targeting PD-1 and CTLA-4 have
resulted in major improvements in the OS of patients with melanoma, NSCLC, and renal cell
carcinoma [39, 40]. In breast cancer, trastuzumab works in part through antibody-dependent cellmediated cytotoxicity [41]. Anti-inflammatory drugs may also have a major impact on cancer
progression, as evidenced by a greater than 50% reduction in relative risk of breast cancer
recurrence identified in the Nurse’s Health Study for breast cancer patients taking daily aspirin
following initial therapy [42]. Together, these data support increased research into the
mechanisms underlying the relationship between immunity, inflammation, and cancer
progression, and suggest that therapies targeting the immune system may have a major impact
on breast cancer recurrence.
Breast cancer recurrence
For patients with breast cancer, following initial diagnosis, early stage breast cancers are locally
resected, whereas patients with locally advanced breast cancers may receive neoadjuvant
chemotherapy prior to surgery, in order to permit surgical resection of their cancer. Metastatic
breast cancer is unlikely to be cured, and therefore goals of treatment in this setting are
prolongation of survival and quality of life [43]. Patients whose primary tumors have been
surgically removed may then undergo adjuvant therapy, in order to delay or prevent disease
recurrence by eliminating subclinical disseminated disease. At this point, patients may receive
targeted therapies based on their tumor’s histopathological subtype, such as tamoxifen to inhibit
ER or trastuzumab and pertuzumab to inhibit HER2. For patients who are not candidates for one
of these therapies, they may have their tumors sequenced, in order to identify targeted therapies
that would provide the maximum efficacy. Despite efforts to choose targeted therapies with the
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maximum efficacy for any particular patient, many patients treated with targeted therapies
ultimately recur, and succumb to their recurrent disease.
Breast cancer recurrence can be categorized as either locoregional recurrence, or distant
recurrence. Survival following locoregional recurrence is generally superior to survival following
distant recurrence. Following breast conservation therapy, local recurrence usually occurs within
the breast, whereas following mastectomy, local recurrence occurs in the chest wall. Regional
recurrence indicates a recurrence in regional lymph nodes. Ten-year overall survival rates
following local recurrence after breast conservation therapy is as high as 80%, however five-year
overall survival rates for patients with recurrence in the chest wall or regional lymph nodes are up
to 52% or 28%, respectively [44]. Patients with distant recurrence are not likely to be cured.
Although targeted therapies have led to improvements in OS for these patients [45, 46], the fiveyear OS for breast cancer patients with metastatic disease is only 22% [47]. Factors that are
prognostic for OS at primary tumor presentation are generally prognostic for RFS, given that
distant disease recurrence is the primary cause of breast cancer-related mortality in these
patients. Residual tumor cells that survive therapy are termed minimal residual disease (MRD),
and are responsible for cancer recurrence.
Different breast cancer subtypes exhibit different recurrence kinetics. While TNBC and HER2positive breast cancer predominantly recur within 5 years of initial therapy, hormone receptorpositive breast cancer has a nearly-constant rate of cancer recurrence for 20 years [48]. As
recurrent disease arises from residual disease that survives initial therapy, disease relapse up to
20 years after initial treatment is consistent with reports detecting MRD in patients decades after
initial therapy [48].
Given that recurrent breast cancer is generally incurable, therapies that eliminate residual breast
cancer prior to acquisition of a recurrent phenotype may decrease the rate of recurrence and
thereby improve OS for breast cancer patients. Given the heterogeneity of oncogenic pathways
driving tumor progression, and the diversity of resistance mechanisms that have been described,
it would be useful to identify biological qualities shared by residual disease in different settings.
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Considering clinical evidence suggesting MRD may be dormant prior to tumor recurrence in
patients with a long recurrence latency, dormancy may offer a therapeutic target in these patients.
However it is unclear whether dormancy plays a role in tumor recurrence where the latency
period is not decades long.
Residual disease and cancer dormancy – Incidence and relevance to recurrence
To develop approaches for preventing tumor recurrence, recent clinical efforts have aimed to
better understand the incidence and biology of residual disease. Residual disease can be
detected as circulating tumor cells (CTCs) in the blood, or disseminated tumor cells (DTCs) in the
bone marrow, by identifying cells expressing tumor-specific markers. Indeed, the 2008 FDA
approval of the CELLSEARCH platform for detecting CTCs, using the epithelial marker EpCAM,
represents both the widespread acceptance of the clinical importance of detecting residual
disease as well as a general reliance on epithelial markers for this process [49]. The ability to
detect MRD has revealed that dissemination can occur early in tumorigenesis, such that up to
40% of early-stage breast cancer patients harbor DTCs [50]. Studies have found that the
presence of MRD following treatment is an independent prognostic indicator for poor RFS in
breast cancer [51], suggesting that this residual disease may give rise to recurrent tumors. This
finding may apply outside of breast cancer as well, as subsequent studies have demonstrated a
connection between detectable MRD and outcome in other cancer types as well [52-59]. In spite
of the paramount clinical importance of understanding the biology of residual disease in order to
develop approaches to prevent recurrence, the biology of MRD remains largely unknown.
Growth rates of breast cancers that recur after a long period of latency are inconsistent with a
Gompertzian growth model following initial therapy, and therefore a period of tumor dormancy
has been proposed to explain long recurrence latency of breast cancer [60, 61]. The idea that
residual disease is dormant is supported by analyses showing that DTC in the bone marrow of
breast cancer patients are frequently Ki67 negative [62-65]. More recently, long recurrence
latencies have been identified for patients with melanoma [66], renal cell carcinoma [67], and
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other cancer types as well [68, 69], suggesting that dormancy may occur in these malignancies
as well.
In spite of the large number of patients with MRD, the association between MRD and recurrence,
and clinical evidence that MRD is dormant, it remains unclear whether dormancy offers an
attractive therapeutic target. First, growing tumors may be comprised predominantly of tumor
cells that are Ki67 negative [70, 71]. Hence, analysis of Ki67 alone may be insufficient to prove
that DTCs are dormant. These cells may instead represent the non-proliferative fraction of a
tumor, or alternatively exhibit cell cycle arrest for a reason other than dormancy, such as
senescence. Further, while patients with hormone receptor positive breast cancer may exhibit a
latency period of more than two decades prior to recurrence, many breast cancer patients recur
within the first few years after treatment, and thus it remains unclear whether residual disease in
these patients undergoes dormancy prior to recurrence. Indeed, as tumors with a diameter
smaller than 1 cm are below the detection limits for modern imaging modalities [72], and the
efficacy of adjuvant chemotherapy is predicated on the idea that subclinical disseminated disease
is actively growing, it is likely that many patients harbor proliferative residual disease at the time
they initially receive therapy. Thus, demonstrating the relevance of cancer dormancy to cancer
recurrence in a broader population of cancer patients remains a critical task.
Residual disease and cancer dormancy – Biology
If a large fraction of the residual disease that gives rise to recurrent tumors is dormant, and thus
dormancy offers an attractive therapeutic target, the next task – developing therapeutic
approaches to eliminate dormant tumor cells or maintain them in a dormant state in order to
prevent recurrence – remains challenging due to the paucity of information on the in vivo biology
of dormancy. Dormancy can be divided into two categories, tumor mass dormancy and cellular
dormancy or quiescence [73]. Tumor mass dormancy occurs when a proliferating population of
tumor cells is unable to grow at a Gompertzian rate due to a countervailing level of cell death
caused by a lack of vasculature (angiogenic dormancy), or an anti-tumor immune response
(immunological dormancy). Cellular dormancy occurs when tumor cells have exited the cell cycle
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for a prolonged period of time, and thus the tumor does not grow. Clinical identification of DTCs
that lack the proliferation marker Ki67 supports a role for cellular dormancy in MRD and tumor
progression. The following section will focus on the biology of cellular dormancy in order to
provide a background necessary for contextualizing subsequent findings in this thesis.
Recent studies have begun to elucidate microenvironmental factors that can contribute to
dormancy of solitary disseminated breast cancer cells in various microenvironments, including the
bone marrow. Mesenchymal stem cells (MSCs) within the bone marrow reside in a quiescent
state within their niche, and can lead to cell cycle arrest of nearby immune cells that had
previously been activated, similar mechanisms may contribute to dormancy of tumor cell in the
bone marrow [74]. Indeed, recent data from in vitro co-culture studies demonstrate that, in an
analogous manner, bone marrow MSCs may induce a dormant state in breast cancer cells by
signaling through exosomal miR-23b [75]. A separate publication recently found that stable
vasculature can promote tumor cell dormancy through secretion of thrombospondin-1, whereas
sprouting neovasculature triggers dormant tumor cell proliferation through periostin and TGF-β1
[76]. While these studies support their in vitro findings by correlating in vivo expression of
components of the molecular pathways identified in vitro with the presence of disseminate tumor
cells, it remains a possibility that the molecular mechanisms identified in these studies that are
able to regulate dormancy in vitro are not the exact same as those that actually regulate
dormancy in vivo. Thus, studies that systematically examine pathways activated or inactivated in
dormant tumor cells in vivo may provide a more accurate understanding of the biology of
dormancy.
Outside of the bone marrow, several studies have identified dormant isolated breast cancer DTCs
in lungs or liver [77, 78]. In an attempt to identify molecular mechanisms underlying dormancy of
DTCs in the lung, a recent study indicates that bone morphogenic protein (BMP) signaling may
promote dormancy, whereas the inhibitor of BMP signaling Coco may allow dormant tumor cells
to resume growth [79]. Additional studies of breast cancer DTCs in cortical bone indicate that
recruiting monocytes to sites of micrometastases may trigger outgrowth of bone metastases from
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previously indolent disease [80]. These studies suggest that a wide variety of mechanisms may
regulate escape from dormancy.
Beyond studies in models of breast cancer, other models have also contributed towards a more
thorough understanding of cellular dormancy. A series of experiments with human head and
neck squamous cell carcinoma (HNSCC) cells in chicken chorioallantoic membranes revealed a
role for urokinase plasminogen activator receptor (uPAR) in cellular dormancy. When expressed
at high levels, uPAR activates the fibronectin receptor integrin α5β1, which binds to fibronectin in
order to organize complexes with focal adhesion kinase or EGFR that up-regulate the ratio of
activated ERK to activated p38, maintaining tumor cells in a proliferative state [81-83]. In
contrast, when low levels of uPAR are present in tumor cells, the disorganized fibronectin fibrils
cannot bind to integrin α5β1, leading to a low ratio of activated ERK to activated p38, thus
promoting tumor cell dormancy [81-82]. Following with the line of reasoning that a low ratio of
active ERK to active p38 can induce dormancy, recent work with dormant HNSCC cells in mouse
bonne marrow suggests that TGF-β2 signaling through a TGF-β3 complex can promote
dormancy by activating p38, which leads to dormancy by up-regulating the transcriptional
repressor DEC2 and repressing the transcription factor FOXM1 [84].
These studies are predicated on a model wherein dormancy occurs when individual tumor cells
metastasize to new sites, but fail to give rise to macrometastases because they undergo cellular
dormancy. The above models do not show, however, that isolated dormant tumor cells that
become dormant at metastatic sites subsequently give rise to recurrences in vivo, as they usually
rely on ex vivo manipulation to switch dormant cells to a proliferative state. As dormancy is
primarily of interest because it may represent a state that tumor cells pass through prior to
recurrence, it is critical that studies investigating residual disease use models that demonstrate
spontaneous recurrence following a period of dormancy in vivo.
The breadth of mechanisms that may underlie dormancy across these different settings raises the
possibility that different therapeutic strategies would be required to target dormancy in different
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settings. From a therapeutic development perspective, this is less attractive than the idea of a
single mechanism or pathway common to all dormant tumor cells.
Towards the end of identifying a single conserved mechanism describing residual disease across
multiple settings, the ‘cancer stem cell’ theory posits the existence of cancer stem cells (CSCs),
which suggests that a single population of tumor cells is responsible both for primary tumor
development, metastatic outgrowth, and resistance to therapy, and further that this tumor cell
population typically exhibits extremely low levels of proliferation consistent with dormancy [85].
As the CSC theory proposes that CSCs are the only cells capable of giving rise to tumors, the
identification of tumor cell populations enriched for tumor initiating cells (TICs) is a means to
identify tumor cell populations enriched for putative CSCs. This assay has identified
CD44+CD24- breast cancer cells as a putative breast cancer stem cell population [86]. Recent
reports demonstrate that breast cancer cells that have undergone an EMT exhibit a CD44+CD24surface phenotype, and are enriched for TICs [87]. Taking these ideas together in the context of
the aforementioned clinical findings, it is appealing to conceive that dormant tumor cells exhibit a
mesenchymal morphology, survive therapy, and give rise to tumors at metastatic sites. Indeed, it
has been proposed that EMT may be associated with dormancy due to its association with stemlike cancer cells [88, 89]. Some clinical reports support the idea that residual disease may have
either a phenotype associated with TICs, such as CD44+CD24- breast cancer cells [90], or be
enriched for tumor cells with a mesenchymal phenotype [37]. However, alternate studies indicate
that residual disease may not necessarily acquire a mesenchymal phenotype [38], and thus the
phenotype of residual disease remains unclear. This may reflect in part the challenge of
unambiguously identifying residual tumor cells that survive therapy and have completely lost
expression of epithelial markers after complete EMT, however methods for detecting residual
disease in humans still rely on markers present in primary tumor cell populations that may no
longer be expressed by residual tumor cells.
Separate studies using inducible transgenic mouse models suggest that residual disease may be
enriched for dormant tumor cells that express markers associated with a stem cell phenotype,
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however these studies fail to use markers that unambiguously identify residual tumor cells, and
consequently it is difficult to determine whether they provide an unbiased picture of residual
disease [91, 92]. Further, these studies do not investigate angiogenic insufficiency or
senescence, so it remains unclear whether residual disease in these models is truly dormant.
Additionally, as neither of these models is reported to demonstrate spontaneous tumor
recurrence, it is unclear whether the findings from these models can be applied to residual
disease that gives rise to recurrent tumors. Interestingly, the report of Ki67 negative residual
disease in models driven by two distinct oncogenes expressed in two different cells of origin
together suggest that exit from the cell cycle may be a general quality of residual tumor cells that
survive targeted therapy.
Together, the above studies demonstrate that a wide variety of mechanisms may control tumor
cell dormancy. Critically, none of the above studies investigating dormancy demonstrate the
presence of a dormant tumor cell population that subsequently gives rise to recurrence in vivo.
Additionally, while some evidence supports the idea that residual disease may be enriched for a
stem cell-like phenotype following oncogenic pathway inhibition, previous studies have not used
unambiguous markers such as fluorescent proteins to identify residual tumor cells, and thus it
remains unclear whether they represent an analysis of all residual tumor cells, or only those that
express markers present on tumor cells in the primary tumors. Thus, models that allow
unambiguous identification of dormant residual tumor cells that give rise to recurrence could
significantly improve our understanding of residual disease that survives oncogenic pathway
inhibition.
Residual disease and cancer dormancy – Therapeutically targeting dormant disease
Although the best strategy to eliminate dormant tumor cells or prevent dormant tumor cells from
re-entering the cell cycle is unclear, a wide array of approaches have emerged. Strategies to kill
residual tumor cells include targeting the cytoskeleton of dormant tumor cells [93], reactivation of
metabolic demand in residual cells unable to increase biosynthetic capability [94], inhibition of the
limited transcriptional machinery [95], or using high throughput screening methods to
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systematically identify methods to kill dormant tumor cells. Alternatively, therapies that maintain
dormant tumor cells in a quiescent state may also prevent tumor recurrence. Towards this end,
strategies that target the pathways maintaining tumor cells in a dormant state, or epigenetic drugs
that can induce a dormancy-like state, have been proposed as another type of dormant-targeted
therapy [96]. A strategy that is less clearly dormancy-specific is targeting kinases involved in
recurrent tumor growth [97], although referring to this as a dormancy-targeting therapy may be
technically incorrect as the therapy’s efficacy is predicated on preventing growth of recurrent
tumors, and as such can’t be distinguished from therapies targeting escape pathways active in
recurrent tumors.
As approaches to therapeutically target dormant disease continue to emerge and mature, models
that exhibit dormancy prior to recurrence in vivo will be critical to their preclinical testing.
Consequently, characterizing the biology of dormant residual disease that gives rise to recurrence
in vivo may provide important insights into such therapies.
Dissertation objectives
Residual disease gives rise to recurrence, however little is known about the generalizable
qualities of residual disease in vivo, thus making it difficult to detect and target. Clinical data
suggest that isolated DTCs unable to give rise to metastases may generally exhibit a dormant
phenotype, however whether residual disease that gives rise to recurrent tumors exhibits
dormancy remains unknown, thus the potential efficacy of targeting dormancy remains unclear.
Further, the molecular profile of dormant residual disease that gives rise to recurrence in vivo
remains unknown, limiting our ability to target residual disease. The goals of this dissertation are
to provide insight into the relevance and biology of cellular dormancy as a general characteristic
of MRD, to identify generalizable qualities associated with residual disease, and to test
therapeutic strategies that prevent the recurrence of residual disease.
Objective 1: Identify generalizable qualities of residual disease across two models of breast
cancer driven by different oncogenes
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Using fluorescent protein to track tumor cells, we identified dormant residual disease present at
sites that previously harbored tumors. Immunofluorescence (IF) staining and intravital labeling
demonstrated that outgrowth of residual disease is not limited by angiogenic insufficiency.
Dormant tumor cells located in minimal residual lesions can be identified both at local sites in
HER2/neu and Wnt1-driven murine models of breast cancer, and also at metastatic sites in these
models. Additionally, we demonstrate that human breast cancer displays a dormant phenotype
following oncogenic pathway inhibition in vivo. Thus, we identify dormancy as a candidate
generalizable quality of residual disease.
We also use gene expression profiling of residual tumor cells in the HER2/neu and Wnt1 models
in order to determine similarities between the molecular profiles of dormant residual disease in
models driven by different oncogenes. This analysis revels a dramatic overlap between the
profile of residual disease in these two different models, including enrichment for gene expression
profiles associated with normal and neoplastic stem-like cells. In spite of previous reports
indicating that an EMT is associated with a dormant stem-like population of tumor cells, we find
that only residual tumor cells in the HER2/neu model exhibit EMT. Surprisingly, we find that
residual disease is not enriched for primary TICs but may be enriched for recurrent tumor TICs,
thereby suggesting an evolution of TIC populations in response to targeted therapy.
Objective 2: Elucidate the role of the immune system and inflammation in dormancy and
recurrence
Our investigation into the generalizable qualities of residual disease revealed that macrophages
are recruited to local HER2/neu residual disease. Macrophages may promote cancer growth and
resistance to therapy, however their impact on dormant residual disease remains unknown. We
hypothesized that macrophages promote breast cancer recurrence through local inflammatory
signaling, and thus that either abrogating inflammatory signaling or ablating macrophages within
residual disease would inhibit tumor recurrence. We investigated the impact of both modulating
inflammation and macrophage ablation on tumor recurrence latency to test our hypothesis.
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We identified strategies that promote both inflammation and tumor recurrence, and found that
dexamethasone administration inhibited tumor recurrence at doses that also ablated
macrophages. Methods targeting c-fms-based signaling were able to ablate the majority of
macrophages within residual disease, however their impact on tumor recurrence was very small
in comparison to the impact of dexamethasone. We found that dexamethasone ablated proinflammatory CD11c+ macrophages, whereas c-fms-targeted therapy did not ablate this
macrophage population, thus providing a tenable explanation for the different efficacy of
dexamethasone and c-fms-targeted therapy.
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Figure Legend
Figure 1.1. Cumulative Number of Targeted Therapy New Medical Entity (NME) Approvals
by the FDA

Figure showing the cumulative number of FDA NME approvals from 1996 – 2013.
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CHAPTER 2
Modeling Cancer in Mice
Introduction to cancer models
Cancer models are a primary tool in the cancer researcher’s armamentarium, as they allow
systematic manipulation of known parameters in order to test specific hypotheses related to
cancer. Ideally, these models faithfully recapitulate the molecular and cellular mechanisms
driving cancer progression in humans, can be experimentally manipulated to precisely answer
questions about these mechanisms, and provide reproducible results either between investigators
or over a period of time. In practice, generating cancer models that meet these ideals is
challenging for several reasons, including the biologically heterogeneity of cancer, and the
complexity of performing experiments in the incompletely-understood multiparametric space
defining biological systems. This can limit the applicability of models, and thus in order to model
various elements of cancer progression, a variety of cancer models have been developed,
including in vitro cell culture, in vivo animal models, and in silico computational representations.
While all of these models have strengths and weaknesses, animal models are uniquely capable
of recapitulating all the major stages of cancer progression on a cellular level within a single
system. Given that 99% of proteins in humans have homologs in mice, the housing and
maintenance cost per animal are lower for mice than for larger animals, and the wide variety of
tools available to genetically manipulate mice, mice represent the most widely adopted animal
model for studying cancer. Various types of mouse models exist, including genetically
engineered mouse models of human cancer (hereafter referred to as GEMMs, although broadly
defined GEMMs may also refer to non-cancer models), xenograft models, and allograft models.
Whereas we will discuss xenograft and allograft mouse models later in this text, we will first focus
on genetically engineered mouse models, due to their central role in this work. As this thesis
focuses predominantly on in vivo work in mouse models, we will not discuss the use of nonmouse animal models, or non-animal models of cancer such as in vitro systems.
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Genetically engineered mouse models (GEMMs)
The first report of a GEMM was published in 1984 [98], and from that time, scientists have used
GEMMs for various applications including validating oncogenes or tumor suppressors, and
studying tumorigenesis in situ [99]. The ability of GEMMs to provide important insights into
human cancer is highlighted by recent efforts using these models in co-clinical trials to investigate
mechanisms underlying drug efficacy, and to discover clinically relevant biomarkers [99].
GEMMs currently used in research have been optimized to recapitulate human tumorigenesis by
using spatial and temporal control of gene expression to recapitulate phenotypes of cancers
driven by a plethora of clinically relevant oncogenic drivers, resulting in models that closely
recapitulate human tumorigenesis. The tools used to develop transgenic mouse models of
cancer have been examined extensively elsewhere [99], but will be briefly reviewed here.
Techniques to control gene expression spatially include both driving oncogene expression
through a tissue-specific promoter and viral gene delivery, the latter of which can also temporally
control gene expression. Additional methods to temporally control gene expression include the
use of tetracycline-regulated promoters, and the estrogen receptor fusion system. For example,
a model where expression of the reverse tetracycline transactivator (rtTA) is controlled by the
mouse mammary tumor virus long terminal repeat (MMTV) allows doxycycline-dependent
expression of downstream oncogenes specifically in mammary epithelial cells [100]. Transgenic
models also permit inclusion of reporters that allow monitoring of gene expression, such as firefly
luciferase downstream of an oncogene to monitor oncogene activity, or tracking of individual
tumor cells through expression of fluorescent proteins such as green fluorescent protein (GFP),
yellow fluorescent protein (YFP) or tdTomato. Newer efforts to develop transgenic models
include using RNAi in lieu of knockouts [101], chimeric organ transplantation models [102], and
humanized knock-in mouse models [103].
In spite of efforts made to optimize the similarities between GEMMs and human cancer, GEMMs
differ from human cancer in several key metrics. Differences in the size of mice compared to
people result in difficulty when modeling many parameters related to size, such as the size of a
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tumor relative to the organ from which it arises or a tumor’s growth rate, and thereby latency and
spread prior to detection. While approximately 99% of mouse proteins have human homologs,
sequence differences in these proteins, as well as different molecular circuitry regulating the
expression of these proteins, makes molecular findings in mice difficult to systematically
extrapolate to humans [104]. The mutational background of tumors that arise in GEMMs may not
reflect that of human cancer, and given that resistance in human cancer can arise from genomic
alterations, this represents a critical hurdle to the use of GEMMs to predict biology of resistance
in humans. The germline background of mice is also constrained to homogenous inbred strains
that fail to reflect the massive genetic diversity of germline variations defining the human
genomes from which human cancers arise. While GEMMs are not always predictive, work is
underway to ‘further improve the predictive potential of GEMMs in clinical studies.’
In spite of differences between GEMMs and human cancer, a wide range of studies indicate that
GEMMs will remain an important tool for studying clinically relevant questions in cancer
progression. The cure for acute promyelocytic leukemia (APL) was developed in part through
experimentation in GEMMs, due to the ability of these models to recapitulate response to therapy
of the human disease [104, 105]. Putative mechanisms underlying the efficacy of several
immune therapies have been identified in GEMMs [106, 107]. GEMMs were used to identify a
role for both the loss of HER2 in previously HER2-positive breast cancer, as well as EMT, in
cancer recurrence several years prior to when these phenomenon were observed in recurrent
cancer in humans [108]. Additional studies reveal a critical role of GEMMs for studying the
biological roles of drug targets and identifying alternative mechanisms underlying resistance to
therapy [103], for identifying mechanisms underlying tumor resistance to therapy [99, 105, 109113]. Thus, GEMMs may be useful models to study both the role of the immune system in
cancer, as well as mechanisms underlying resistance to targeted therapy.
Non-GEMM animal models
Mouse models other than GEMMS, such as xenograft and allograft models, provide alternative
approaches to modeling cancer in mice, and are associated with unique strengths and
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drawbacks. These models involve implantation of tumor cells into host mice. Orthotopic
implantation of tumors cells, wherein tumor tissue is implanted into the organ associated with that
tumor type, is preferred because the microenvironmental signals impacting the implanted tumor
cells are more likely to be analogous to those impacting an autochthonous tumor. An example of
orthotopic implantation is implantation of breast cancer cells into the mammary gland of a mouse.
A less desirable alternate approach is ectopic implantation, wherein tumor cells are implanted into
a site not normally associated with the normal growth of those tumor cells. An example of an
ectopic implantation is subcutaneous implantation of breast cancer cells. Other mouse models
for cancer, including carcinogen-induced and spontaneous cancer models, are discussed in detail
elsewhere but their discussion is not pertinent to this thesis [99].
Xenograft models involve the use of human cancer cells to grow cancer in mice, and extremely
immunocompromised mice are often used in order to minimize the mouse host’s anticancer
immune response to the implanted cells. Human cancer cells in mice can contain the same
genetic mutations and express the same proteins present in cancers in patients, and thus the
efficacy of therapeutics targeting human proteins may be more faithfully recapitulated when
generating orthotopic tumors using human tumor cells than mouse tumor cells. The term
‘xenograft’ model used in isolation frequently refers to the use of a human cancer cell line
cultured in plastic prior to injection in mice. In vitro culture acts as a bottleneck that can skew the
phenotype of tumor cells away from the phenotype they demonstrate in humans. In contrast, a
newer method of establishing xenografts, implanting complete human cancer – including stroma
– directly into mice, can result in both faithful recapitulation of the genotype of the donor tumor, as
well as generation of a human stroma derived from the donor tumor stroma. This approach
allows investigators to generate biological replicates of the same donor tumor, and thus perform
controlled experiments in order to test hypotheses about the donor tumor. While GEMMs and
human cancer cell lines may exhibit genomic alterations that do not reflect precisely the
mutations found in cancer patients, patient-derived xenograft (PDX) models are thought to more
faithfully recapitulate these mutations, and thus may be useful for identifying genomic alterations
that underlie resistance in vivo. A significant disadvantage to the use of PDX models is that it can
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be challenging to manipulate the tumor cells in order to test experimental hypotheses, as
methods for tumor cell manipulation – such as overexpression or knockout of target proteins –
are typically designed for in vitro culture. Another disadvantage to xenograft models is that
dramatically immunocompromised mice such as NOD/scid/Il2γnull (NSG) mice are more likely to
allow engraftment and growth of tumor cells than mildly immunocompromised mice such as nu/nu
mice, which dramatically curtails the potential for studying immunity in cancer progression in
these models.
In contrast to xenograft models, allograft models involve implantation of cancer cells arising from
a mouse into a separate host mouse. The host mouse may either be immunocompromised, or
alternatively may be from the same strain and genotype, called a syngeneic allograft. While
these models may not recapitulate the specific mutational aberrations present in human cancers,
and mouse proteins may lack exact homology to their closest human homologs thereby
inaccurately representing the efficacy of therapeutics developed to target human cancer cells,
these models have several advantages over xenograft models. The ligands and receptors on the
implanted tumor cells will be from the same species as the microenvironmental factors that
support the growth of the implanted tumor cells, thus the impact of the microenvironment on
tumor cells will more accurately represent what would be present in an autochthonous tumor than
would be the case for a xenograft tumor. Further, the use of syngeneic hosts enables
investigators to produce syngeneic tumors in multiple animals with a fully intact immune system,
thereby providing a system well-suited to test hypotheses about the role of immunity in cancer.
Disadvantages of allograft models and GEMMs relative to xenograft models can be partially
overcome. Using therapeutics developed against mouse proteins, homologous to therapeutics
developed against human proteins, allows one to perform preclinical testing in GEMM and
allograft mouse models with intact immune systems. There are also circumstances in which
therapeutics used in humans have pharmacodynamic profiles in mice analogous to those in
humans, which further permits preclinical testing in mouse models.
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CHAPTER 3
Modeling Dormant Residual Disease and Breast Cancer Recurrence
The vast majority of breast cancer deaths are due to disease relapse following a period of clinical
remission after treatment. In this regard, a cardinal feature of human breast cancers is the
survival and persistence of residual tumor cells in a latent state despite treatment of the primary
tumor. These surviving tumor cells, termed MRD, serve as the reservoir from which recurrent
breast cancers arise. At present, little is known about the biology of MRD or the nature of the
latent state in which they reside. Using conditional transgenic mouse models for human breast
cancer driven by either HER2/neu or Wnt1, we demonstrate that residual tumor cells surviving
oncogenic pathway inhibition exhibit cellular dormancy at local as well as metastatic sites. In an
analogous manner, we find that human breast cancer cells are quiescent following targeted
therapy in vivo. Residual tumor cells from both HER2/neu and Wnt1-induced tumors exhibit a
gene expression program characteristic of normal and neoplastic mammary stem cells and
cellular quiescence, whereas EMT transition occurred in HER2/neu, but not Wnt1, residual
disease. Surprisingly, while both HER2/neu and Wnt1 residual tumor cells displayed phenotypic
properties associated with tumor initiating cells (TICs), functional assays revealed that residual
tumor cells were not enriched for primary tumor TICs , but were instead enriched for TICs
capable of giving rise to recurrent tumors. Together, our data reveal that targeted therapies
predicated on oncogene addiction give rise to a small population of dormant tumor cells that are
capable of re-entering the cell cycle and giving rise to recurrent tumors, and suggest that cellular
dormancy represents a potential therapeutic target for preventing recurrent breast cancer.
Modeling oncogenic pathway inhibition
The recent increase in the clinical adoption of targeted therapies, in combination with the
dramatic rate of relapse following targeted therapy, have spurred investigation into the biology of
residual disease that survives therapy and gives rise to tumor recurrence. Importantly, while
primary breast cancers can be cured, recurrent breast cancers cannot. Thus, therapeutic
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targeting of MRD could represent an attractive approach to reducing breast cancer recurrence by
depleting the reservoir of residual tumor cells that persists following therapy, or otherwise
preventing them from giving rise to recurrent cancers. Unfortunately, little is known about the
biology of MRD or the pathways that govern the behavior of these cells.
Mounting clinical evidence suggests that tumor dormancy may offer a therapeutic window through
which to target MRD and thereby prevent tumor recurrence [114-117]. For example, DTCs in the
bone marrow or circulating tumor cells (CTCs) in the blood of cancer patients have been reported
to be quiescent and to persist throughout treatment, suggesting that recurrent cancers may arise
from dormant tumor cells [118-120]. Nevertheless, it is also possible that tumor relapse in
patients results from proliferative, yet subclinical, micrometastases that survive therapy. If true,
this would suggest that dormancy is unlikely to constitute a useful therapeutic target. In light of
this uncertainty, determining whether dormancy plays a role in tumor cell survival and recurrence
is essential for understanding whether MRD represents a stage of neoplastic progression that
would be vulnerable to therapies targeting cellular dormancy.
At present, remarkably little is known about the biology of dormancy. This reflects difficulties in
identifying and isolating dormant tumor cells in humans, as well as the general lack of animal
models for studying dormancy in vivo. To this end, we previously described doxycyclinedependent conditional transgenic mouse models for breast cancer in which HER2/neu, Wnt1, or
c-MYC pathway inhibition results in the regression of primary mammary tumors to a non-palpable
state, persistent MRD, and eventual relapse following a latent period of remission [108, 121, 122].
Notably, recurrent tumors arising in the HER2/neu-induced tumor model were frequently HER2negative and had undergone an EMT. In an analogous manner, clinical observations have
subsequently revealed that recurrent cancers, as well as MRD, can exhibit phenotypes distinct
from the primary tumors from which they arose, both with respect to EMT and to the loss of HER2
expression in breast cancers that were previously HER2+ [37, 123, 124]. These findings highlight
the plasticity of neoplastic progression and suggest that conditional transgenic mouse models
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may provide a tractable approach to identifying residual tumor cells and elucidating mechanisms
of cancer progression following therapy [108, 125, 126].
The biological properties of residual tumor cells that give rise to recurrent cancers following a
variable latency period have not, as yet, been described in vivo. In principle, at least three types
of tumor dormancy have been described that could potentially contribute to the latent period of
MRD prior to tumor recurrence: angiogenic dormancy, cellular dormancy and immunological
dormancy. At present, however, the nature of the latent state in which residual tumor cells reside
following oncogenic pathway inhibition are unknown. As such, an improved understanding of
tumor dormancy will be required to enable the rational design of strategies for detecting and
eliminating MRD.
To address this critical gap in knowledge, we now report the use of conditional transgenic mouse
models for HER2/neu and Wnt1-induced breast cancers to identify features of MRD in vivo that
are shared for tumors driven by different oncogenes. By combining cell sorting with gene
expression profiling, we demonstrate that residual tumor cells that survive oncogenic pathway
inhibition in vivo exhibit cellular dormancy and express markers characteristic of mammary stem
cells. We further demonstrate cellular dormancy at metastatic sites in tumor-bearing mice, and in
human breast cancer xenografts treated with anti-HER2 therapies. Contrary to expectation,
however, limiting dilution assays revealed that residual tumor cells are not enriched for primary
TICs. In aggregate, our observations suggest that cellular dormancy may be a general feature of
residual tumor cells surviving oncogenic pathway inhibition and provide new insights into
biological properties of MRD relevant to their detection and elimination.
The kinetics of tumor recurrence following oncogene inhibition suggest dormant residual
disease
We previously described conditional bitransgenic mouse models for HER2/neu and Wnt1-induced
mammary tumorigenesis that recapitulate key features of breast cancer progression as it occurs
in patients, including primary tumor formation, response to therapy, and a variable latency period
prior to spontaneous tumor recurrence [108, 121, 127]. In these models, doxycycline
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administration induces oncogene expression in the mammary epithelium resulting in the
formation of primary mammary adenocarcinomas. Analogous to the treatment of human cancers
with targeted therapies, doxycycline withdrawal in tumor-bearing mice results in oncogenic
pathway inhibition followed by primary tumor regression due to oncogene addiction [121, 127].
However, similar to the phenomena of resistance and relapse in patients treated with targeted
therapies, most mice develop spontaneous recurrent tumors following a variable period of
latency. As such, these models provide an opportunity to study the phenotype of residual tumor
cells that survive targeted therapy and are capable of giving rise to tumor recurrence.
To identify characteristics of residual tumor cells that are shared between HER2/neu and Wnt-1driven tumor models, we first wished to determine whether the kinetics of tumor recurrence are
similar in these models. Therefore, we monitored tumor-bearing MMTV-rtTA;TetO-HER2/neu
(MTB;TetO-HER2/neu) and MMTV-rtTA;TetO-Wnt1 (MTB;TetO-Wnt1) bitransgenic mice in which
primary tumors had regressed to a non-palpable state following oncogenic pathway inhibition.
Consistent with previous observations, tumors recurred with stochastic kinetics following
oncogenic pathway inhibition in both the HER2/neu and Wnt1 models (Figure 3.1A, C).
A recent study using inducible mouse models for lymphoma and leukemia suggested that longterm tumor regression following oncogenic pathway inhibition may require the adaptive immune
system [128]. To determine whether adaptive immunity is required for sustained regression of
mammary adenocarcinomas in the HER2/neu or Wnt1 models, we injected limited passage tumor
cells generated from primary mammary tumors arising in MTB;TetO-HER2/neu (HER2/neuPrim1) and MTB;TetO-Wnt1 (Wnt1-Prim1) mice into the mammary fat pads of
immunocompromised female nu/nu mice maintained on doxycycline. Following primary tumor
formation, doxycycline was withdrawn to induce oncogene down-regulation and tumor regression.
Mice bearing fully regressed orthotopic tumors were then monitored for tumor recurrence.
Orthotopic primary tumors recurred with stochastic kinetics following a variable latency period,
paralleling our findings in intact MTB;TetO-HER2/neu and MTB;TetO-Wnt1 mice (Figure 3.1B, D).
Notably, orthotopic tumors recurring after either short or long intervals exhibited similar growth
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rates – a feature that was also observed for recurrent tumors arising in intact mice (Figure 3.1E).
These data demonstrate that the kinetics of tumor recurrence in orthotopic mouse models parallel
those in intact mice and further indicate that a competent adaptive immune system is not required
for sustained periods of tumor regression of up to 200 d following oncogenic pathway inhibition in
genetically engineered mouse models.
Our observation that the growth rates of recurrent tumors – in both intact and orthotopic mouse
models – are independent of the length of the latent period that preceded their detection was
reminiscent of observations in breast cancer patients suggesting the potential existence of a
dormant phase between the treatment of primary tumors and their subsequent recurrence at local
or distant sites [115]. Therefore, to address whether mice bearing fully regressed mammary
tumors harbor dormant residual disease, we first readministered doxycycline to intact MTB;TetOHER2/neu mice whose primary tumors had regressed to a non-palpable state following
doxycycline withdrawal, but had not exhibited spontaneous tumor recurrences when maintained
off doxycycline for a period of six months.
Following doxycycline re-administration and re-expression of the HER2/neu transgene, all mice
developed recurrent tumors at the original sites of their primary tumors within two weeks, but did
not develop tumors at other sites (Figure 3.1F). This finding demonstrates that essentially all
mice bearing tumors that have regressed to a non-palpable state harbor residual cancer cells that
are capable of giving rise to recurrent tumors. Moreover, since the median latency for
spontaneous tumor recurrence was 17 wk, and since more than a year was required for 95% of
mice to recur, the observation that HER2/neu transgene reactivation resulted in the appearance
of recurrent tumors within 2 wk strongly suggests that mice bearing fully regressed primary
mammary tumors harbor dormant residual disease.
Minimal residual lesions contain residual tumor cells
The molecular analysis of dormant residual tumor cells first requires their identification and
isolation. To identify residual cancer cells, doxycycline was withdrawn from tumor-bearing
MTB;TetO-HER2/neu and MTB;TetO-Wnt1 mice to induce oncogenic pathway inhibition and

28

tumor regression. Mice were sacrificed 56 d following doxycycline withdrawal and carmine
staining was performed on whole-mounted mammary glands that either did, or did not, harbor
tumors prior to doxycycline withdrawal. This analysis revealed the presence of abnormal
histological lesions in mammary glands that had previously harbored a primary tumor, but not in
mammary glands that had not harbored tumors (Figure 3.2A, B arrows). Hematoxylin and eosin
(H&E) staining of tissue sections from previously tumor-bearing glands revealed that residual foci
were densely cellular (Figure 3.2C, D).
To determine whether abnormal foci observed in whole mounts and histological sections
contained residual tumor cells that had survived oncogenic pathway inhibition, or were instead
composed of host stromal cells or residual scar tissue, doxycycline-dependent primary tumor
cells derived from HER2/neu and Wnt1 primary tumors were stably transduced to express H2BeGFP and injected orthotopically into the mammary glands of female nu/nu mice maintained on
doxycycline. Following primary tumor formation, doxycycline was withdrawn to induce tumor
regression and mice were sacrificed 56 d later.
H&E staining of histological sections from residual lesion-bearing mammary glands revealed
cellular foci within a dense eosinophilic extracellular matrix (ECM) similar to those identified in
intact mice (Figure 3.2E). Fluorescence microscopy confirmed the presence of eGFP-labeled
tumor cells within these residual foci, which we term minimal residual lesions (MRLs) (Figure
3.2F).
As metastatic breast cancer is the primary cause of mortality for this disease, we also wanted to
establish models for systemic metastases. Towards this end, we performed intracardiac injection
of HER2/neu-Prim1 tumor cells into the left ventricle of nu/nu mice on doxycycline. Injection into
the left ventricle allows tumor cells to bypass the lungs, which otherwise serve as the primary
metastatic site for the majority of tumor cells injected intravenously. Using this system, we were
able to generate systemic metastases in the nu/nu mice, which we observed both with
bioluminescence firefly luciferase imaging (Figure 3.3A) and with GFP fluorescence upon gross
dissection (Figure 3.3C). Consistent with our previous observations of metastatic disease [127],
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luciferase activity was completely diminished following doxycycline withdrawal, indicating that the
oncogene can be turned off at metastatic sites following doxycycline withdrawal (Figure 3.3B).
To develop a model of systemic metastases in which tumor cells specifically express fluorescent
proteins, but that had been minimally manipulated in vitro, we crossed MTB;TetO-HER2/neu mice
with TetO-TurboCre (TTC);Rosa26-lox-stop-lox-YFP (rYFP) mice to generate MTB;TetOHER2/neu;TTC;rYFP mice in which doxycycline administration results in the inducible expression
of both HER2/neu and cre recombinase specifically in mammary epithelial cells. Consequently,
doxycycline treated mice harbor fluorescent mammary epithelial cells, due to Cre-mediated
excision of the stop cassette preceding YFP, that HER2/neu-induced mammary
adenocarcinomas with yield fluorescently-labeled tumor cells. Alternatively, the fluorophore
tdTomato was used in place of the fluorophore YFP in some mice, as tdTomato is dramatically
brighter than YFP. Enzymatically digested primary doxycycline-dependent tumors from these
quadtransgenic reporter mice were injected orthotopically into nu/nu mice to generate ‘no culture’
orthotopic models, i.e. orthotopic models that had not been cultured, analogous to an allograft
version of a PDX model.
Mice bearing no culture orthotopic tumors developed systemic metastases (Figure 3.4). There
was a wide range of tumor growth rates across all tumors injected from the same donor, and the
orthotopic tumors that grew the slowest on doxycycline gave rise to the greatest number of
metastases in locations other than the lung. In general, 1 out of 5 mice would have primary
orthotopic tumors that grew sufficiently slow to generate liver metastases, and bone marrow
metastases. While primary metastases formed in mice on doxycycline (Figure 3.4A), upon
doxycycline withdrawal, metastases regressed and left disseminated residual lesions in different
organs, including lung, liver, and bone marrow (Figure 3.4B, C).
Given our observations that these mice can develop systemic disease, we next wanted to know
whether we could use these mouse models to study CTCs and DTCs, due to the fact that there is
a large clinical interest in these populations but the biology connecting these populations to
residual disease that gives rise to recurrence is poorly understood. We first investigated whether
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MTB/TAN/TTC/rYFP mice could be used to study these populations. Flow cytometry revealed
that peripheral blood leukocytes from MTB/TAN/TTC/rYFP mice expressed YFP (Figure 3.5).
This occurred only in mice that had both the MTB, TTC, and rYFP transgenes (Figure 3.5A, data
not shown). Presumably this occurred due to promiscuous activity from the MMTV-LTR promoter
in the MTB transgene, as previous studies have indicated that MMTV-LTR may be active in
leukocyte populations. MTB/oncogene mice do not develop hematological malignancies,
because the expression of oncogenes in leukocytes is vanishingly small even in the presence of
doxycycline. Thus we were surprised that YFP fluorescence occurs in the absence of
doxycycline in leukocytes. This speaks in part to the strength of the Cre-based reporter system,
and suggests that even low level MMTV activation of Cre is sufficient to lead to excision of the
stop locus upstream of YFP. This phenomenon did not occur in all MTB/TAN/TTC/rYFP mice,
and some mice exhibited YFP expression in only a fraction of their peripheral blood leukocytes
(data not shown). Upon establishing orthotopic no culture tumors with this system, the extreme
rarity of CTC and DTCs combined made it challenging to reliably distinguish fluorescent reporter
tumor cells from leukocyte doublets in vivo (data not shown).
As an alternative approach to identify CTC and DTCs, we established orthotopic H2BeGFPlabeled HER2/neu-Prim1 tumors in nu/nu mice. Upon generation of primary doxycyclinedependent bilateral tumors with a mean diameter of 4cm, we were able to use flow cytometry of
blood drawn from a right ventricle cardiac puncture to identify a large number of CTCs in some of
these mice (Figure 3.6A, B). Fluorescence imaging for Hoechst and GFP on sections of frozen
decalcified bone revealed DTCs (Figure 3.6 C-F). We then performed flow cytometry for GFP+
events on additional nu/nu mice with smaller tumor burdens (‘small tumor’ = 5mm diameter, ‘large
tumor’ = 15mm diameter), and found a small number of GFP+ events in the blood and bone
marrow (Figure 3.6 G). We also identified events in the blood and bone marrow at various stages
of dormancy and tumor recurrence. Due to the small number of events identified in these studies,
it was not possible to definitively say that these events were indeed tumor cells and were not
simply rare events with high levels of autofluorescence.
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Residual tumor cells exhibit cellular dormancy
Based on the stochastic kinetics of mammary tumor recurrence that we observed in MTB;TetOHER2/neu and MTB;TetO-Wnt1 mice, as well as the similar growth rates exhibited by recurrent
tumors irrespective of their latency to recurrence, we hypothesized that residual tumor cells
surviving oncogene down-regulation exhibit cellular dormancy. To test this hypothesis, we
generated orthotopic primary tumors from H2B-eGFP-labeled HER2/neu-Prim1 cells and
sacrificed mice bearing primary tumors at 0, 28 d or 56 d following oncogene down-regulation.
IF for Ki67 performed on tissue sections from primary tumors and MRLs revealed Ki67
expression in 0.25% and 0.17% of residual tumor cells at 28 d and 56 d following HER2/neu
down-regulation, respectively (Figure 3.7A, D). In contrast, primary tumor cells exhibited rates of
Ki67 positivity that were greater than 40-fold higher (p-value primary tumor: vs. 28 d MRL =
0.011; primary tumor vs. 56 d MRL = 0.029). This finding indicates that residual tumor cells are
quiescent following oncogene down-regulation.
In order to distinguish slow cycling cells from tumor cells undergoing prolonged cell cycle arrest,
as would be anticipated for dormant tumor cells, we evaluated tumor cell proliferation rates over
extended periods of time. Orthotopic primary tumors and MRLs were generated, as above, from
H2B-eGFP-labeled HER2/neu-Prim1 or Wnt1-Prim1 tumor cells in nu/nu mice and osmotic
pumps were then employed to deliver bromodeoxyuridine (BrdU) for 2 wk to label cells that
underwent DNA synthesis during that period.
Whereas greater than 90% of HER2/neu-Prim1 tumor cells were labeled with BrdU over the 2 wk
period prior to sacrifice, fewer than 9% of HER2/neu-Prim1 residual tumor cells incorporated
BrdU over the same time period (Figure 3.7B, E). In an analogous manner, greater than 95% of
Wnt1-Prim1 tumor cells were labeled with BrdU over a 2 wk period, while fewer than 8% of Wnt1Prim1 residual tumor cells incorporated BrdU during this same period (Figure 3.7C, F). These
findings suggest that residual tumor cells from either HER2/neu or Wnt1-induced mammary
tumors reside in a latent G0-like state following oncogene down-regulation, or are extremely slow
cycling.
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The finding that the vast majority of residual tumor cells fail to incorporate BrdU over extended
periods of time did not distinguish between the possibility that residual tumor cells were dormant
– existing in a reversible state of cell cycle arrest – and the possibility that these cells had
irreversibly exited the cell cycle as might occur if cells had undergone senescence or terminal
differentiation. To address this question, we generated orthotopic primary tumors and MRLs from
H2B-eGFP-labeled HER2/neu-Prim1 or Wnt1-Prim1 tumor cells and then re-administered
doxycycline to mice for 72 hr. Mice were then injected with BrdU 2 hr prior to sacrifice in order to
label proliferating cells.
In both the HER2/neu-Prim1 and Wnt1-Prim1 models, residual tumor cells in MRLs in which
oncogene expression had been reactivated incorporated BrdU at rates similar to primary tumor
cells. In contrast, residual tumor cells within MRLs in which oncogene expression had not been
reactivated incorporated BrdU at ~20-fold lower rates (Figure 3.7G-J; p-value <0.001 for dormant
residual tumor cells vs. primary tumor cells or vs. reinduced residual tumor cells in both
HER2/neu and Wnt1 models). Together, these findings demonstrate that residual tumor cells
exist in a reversible state of cell cycle arrest following oncogenic pathway inhibition, suggesting
that these cells exhibit cellular dormancy.
As cellular dormancy is also associated with a low rate of apoptosis, we used IF to quantify the
number of tumor cells in the HER2/neu model that expressed the apoptosis marker cleaved
caspase-3 (CC-3). While primary tumor cells exhibited more than 2% CC-3 expression, dormant
residual tumor cells rarely expressed CC-3 at 28d after doxycycline withdrawal, and no residual
tumor cells expressed CC-3 56 days after doxycycline withdrawal (Figure 3.7 K, L). This finding
further supports the possibility that residual tumor cells are dormant.
Residual disease is well vascularized and is not hypoxic
Our findings to this point suggested that the latent period between primary tumor regression and
spontaneous tumor recurrence might be explained if residual tumor cells existed in a state of
cellular dormancy. In contrast, prior reports have suggested that sustained tumor regression
following oncogenic pathway inhibition may be attributable to a lack of functional vascularization
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[129, 130]. Angiogenic dormancy refers to the state in which ongoing cellular proliferation is
counterbalanced by hypoxia-induced apoptosis resulting from inadequate vascularization [131].
Although the extremely low rates of proliferation that we observed in residual tumor cells within
MRLs suggested a model other than angiogenic dormancy, this finding did not exclude the
possibility that hypoxia due to a limiting blood supply might contribute to the dormant state of
residual tumor cells.
To assess the state of vascularization within MRLs, we first performed IF for the endothelial cell
marker CD31 on tissue sections from MRLs harvested from orthotopic HER2/neu-Prim1 and
intact MTB;TetO-Wnt1 mouse tumor models. This analysis demonstrated that both HER2/neu
and Wnt1 residual lesions are densely vascularized (Figure 3.8A, B). Indeed, CD31 staining
revealed that the density of blood vessels within MRLs is similar to, or greater than, that present
within actively growing primary tumors (Figure 3.8B).
The pattern of CD31 staining that we observed in MRLs was consistent with the maintenance of a
competent microvasculature following tumor regression. However, CD31 staining could not
definitively demonstrate that blood vessels within MRLs were functional. To address this, mice
bearing orthotopic MRLs generated from H2B-eGFP-labeled HER2/neu-Prim1 tumor cells 28 d
following HER2/neu down-regulation were intravenously (i.v.) injected with Lectin-StreptavidinAlexaFluor647 (Lectin-AF647) to label patent blood vessels. Virtually all CD31 staining colocalized with Lectin-AF647, demonstrating that blood vessels within MRLs are well perfused
(Figure 3.9).
Though the above data suggested that MRLs contain a patent and robust vasculature, we could
not exclude the possibility that regions of hypoxia existed within MRLs. To address this, we
generated mice bearing orthotopic MRLs from H2B-eGFP-labeled HER2/neu-Prim1 tumor cells
and intravenously injected those mice with Lectin-AF647, Hoechst 33342 and pimonidazole prior
to sacrifice. Pimonidazole forms covalent adducts with proteins in hypoxic microenvironments
(pO2<10mmHg) and is sufficiently sensitive to detect physiological hypoxia surrounding hepatic
veins [132].
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IF to detect pimonidazole adducts in control experiments revealed that, as anticipated, such
adducts were present within low-oxygen tension regions of the liver adjacent to hepatic veins
(Figure 3.8C, arrowhead), but absent from well-oxygenated regions adjacent to the hepatic
arterial vasculature (Figure 3.8C, arrow). Strikingly, virtually no pimonidazole staining was
observed in MRLs examined from multiple animals, indicating that residual tumor cells within the
MRL are not present within a hypoxic microenvironment (Figure 3.8C).
As some prior reports have suggested that diffusion of small molecules out of blood vessels may
be limited within a desmoplastic environment [133], Hoechst 33342 was injected into MRLbearing mice to assess whether the absence of pimonidazole staining might be due to restricted
diffusion of pimonidazole within MRLs. Specifically, the distribution of i.v. injected Hoechst
33342 was evaluated by fluorescence microscopy in order to visualize the ability of small
molecules to diffuse within the MRL. Livers from mice bearing MRLs served as positive controls.
Intravenously injected Hoechst 33342 efficiently labeled the nuclei of cells in both livers and
MRLs, indicating that small molecules within the circulation can diffuse out of the vasculature and
gain access to residual tumor cells within MRLs (Figure 3.8C).
In aggregate, data from both HER2/neu and Wnt1 tumor models support the hypothesis that
MRLs are well-vascularized with a patent vasculature, and that dormant residual tumor cells
within MRLs are not hypoxic. Accordingly, these findings suggest that the dormant state of
residual tumor cells observed following oncogenic pathway inhibition is not due to the limited
delivery of oxygen or nutrients resulting from an inadequate blood supply.
Residual metastatic tumor cells recapitulate features of local residual disease
As distant recurrence is the primary cause of mortality from breast cancer, we wished to
determine whether our findings were also true for micrometastatic disease. We therefore asked
whether, following oncogenic pathway inhibition, residual lung metastases demonstrated cellular
dormancy in the context of a well-vascularized microenvironment.
Fluorescent primary tumors from doxycycline-induced MTB;TetO-HER2/neu;TTC;rYFP mice were

35

enzymatically dissociated and injected orthotopically into nu/nu mice. Mice that developed
orthotopic primary tumors also harbored lung metastases. Doxycycline was withdrawn from a
cohort of these mice to induce regression of lung metastases, as previously reported [127], and
lung metastases in mice on doxycycline were compared to residual metastatic foci 28 d following
doxycycline withdrawal.
Lung metastases in tumor-bearing mice maintained on doxycycline were histopathologically
similar to primary tumors and were composed of well-delineated epithelial and stromal
compartments (Figure 3.10A). In contrast, residual YFP+ tumor cells were scattered throughout
an eosinophilic stroma within metastatic foci that had regressed in the lungs of mice in which
HER2/neu had been down-regulated. IF for Ki67 revealed that the majority of tumor cells within
metastases were Ki67+ in mice on doxycycline, whereas metastatic tumor cells within residual
foci were uniformly Ki67-negative (Figure 3.10B).
Consistent with our observations in local residual disease, staining for CD31 revealed that
residual metastatic foci in the lungs of tumor-bearing mice were well-vascularized (Figure 3.10C).
Human breast cancer cells exhibit quiescence following targeted therapy
Given that murine mammary tumor cells exhibit cellular dormancy following oncogene pathway
inhibition, we reasoned that residual human breast cancer cells that survive targeted oncogenic
pathway inhibition might also be dormant. To address this possibility, we generated orthotopic
xenografts from GFP-labeled BT474M1 breast cancer cells in NOD/scid/Il2γnull (NSG) mice that
had been oophorectomized and implanted subcutaneously with 17β-estradiol pellets. All mice
developed orthotopic tumors at sites of injection. Consistent with the identity of BT474M1 tumor
cells as a HER2-dependent breast cancer cell line, IF revealed that tumor cells in the primary
tumor expressed HER2 (Figure 3.11A). Tumors also gave rise to a large number of
micrometastases, comprised of individual GFP+ tumor cells seeding the lungs of these mice
(Figure 3.11B). In spite of analyzing a large number of tissue sections, metastases with more
than 1 or 2 cells in isolation were not observed, suggesting that these tumor cells were not able to
grow in the lung. Following the development of 1cm tumors, HER2 signaling was inhibited by
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triplet anti-HER2 therapy comprised of Trastuzumab, Pertuzumab, and Lapatinib, and estrogen
receptor (ER) signaling was down-regulated by removal of 17β-estradiol pellets (Figure 3.12A).
Tumors treated with combination anti-HER2 and anti-ER therapy rapidly regressed to a nonpalpable state, whereas untreated tumors continued to grow (Figure 3.12B). Mice were sacrificed
72 hr after treated tumors had regressed to a non-palpable state
Fluorescence microscopy performed on sections from mammary glands that had previously
harbored tumors revealed scattered GFP+ residual tumor cells (Figure 3.12C-D). In light of our
observations of cellular dormancy in residual HER2/neu-Prim1 tumor cells, we next asked
whether residual BT474M1 tumor cells that survived targeted therapy are quiescent. IF for Ki67
revealed that scattered residual tumor cells were predominantly quiescent, with only ~2%
expressing Ki67 (Figure 3.12C, E). In contrast, greater than 25% of untreated primary tumor cells
were Ki67+. These findings suggest that residual human breast cancer cells that survive targeted
therapy are quiescent, and provide a conceptual link between murine residual disease following
oncogene down-regulation and residual human breast cancer cells following targeted therapy.
We next asked whether the microenvironment of quiescent residual human breast cancer
xenografts was similar to that seen in dormant residual disease in the mouse. IF staining for
CD31 in BT474M1 residual lesions revealed a rich vasculature (Figure 3.12D). Together, our
findings suggest that quiescent residual tumor cells residing in a well-vascularized
microenvironment may be a general feature of residual disease following oncogenic pathway
inhibition.
Residual disease juxtaposed with normal mammary ducts is not dormant
While observing residual disease, labeled for 2 weeks with BrdU, 56d after doxycycline
withdrawal in HER2/neu-Prim1 orthotopic residual lesions in nu/nu mice, we identified a small
number of residual lesions with regions of GFP+ tumor cells that were uniformly BrdU+ (Figure
3.13). We found that these tumor cells surrounded normal mouse mammary ducts, identified as
cells that did not express GFP but expressed epithelial cytokeratins as stained by a pancytokeratin antibody (Figure 3.13). Staining for the mesenchymal tumor cell marker PDGFR-β
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revealed that these tumor cells exhibited a mesenchymal phenotype (Figure 3.14A-C). To
determine whether this phenomenon was an event that promoted tumor recurrence, we
performed a recurrence assay using HER2/neu-Prim1 orthotopic tumors in syngeneic TAN
monotransgenic mice that either had the normal mammary epithelium surgically removed (fat pad
clearing surgery) prior to puberty, or that had a sham surgery (Figure 3.14D). The mammary fat
pads in mice that underwent fat pad clearing surgery would presumably not contain the normal
mammary ducts that gave rise to these duct-juxtaposed proliferative foci, and thus allowed us to
test whether this phenomenon promoted tumor recurrence. Mammary fat pad clearing did not
delay the time to recurrence in this model, instead there was a trend towards an increased rate of
recurrence in mice with fat pad clearing, although this result was not statistically significant
(Figure 3.14E).
We then looked at local residual disease in the BT474M1-GFP model, and identified a similar
phenomenon, wherein residual BT474M1-GFP tumor cells that were encapsulated inside of
normal mouse mammary ducts (between red arrows) expressed much higher levels of Ki67
(white arrows) than the scattered BT474M1-GFP residual tumor cells that were not juxtaposed
with normal mouse mammary duct (Figure 3.14 F-I).
Together, these findings suggest that signaling from normal parenchymal or stromal tissue may
allow residual cells to enter the cell cycle. This may occur through signaling of growth factors
(e.g. PDGF) through RTKs on the surface of residual tumor cells (e.g. PDGFR-β). This finding is
consonant with a previously published role for microenvironmental signaling in impacting residual
disease following targeted therapy [134].
Gene expression profiling of residual tumor cells reveals enrichment for genes associated
with dormancy
Our finding that tumor cells surviving oncogenic pathway down-regulation are quiescent within a
richly vascularized, non-hypoxic microenvironment suggested that these cells exist in a state of
cellular, rather than angiogenic, dormancy. The in vivo molecular profile of dormant tumor cells
that survive treatment and give rise to recurrent tumors has not been reported, and the
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mechanisms maintaining these cells in a quiescent state are largely unknown. While disparate
mechanisms that promote quiescence have been identified in some model systems, it is unclear
whether these mechanisms are relevant to dormant tumor cells that survive therapy and give rise
to recurrent tumors in vivo.
To assess the molecular phenotype of residual tumor cells and to identify candidate mechanisms
potentiating cellular dormancy in the context of oncogenic pathway inhibition, we performed gene
expression profiling on purified dormant residual tumor cells that were isolated using
fluorescence-assisted cell sorting (FACS). Using no culture orthotopic MTB/TAN/TTC/rYFP
residual lesions, we found that approximately 618 residual tumor cells were required in order to
obtain the minimum 500pg RNA, with RNA integrity number >7.0, necessary for whole
transcriptome amplification prior to genome expression profiling (Figure 3.15, Table 3.1). H2BeGFP-labeled HER2/neu-Prim1 or Wnt1-Prim1 tumor cells were injected into the mammary fat
pads of nu/nu mice and the resulting orthotopic primary tumors, MRLs at 28 d post HER2/neu
down-regulation, and recurrent tumors were harvested, enzymatically digested, and GFP+ tumor
cells were FACS-isolated. RNA isolated from GFP+ tumor cells, as well as GFP- stromal cells
isolated from recurrent tumors, was used to perform microarray expression profiling (Figure
3.16A).
Principal component analysis revealed tight clustering between biological replicates from each
FACS-isolated cell population, and further indicated that residual tumor cells exhibit a gene
expression pattern that is unique compared to either primary or recurrent tumor cells (Figure
3.16B). To identify functionally related groups of genes that were differentially expressed within
residual tumor cells compared to either primary or recurrent tumors, DAVID gene ontology
analysis was performed on genes differentially up- or down-regulated in residual tumor cells
compared to all other tumor cell types for both the HER2/neu and Wnt1 models. Genes downregulated in residual tumor cells in each of these data sets were dramatically enriched for
ribosomal- and cell cycle-related gene sets (Table 3.2). Indeed, consistent with our observation
that residual tumor cells are quiescent, transcripts for cyclins and cyclin-dependent kinases were
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down-regulated as much as 90% in residual tumor cells (Figures 3.16C). As ribosomal
biogenesis can be regulated by mTOR activity [135], we quantified mTOR pathway activity using
a previously described method [136]. This revealed significant down-regulation of mTOR
pathway activity in both HER2/neu and Wnt1 residual tumor cells compared to their
corresponding primary or recurrent tumors (Figure 3.16D, E). Conversely, differentially upregulated transcripts in residual tumor cells were enriched for secretory and ECM gene sets,
including genes such as fibronectin (Table 3.3). Consistent with this, IF for collagen type-I and
fibronectin revealed an abundant desmoplastic stroma within MRLs, whereas collagen type-IV
expression was restricted to blood vessels (Figure 3.17A-F). Performing the same staining on
tissue sections of residual no culture MTB/TAN/TTC/rYFP metastases and on BT474M1-GFP
residual disease, we observed strikingly similar findings in both of these models to what was
observed in local dormant HER2/neu residual disease (3.17G-O). Interestingly, while collagen
type-IV was localized to blood vessels in BT474M1-GFP residual disease (Figure 3.17O), it was
located throughout the whole ECM of residual metastases (Figure 3.17L).
In light of our observation that proliferation-related transcripts are markedly down-regulated in
residual tumor cells, we sought to identify candidate mechanisms that might potentiate cellular
dormancy. In this regard, the transcriptional repressor Dec2 exhibited the greatest up-regulation
amongst all transcription factors, and the transcription factor Foxm1 was significantly downregulated, in residual tumor cells in both the HER2/neu and Wnt1 models. Previous in vitro
analyses of dormant squamous carcinoma cell lines have suggested uPAR down-regulation, or
up-regulation of TGFβ-II/TGFβR-III signaling, as a cause of a low ERK:p38 signaling ratio that upregulates DEC and down-regulates FOXM1 [137, 138]. Consistent with these in vitro
observations, we found that residual tumor cells in vivo up-regulated Tgfbr3 (TGFβR-III), as well
as its ligand Tgfb2 (TGFβ-II), and markedly down-regulated Plaur (uPar) compared to either
primary or recurrent tumor cells (Figure 3.16G).
Additionally, we found that Thrombospondin-1 (Thsb1) was up-regulated ~3-fold in residual tumor
cells in both the HER2/neu and Wnt1 models (p-values <0.01). Thsb1 has been implicated in
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promoting dormancy of isolated breast cancer cells unable to form metastases upon seeding
metastatic sites in xenograft models [137], however data supporting a role in dormant residual
disease that survives therapy and gives rise to recurrence has not been reported.
Our finding – that molecular mechanisms mediating dormancy in disparate models intended to
replicate the conditions of isolated DTCs might contribute to dormancy of residual tumor cells that
survive therapy and give rise to recurrent tumors – suggested that quiescent tumor cells may
possess similar molecular features in multiple biological contexts. In support of this possibility, we
found that a dormancy gene expression signature, derived from a p38-induced in vitro dormancy
model in combination with an in vivo angiogenic dormancy model [139], was significantly upregulated in dormant residual tumor cells compared to all other cell types (Figure 3.16F).
Together, these findings reveal that dormant tumor cells surviving oncogenic pathway inhibition
exhibit molecular features analogous to those observed in disparate models of dormant tumor
cells. This suggests that the molecular mechanisms regulating dormancy may be conserved
across dormant tumor cells derived from distinct cancer types and driven by distinct oncogenic
pathways, and in differing biological contexts.
No culture models fail to recapitulate gene expression or genomic alterations of intact
tumors
We next wanted to extend our findings to a model that had been minimally manipulated in vitro,
so generated no culture orthotopic tumors in nu/nu mice using MTB/TAN/TTC/rYFP donors’
primary tumors. Prior to extending our gene expression analysis findings to this model, we
wanted to determine whether these orthotopic tumors faithfully recapitulated their quadtransgenic
donor tumors. For mutational analysis, we performed both array comparative genomic
hybridization (aCGH) to analyze copy number alterations and deletions, and whole exome
sequencing to identify non-synonymous mutations. To analyze gene expression, as we had done
before for the H2B-eGFP-labeled HER2/neu-Prim1 and Wnt1-Prim1 models, we sorted out
YFP+DAPI-CD45- tumor cells from the primary intact donor tumor and from the resulting primary
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orthotopic tumors, and performed gene expression analysis with RNA-Seq on the FACS-isolated
tumor cells.
Surprisingly, although tumors from intact mice had been injected orthotopically into nu/nu mice,
including both tumor and stromal cells that had never been cultured in vitro, there were significant
and reproducible differences between the no culture orthotopic tumors and the primary intact
donor tumors from which they arose. aCGH analysis revealed that orthotopic no culture tumors
had up to several thousand-fold more copy number gains, but up to several-hundred fold fewer
copy number loses (Table 3.4). Several copy number gains that were exclusively detected in
orthotopic primary tumors were identified across all of the orthotopic tumors, independent of the
donor tumor, but were not identified in any of the donor tumors (Figure 3.18A). Mutational
profiling revealed a loss of non-synonymous mutations in the majority of orthotopic tumors arising
from 2 of the 3 donor tumors, and a maintenance of the same number of mutations in orthotopic
tumors from a third donor (Figure 3.18B). Unsupervised hierarchical clustering of these
mutations revealed that the intact tumors clustered together along with 4 of the 9 orthotopic
tumors, but that the remaining 5 orthotopic tumors with few mutations clustered separately
(Figure 3.18C). PCA of gene expression analysis on FACS-isolated tumor cells revealed that
intact donor tumors clustered together well, however they did not cluster with orthotopic tumors,
and orthotopic tumors clustered together with other tumors from the same donor, but not across
donors (Figure 3.18D). Gene expression pathway analysis of the pathways up-regulated and
down-regulated in orthotopic tumors compared to primary tumors (Figure 3.18E) revealed that
several pathways were repeatedly up-regulated in orthotopic tumors compared to intact tumors,
including pathways associated with proliferation, Met, Myc, and TGF-β (Figure 13.8F).
Together these data reveal the surprising result that orthotopic tumors generated by injecting
whole tumor digest directly from a donor tumor into a nu/nu mouse recipient do not recapitulate
the mutational or gene expression profiles of their donor tumors. It seems unlikely that these
mutations were newly acquired in the time between digestion of the primary tumor and growth of
the resulting orthotopic tumors. Thus, a plausible explanation for these findings is the existence
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of subclones that are well-suited for growth in the orthotopic model. One possible explanation for
the recurrent copy number gains and losses is that these alterations promote tumor cell growth in
an orthotopic setting by augmenting growth related pathways that are recurrently up-regulated,
including Myc and Met. These may be present in orthotopic tumors and absent from intact
tumors because of the particular barriers that need to be overcome for a tumor cell to grown
during orthotopic injection, such as surviving digestion into a single cell suspension and surviving
the host immune response to orthotopic injection. Given that an analogous strategy – injecting
whole tumors from patients into immunocompromised mice - is used to generate PDX mouse
models, these results warrant caution in interpreting results found from PDX models, and suggest
that further study is necessary to better characterize PDX systems.
Gene expression profiling in the no culture orthotopic model
We next performed gene expression profiling on FACS-isolated tumor cells from primary,
residual, and recurrent tumors in order to determine whether results in this model would
recapitulate what we had seen in the HER2/neu-Prim1 and Wnt1-Prim1 models.
First we wanted to determine whether recurrent tumors in this model displayed a mesenchymal
phenotype, as was the case for intact tumors and orthotopic HER2/neu-Prim1 tumors. We
analyzed the phenotype of recurrent tumors in nu/nu mice injected orthotopically with
MTB/TAN/TTC/rYFP tumor cells that had not been cultured in vitro. While practically all recurrent
tumors in intact MTB/TAN mice display a mesenchymal phenotype, a subset of recurrent tumors
in the no culture orthotopic system displayed an epithelial phenotype as identified by IF (Figure
3.19A-C). These epithelial recurrent tumors appear to have reactivated the HER2/neu oncogene,
as they display staining for HER2 by IF, and also express greater than 500,000-fold more
luciferase activity than other recurrent tumors of the same size (Figure 3.19B, D). Thus, all
recurrent tumors in subsequent analyses were first determined to have a mesenchymal
phenotype prior to analysis.
For each of 8 donor tumors arising in MTB/TAN/TTC/rYFP mice, tumor cells from primary
doxycycline-dependent tumors were injected orthotopically and bilaterally into 20 nu/nu mice on
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doxycycline. All 320 injected sites developed primary tumors. 4 nu/nu mice with orthotopic
primary tumors arising from each of the 8 donor tumors were sacrificed, tumors were
enzymatically digested, and RNA was acquired from FACS-isolated primary tumor cells. The
remaining 16 mice from each cohort were deinduced. For each cohort, 6 mice were sacrificed
with residual lesions 28 days after doxycycline withdrawal, and all 12 residual lesions were
digested and tumor cells were FACS-isolated for RNA. Over 80% of residual lesions did not yield
a sufficient number of tumor cells necessary to perform WTA and gene expression profiling. Of
the remaining 20 tumors (on 10 mice) in each cohort, only 4 cohorts developed at least 3
recurrent tumors with a mesenchymal phenotype. Recurrent tumor cells were FACS-isolated
from all recurrent tumors that arose in these mice. From 8 donors, only 1 series of orthotopic
primary, residual, and recurrent tumors had at least 3 residual lesion samples with >618 tumor
cells, and at least 3 mesenchymal recurrent tumors.
Pathway analysis of FACS-isolated tumor cells revealed that, consistent with our observations in
the HER2/neu-Prim1 and Wnt1-Prim1 models, mTOR pathway activity was significantly
decreased in dormant tumor cells, whereas residual tumor cells also exhibited a high dormancy
score (Figure 3.20). Also in line with our observations in the previously analyzed models, DAVID
analysis of differentially expressed genes revealed up-regulation of genes associated with
disulfide bonds, secreted and signal pathways, and down-regulation gene families associated
with proliferation (Table 3.5). Interestingly, extracellular matrix gene groups were not upregulated in this model, and residual tumor cells did not display enrichment for an EMT signature
(Table 3.5). Consistent with our expectation that Dec2 plays a critical role in dormant tumor cells,
we found that it was the most up-regulated transcription factor in dormant tumor cells compared
to primary and recurrent tumor cells.
These findings further corroborate several of our earlier observations in the HER2/neu-Prim1 and
Wnt1-Prim1 models, in particular the down-regulation of biosynthetic activity in dormant tumor
cells, and the possibility that Dec2 plays a key role in regulating dormant residual tumor cells that
survive oncogenic pathway inhibition.
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Dormant residual HER2/neu tumor cells exhibit a mesenchymal phenotype
While residual disease in the setting of neoadjuvant chemotherapy or hormonal therapy in
patients has been reported to be enriched for a mesenchymal phenotype [37], whether residual
tumor cells are enriched for a mesenchymal phenotype following oncogene pathway inhibition is
unknown. To address this, we investigated the expression of transcripts encoding epithelial and
mesenchymal proteins in FACS-isolated tumor cells. Transcripts associated with a mesenchymal
phenotype, including Cdh2 (N-Cadherin), were up-regulated in residual HER2/neu tumor cells
compared to primary tumor cells, whereas transcripts associated with an epithelial phenotype,
including Epcam, and Krt8 (Cytokeratin 8) were down-regulated in residual tumor cells (Figure
3.21A). In contrast, residual tumor cells in the Wnt1 model did not up-regulate the mesenchymal
marker Cdh2, but did up-regulate the epithelial markers Epcam and Cdh1 (E-Cadherin), as well
as the myoepithelial marker Krt14 (CK14) (Figure 3.21B). Consistent with their expression in
both myoepithelial and mesenchymal cells, Pdgrfb and Acta2 were also up-regulated in both
HER2/neu and Wnt1 residual disease (Figure 3.21). Together, these data suggest that dormant
residual disease in the HER2/neu model may be enriched for tumor cells that have undergone
EMT, whereas dormant residual disease in the Wnt1 model may be enriched for tumor cells with
a myoepithelial phenotype.
To directly address the mesenchymal versus epithelial phenotype of residual disease in the
HER2/neu and Wnt1 models, we generated primary tumors and MRLs from H2B-eGFP labeled
HER2/neu-Prim1 and Wnt1-Prim1 tumor cells. Sections of primary tumors and MRLs were
stained for the luminal epithelial marker CK8 as well as the myoepithelial marker CK14. As
anticipated, primary tumor cells in both the HER2/neu and Wnt1 models expressed the epithelial
marker CK8, and a subset of tumor cells in the Wnt1 tumor expressed the myoepithelial marker
CK14 (Figure 3.22A, B). In contrast, residual HER2/neu tumor cells lost expression of epithelial
marker CK8, whereas residual Wnt1 tumor cells expressed CK8 and CK14 (Figure 3.22A, B).
To determine whether residual tumor cells might display a mesenchymal phenotype, we
performed IF for the mesenchymal markers PDGFR-β and S100A4 (fibroblast-specific protein-1).
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Residual HER2/neu-Prim1 tumor cells expressed both PDGFR-β (Figure 3.22D) and FSP-1
(Figure 3.23). Tumor cells in the residual lesion that expressed either the mesenchymal marker
S100A4 or the epithelial marker CD24 were admixed throughout the residual lesion (Figure 3.23).
To confirm the mesenchymal phenotype of HER2/neu residual tumor cells, we performed IF using
a pan-cytokeratin antibody as well as 7 additional epithelial markers, including CK5, CK18, CK19,
EpCAM, E-Cadherin, P-Cadherin, and p63. Whereas expression of each of these epithelial
markers was detectable in normal mammary ducts, their expression was undetectable in the vast
majority of residual HER2/neu tumor cells (Figure 3.22E-T). These data confirm that residual
HER2/neu tumor cells have undergone EMT and generally lack expression of epithelial-specific
markers.
The presence of tumor cells within HER2/neu residual neoplastic lesions that exhibit some
features of EMT raised the possibility that a pre-existing population of mesenchymal-like tumor
cells within HER2/neu primary tumors might be enriched in residual disease following oncogene
down-regulation. To address this possibility, we performed multicolor flow cytometry on orthotopic
H2B-eGFP-labeled HER2/neu-Prim1 primary tumors and MRLs to evaluate expression of the
epithelial marker CD24 in combination with either PDGFR-β or CD49e as markers of the
mesenchymal-like phenotype. Flow cytometry identified rare populations of CD24–PDGFR-β+
and CD24–CD49e+ primary tumor cells that were dramatically enriched in MRLs following
HER2/neu down-regulation (Figure 3.24A-D). We were also able to identify epithelial and
mesenchymal populations in HER2/neu-Prim1 tumor cells in vitro (Figure 3.24E), indicating that
mesenchymal tumor cells in orthotopic tumors may arise either through EMT in vivo, or from this
pre-existing population of mesenchymal tumor cells present in vitro.
Together, these findings demonstrate that HER2/neu-induced primary tumor cells are
predominantly epithelial, but contain a small population of mesenchymal-like tumor cells that is
dramatically enriched among those tumor cells that survive HER2/neu down-regulation and
persist in MRLs in a dormant state. In contrast, both primary and residual tumor cells from Wnt1induced tumors express epithelial markers characteristic of luminal and myoepithelial cells.
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We wanted to determine whether residual tumor cells in intact quadtransgenic
MTB/TAN/TTC/rYFP mice also exhibited EMT. IF staining for CK5 and CK8 revealed cytokeratinnegative, spindle-shaped tumor cells (Figure 3.25). Flow cytometry on intact residual tumor cells
revealed a large population of YFP+CD45-DAPI- tumor cells that were EpCAM-CD24PDGFRβ+CD49e+, consistent with a mesenchymal phenotype (Figure 3.26B-D).
Finally, we wanted to know whether residual tumor cells at metastatic sites also exhibited EMT in
the HER2/neu model following doxycycline withdrawal. IF of tissue sections from residual
metastases-bearing lungs in nu/nu mice with no culture orthotopic MTB/TAN/TTC/rYFP tumors
revealed that residual tumor cells at metastatic sites had lost expression of CK8 and acquired
expression of vimentin, consistent with an EMT phenotype, analogous to our observations for
local residual disease (data not shown).
Mesenchymal tumor cell markers CD49e and PDGFR-β are markers of poor recurrencefree survival in HER2+ breast cancer
As tumor cells with mesenchymal features have been associated with treatment resistance and
disease progression, we reasoned that elevated expression of CD49e and/or PDGFR-β in HER2+
breast cancers might be associated with an increased risk of relapse in breast cancer patients.
First, we asked whether residual human breast cancer showed down-regulation of the epithelial
marker EpCAM and up-regulation of the mesenchymal marker CD49e. We found that EpCAM
was significantly down-regulated, while CD49e was significantly up-regulated in residual disease
(Figure 3.27A). Also, decreased EpCAM was correlated with increased CD49e expression in
these samples (Figure 3.27B), consistent with an enrichment for mesenchymal disease following
therapy. To test whether enrichment for mesenchymal markers was prognostic for poor RFS, we
performed a multivariate meta-analysis across 14 publicly available clinical data sets containing
information on HER2 status, gene expression data, clinical outcomes, tumor grade, and tumor
size. 10-year RFS analysis was performed as a continuous function of the levels of expression of
the mesenchymal markers (CD49e and PDGFR-β) and epithelial markers (EpCAM and CD24)
that were previously used to identify epithelial and mesenchymal tumor cells by flow cytometry in
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MTB;TetO-HER2/neu;TTC;rYFP mice.
Multivariate Cox hazard ratio analysis was performed on HER2+ breast cancers and was
adjusted for tumor grade and tumor size. For patients with HER2+ breast cancer, expression of
each of the mesenchymal markers CD49e and PDGFR-β was associated with a higher
probability of recurrence in both 10-year RFS analyses, whereas neither EpCAM nor CD24 was
associated with RFS after 10 years of follow-up (Figure 3.27C-F).
These results indicate that expression of PDGFR-β and CD49e are independent indicators for
decreased RFS in patients with HER2+ breast cancer and, when taken together with our findings
in mice, raise the possibility that this association may reflect the presence of mesenchymal-like
tumor cells that are resistant to treatment.
Dormant residual tumor cells express a mammary stem cell signature
Tumor cells that undergo EMT may acquire properties of normal mammary stem cells in some
models [140]. Therefore, we evaluated whether residual tumor cells that survive oncogene downregulation exhibit a gene expression profile similar to that of normal mammary stem cells.
Indeed, in both Wnt1-Prim1 and HER2/neu-Prim1 models, genes reported to be enriched in
human mammary stem cells were significantly up-regulated in dormant residual tumor cells
compared to all other tumor cell types (Figure 3.28A, B, p-value HER2/neu: 2.7E-24, p-value
Wnt1: 1.3E-14) [141]. Consistent with this, the normal human mammary stem cell marker CD10
[142] was up-regulated nearly 25-fold in HER2/neu residual tumor cells, and ~7-fold in Wnt1
residual tumor cells, compared to all other FACS-isolated tumor cells (Data not shown).
As stem-like properties of TICs may be distinct from those of normal mammary stem cells, we
also investigated the expression of genes associated with neoplastic human mammary stem-like
cells [143, 144]. Expression analysis revealed that residual tumor cells in both HER2/neu and
Wnt1 models were enriched for genes up-regulated in tumorigenic breast cancer stem-like cells
(Figure 3.28C, D, p-value HER2/neu: 0.001, p-value Wnt1: 4.7E-21) [145]. Additionally, the
putative breast cancer stem cell marker Aldh1a3 was up-regulated in residual tumor cells in both
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the HER2/neu (~2-fold (FDR<0.05) and Wnt1 models (~5-fold (FDR<10-6) [146] (data not shown).
Collectively, these findings indicate that dormant tumor cells that survive HER2/neu or Wnt1
down-regulation exhibit a gene expression profile with similarities to normal mammary stem cells
as well as tumorigenic breast cancer cells.
Residual Wnt1 tumor cells are enriched for cells with normal mammary stem cell
properties
Our previous observations led us to propose that residual tumor cells may have properties of
normal mammary stem cells, such as the ability to give rise to a mammary tree. Consistent with
this possibility, we observed YFP+ structures with mammary duct morphology growing out of
MTB/TWNT/TTC/rYFP no culture orthotopic residual lesions, in many residual lesions less than
10 weeks after doxycycline withdrawal (Figure 3.29A). These structures were not observed in
over 30 MTB/TAN/TTC/rYFP residual lesions more than 32 weeks after deinduction (Figure
3.29B). A key feature of normal mammary stem cells is their ability to reconstitute a mammary
ductal tree when injected into a mammary fat pad that has been cleared of epithelial cells. To
determine whether residual tumor cells were enriched for cells with normal mammary stem cell
properties, we injected 1,000 tumor cells from either primary tumors or residual lesions into
cleared mammary fat pads in syngeneic TAN/TTC/rYFP mice. After 2 months, more than half of
the sites injected with residual lesion tumor cells formed mammary epithelial ductal trees,
whereas only 2 of 12 sites formed ductal trees when injected with tumor cells from a primary
tumor (Figure 3.29 C-D).
Residual HER2/neu tumor cells are not enriched for primary TICs
Our observations that residual tumor cells are capable of giving rise to recurrent tumors, possess
mesenchymal features, and are enriched for transcripts associated with normal mammary stem
cells as well as tumorigenic breast cancer cells, suggested the possibility that residual tumor cells
might be functionally enriched for TICs. To test this hypothesis in a model with minimal ex vivo
manipulation, we used MTB;TetO-HER2/neu;TTC;rYFP mice to isolate fluorescently labeled
tumor cells in autochthonous tumors that had not been cultured in vitro.
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To validate this model, we first addressed whether residual tumor cells in MTB;TetOHER2/neu;TTC;rYFP mice were enriched for mesenchymal tumor cells compared to primary
tumor cells, as we had observed in HER2/neu-Prim1 orthotopic tumors. Indeed, primary tumor
cells in MTB;TetO-HER2/neu;TTC;rYFP mice were predominantly CD24+EpCAM+Cd49ePDGFRβ- (7.4-fold enrichment vs. residual lesion, p-value <0.001), demonstrating an epithelial
phenotype, whereas residual tumor cells were predominantly CD24-EpCAM-CD49e+PDGFRβ+
(3-fold enrichment vs. primary tumor, p-value <0.001), reflecting a mesenchymal phenotype
(Figure 3.26B-E). These findings indicate that residual lesions derived from primary tumors
arising in MTB;TetO-HER2/neu;TTC;rYFP mice, as well as residual lesions derived from
HER2/neu-Prim1 orthotopic tumors tumor cells, are enriched for tumor cells with mesenchymallike properties.
Next, we asked whether residual tumor cells are functionally enriched for TICs by performing
limiting dilution experiments on YFP+CD45-DAPI- tumor cells isolated from primary tumors (n=3)
or residual lesions (n=3) arising in MTB;TetO-HER2/neu;TTC;rYFP mice. Isolated viable tumor
cells were injected into the mammary fat pads of nu/nu mice on doxycycline, and mice were
monitored for 4 months for tumor development. TIC frequency was calculated based upon the
fraction of mice that developed tumors when injected with a given number of tumor cells [147].
Whereas injection of 50,000 tumor cells from each of the 3 primary tumors tested resulted in
tumor formation at 100% of injected sites, injection of an equivalent number of tumor cells
isolated from 2 of the 3 residual lesions tested failed to give rise to any tumors at any of the 8
sites injected after 4 months (Table 3.6). The remaining residual lesion exhibited a TIC frequency
similar to that observed for one of the primary tumors. These findings raise the possibility that
residual tumor cells may not be enriched for TICs compared to primary tumor cells.
The extremely wide range of TIC frequencies observed among primary tumors, and among
residual lesions, suggested that factors such as somatic genetic heterogeneity between tumors
might influence TIC frequency. To control for this possibility, we generated matched pairs of
syngeneic orthotopic primary tumors and residual lesions by orthotopically injecting tumor cells
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from doxycycline-dependent primary tumors arising in MTB;TetO-HER2/neu;TTC;rYFP mice into
nu/nu mice on doxycycline. We then withdrew doxycycline from a cohort of mice bearing primary
tumors to generate syngeneic orthotopic residual lesions from the same donor tumor.
Using these syngeneic pairs of orthotopic primary tumors and residual lesions, we performed
limiting dilution experiments to quantify the TIC frequency in primary tumors and residual lesions
generated from the same intact donor tumor. As before, while substantial variation was observed
in TIC frequencies for different primary tumors, in no case were TICs enriched in tumor cells
isolated from residual lesions compared to tumor cells isolated from the corresponding syngeneic
primary tumor (Table 3.7). Specifically, for the two donor primary tumors analyzed, the TIC
frequencies of primary tumor cells were ~18-fold and 1,000-fold higher than the TIC frequencies
in residual tumor cells from the same donor tumor, and these results were statistically significant.
As HER2/neu residual lesions were enriched for mesenchymal tumor cells compared to primary
tumors, we considered the possibility that mesenchymal tumor cells within residual lesions might
not be enriched for TICs, but that residual epithelial tumor cells – which constitute only a minority
of tumor cells in residual lesions – might exhibit an increased TIC frequency. To address this
possibility, we isolated epithelial (EpCAM+CD49e-) tumor cells from an intact MTB;TetOHER2/neu;TTC;rYFP primary tumor and residual lesion, and performed limiting dilution
experiments to measure the TIC frequency of epithelial tumor cells from primary tumors and
residual lesions.
Consistent with our observations above quantifying TIC frequency in HER2/neu primary tumors
and residual lesions, we found that epithelial tumor cells from residual lesions were not enriched
for TICs compared to epithelial tumor cells from primary tumors (Table 3.8). These findings
suggest that the failure to observe TIC enrichment among residual tumor cells is not a
consequence of changes in the epithelial vs. mesenchymal composition of primary tumors
compared to residual lesions.
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When taken together, our observations indicate that residual tumor cells that survive HER2/neu
down-regulation in HER2/neu-induced mammary tumors are not enriched for TICs compared to
primary tumor cells.
Residual Wnt1 tumor cells are not enriched for primary TICs
We next asked whether the observation that HER2/neu residual tumor cells are not enriched for
TICs would also be true for Wnt1-induced mammary tumors using an analogous approach in
MTB;TetO-Wnt1;TTC;rYFP mice. As CD24+Thy1+ mammary tumor cells from MMTV-Wnt1 mice
have previously been reported to possess TIC properties, we first performed a limiting dilution
experiment to ask whether CD24+Thy1+ tumor cells in Wnt1-driven primary tumors were
enriched for TICs compared to non-CD24+Thy1+ tumor cell populations [148, 149]. Consistent
with prior reports, we found that CD24+Thy1+ tumor cells were enriched ~10-fold for TICs
compared to non- CD24+Thy1+ tumor cell subsets (Figure 3.26F).
To assess whether residual Wnt1 tumor cells were enriched for TICs, we next determined
whether residual tumor cells that had survived Wnt1 pathway down-regulation were enriched for
CD24+Thy1+ tumor cells compared to primary tumor cells. Flow cytometry performed on primary
tumors and residual lesions from MTB;TetO-Wnt1;TTC;rYFP mice revealed that tumor cells within
residual lesions were enriched ~8-fold for CD24+Thy1+ tumor cells compared to primary tumors
(Figure 3.26G-H, p-value = 0.002). Indeed, whereas <5% of primary tumor cells were
CD24+Thy1+, ~40% of residual tumors cells exhibited a CD24+Thy1+ phenotype.
The above results suggested that residual tumor cells surviving oncogenic pathway inhibition in
MTB;TetO-Wnt1;TTC;rYFP mice are enriched for cells with a cell surface phenotype that has
been associated with TICs in primary tumors. However, these experiments did not address
whether residual tumor cells are, in fact, functionally enriched for TICs. To address this question,
we performed limiting dilution studies using sorted YFP+CD45-DAPI-tumor cells isolated from
primary tumors and residual lesions arising in MTB;TetO-Wnt1;TTC;rYFP mice. Contrary to
expectations based upon enrichment for CD24+Thy1+ cells in residual lesions, we observed a 4fold decrease in TIC frequency in residual tumor cells compared to primary tumor cells (Table
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3.9). Thus, despite our observations that CD24+Thy1+ primary tumor cells are enriched 10-fold
for TICs compared to non-CD24+Thy1+ tumor cells, and that CD24+Thy1+ tumor cells are
enriched 8-fold in residual lesions compared to primary tumors, we did not observe functional
enrichment for TICs in Wnt1 residual disease.
While this result was consistent with our observation that residual HER2/neu tumor cells are not
enriched for TICs, we wished to extend these findings by addressing the possibility that genetic
heterogeneity among tumors might result in differing TIC frequencies for different donor tumors.
Accordingly, we generated syngeneic pairs of orthotopic primary tumors and residual lesions in
nu/nu mice from individual tumors arising in MTB;TetO-Wnt1;TTC;rYFP mice using an approach
analogous to that performed above for MTB;TetO-HER2/neu;TTC;rYFP mice. Limiting dilution
studies were then performed using YFP+CD45-DAPI- tumor cells isolated from syngeneic
orthotopic primary tumors or residual lesions. This analysis revealed that, for each of the donor
tumors tested, residual Wnt1 tumor cells exhibited ~ 7- to 11-fold lower TIC frequencies
compared to primary tumor cells (Table 3.10). These findings further support the conclusion that
residual tumor cells are not enriched for TICs relative to primary tumor cells in Wnt1-induced
mammary tumors, and are consistent with the lack of enrichment for TICs that we observed in
residual tumor cells in HER2/neu-induced mammary tumors.
In aggregate, our data using tumor cells isolated directly from intact mice, or from syngeneic pairs
of orthotopic primary tumors and residual lesions, suggest that residual tumor cells are not
enriched for TICs in either the HER2/neu or Wnt1-induced tumor models.
Residual disease may be enriched for recurrent tumor TICs
Despite our finding that residual tumor cells do not appear to be enriched for TICs compared to
primary tumor cells in the setting of oncogene activation (i.e. when injected into nu/nu mice
maintained on doxycycline), we considered the possibility that residual tumor cells might be
enriched for TICs in the setting of oncogene inactivation. If true, this would be consistent with our
observation that – when maintained off doxycycline for long periods of time – mice bearing fully
regressed HER2/neu or Wnt1 mammary tumors eventually develop spontaneous tumor
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recurrences that do not express the initiating oncogene (e.g. HER2/neu or Wnt1) [108, 121].
That is, assays for TICs performed in the presence of oncogene activation may detect TICs
capable of forming primary tumors, whereas assays for TICs performed in the absence of
oncogene activation may detect TICs capable of forming recurrent tumors. In this regard,
enrichment for cells in primary tumors capable of giving rise to recurrent tumors (i.e. recurrent
tumor TICs) might occur during primary tumor regression induced by doxycycline withdrawal by
virtue of the apoptotic elimination of primary tumor cells that could not survive oncogenic pathway
down-regulation.
To address this question, we generated orthotopic primary tumors from H2B-eGFP HER2/neuPrim1 tumor cells and isolated primary tumor cells from tumor-bearing mice on doxycycline, as
well as residual tumor cells from mice bearing fully regressed tumors maintained off doxycycline.
Each set of primary or residual tumor cells was injected into cohorts of nu/nu mice that were
maintained either on or off doxycycline.
Consistent with our observations in intact MTB;TetO-HER2/neu;TTC;rYFP mice, we did not
observe enrichment for TICs among residual tumor cells when injected into mice on doxycycline.
In contrast, when injected into nu/nu mice not on doxycycline, we observed a ~7-fold increase in
TIC frequency among residual tumor cells compared to primary tumor cells (Table 3.11). These
findings raise the intriguing possibility that TICs for primary tumors and recurrent tumors may be
distinct and that HER2/neu down-regulation results in enrichment for recurrent tumor TICs, but
not primary tumor TICs.
Residual lesion expression of proteins for transcripts up-regulated in residual disease
Identification of dormant tumor cells in humans is challenging in large part due to the lack of
positive markers for dormancy. Given our observation that particular transcripts were repeatedly
up-regulated in residual tumor cells compared to primary and recurrent tumor cells, we wanted to
know whether these might serve as markers of dormancy tumor cells. The majority of proteins
whose transcripts were up-regulated in residual disease showed expression in both normal
mammary epithelial cells and residual lesion cells (Figure 3.30A). Dec2 was expressed at
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various levels in tumor cells in primary tumors, and showed slight enrichment in nuclei (Figure
3.30B, left). In contrast, Dec2 was expressed at high levels in the nucleus of residual lesion
tumor cells, consistent with a role for Dec2 in transcriptional regulation of dormant residual tumor
cells (Figure 3.30B, left). These findings suggest that nuclear expression of Dec2 may serve as a
protein marker for dormant tumor cells in clinical samples.
Discussion
Defining the biology of MRD is an important, but elusive, goal with important implications for the
prevention and treatment of recurrent cancers. Using genetically engineered mouse models for
human breast cancer driven by two different oncogenic pathways, we report in vivo evidence that
tumor cells surviving targeted therapy exhibit cellular dormancy following oncogenic pathway.
Residual tumor cells exhibit reversible cell cycle arrest following oncogenic pathway inhibition
despite the presence of a robust and functional vasculature, irrespective of the presence or
absence of an adaptive immune system, and without exhibiting signs of senescence. Consistent
with this, gene expression profiling of residual tumor cells isolated in vivo following oncogenic
pathway inhibition revealed clear evidence of cellular quiescence. In an analogous manner, we
found evidence for cellular dormancy in mice bearing xenografted human breast cancer cells
treated with targeted therapies, and in mice bearing residual metastatic disease following
oncogenic pathway inhibition – novel observations of particular clinical interest given that distant
recurrence is the primary cause of mortality among breast cancer patients. In aggregate, we
conclude that residual tumors cells that survive targeted down-regulation of a dominant
oncogenic pathway exist in a state of cellular dormancy, and that recurrent tumor outgrowth in
this context is limited neither by angiogenic insufficiency nor by the immune system.
In providing the first expression profiling analysis of purified residual tumor cells and along with
matched primary and recurrent tumor cells, one of the most important findings of the present
study is its clear demonstration that residual tumor cells represent a distinct tumor cell state that
has little resemblance to actively growing primary or recurrent tumors. This has significant
implications for both the detection and treatment of residual disease. Given the unique
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phenotype of residual tumor cells, it seems likely that phenotypic markers specific to primary or
recurrent tumor cells may fail to detect some – or perhaps even many –residual tumor cells. In
an analogous manner, therapeutic approaches predicated on the increased proliferative or
metabolic activity commonly associated with actively growing tumor cells may fail to impact the
long-term survival or regrowth of residual tumor cells that are quiescent. These findings extend in
vitro findings that residual tumor cells express a unique phenotype [150], and further indicate a
need for strategies to more effectively detect and target residual disease.
Notably, dormant residual tumor cells in both the Wnt1 and HER2/neu models were enriched for
expression signatures associated with normal, as well as neoplastic, mammary stem-like cells.
Residual tumor cells in each of these models were also enriched for phenotypes reported to be
associated with TICs – EMT in the case of HER2/neu, and a CD24+Thy1+ cell surface phenotype
in the case of Wnt1. Despite these suggestive phenotypic traits, however, functional studies
revealed that residual tumor cells were not enriched for primary tumor TICs, whether isolated
directly from transgenic mice or from mice bearing syngeneically paired orthotopic primary tumors
and residual disease. These findings suggest that the phenotypes of TICs may differ in primary
tumors and MRD, and imply that caution may be indicated in attempting to infer functional
properties of residual tumor cells based upon cell surface phenotypes defined in TICs in primary
tumors.
Although residual tumor cells failed to show enrichment for TICs relative to primary tumor cells in
the setting of oncogene activation, tumor cells isolated from residual lesions were enriched for
TICs capable of giving rise to recurrent tumors in the setting of oncogene inhibition. This
intriguing finding suggests that the evolution of tumors, from primary to recurrent, may be driven
by distinct TIC populations. The possibility that different TIC populations support primary versus
recurrent tumor growth is supported by our prior findings that recurrent tumors in MTB;TetOHER2/neu mice exhibit a phenotype distinct from primary tumors [108]. This, in turn, is consistent
with clinical reports indicating that recurrent tumors may exhibit a phenotype distinct from primary
tumors [37, 123, 124]. In aggregate, our data suggest that the underlying basis for this
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phenotypic shift may result from a change in the TIC populations driving primary versus recurrent
tumor growth.
Interestingly, while residual disease in both HER2/neu and Wnt1 mouse models exhibited a gene
expression profile enriched for features of normal and neoplastic human mammary stem-like
cells, we only observed enrichment for tumor cells with an EMT phenotype in HER2/neu residual
disease, and not in Wnt1 residual disease, despite the association between EMT and stem-like
cells reported in some contexts [140]. While some clinical reports indicate that residual disease
may be enriched for tumor cells with a mesenchymal phenotype [37], observations in circulating
tumor cells suggest that residual tumor cells with an epithelial phenotype disease may be
enriched in certain therapeutic settings [38]. Consequently, our findings that HER2/neu residual
disease is enriched for cells exhibiting EMT, whereas Wnt1 residual disease is not, and that
neither HER2/neu nor Wnt1 residual disease is enriched for primary tumor TICs, suggests that
the properties of TICs, mammary stem cells and EMT may not be tightly linked or, at the very
least, are likely to be context-dependent.
Despite the dramatic differences between the HER2/neu and Wnt1 oncogenic pathways, and
between the cellular phenotype of tumors driven by each of these oncogenes [121, 127], residual
tumor cells in both models exhibited a prolonged, but reversible, cell cycle arrest following
oncogenic pathway inhibition. Indeed, in each model greater than 90% of primary tumor cells –
but fewer than 10% of residual tumors cells – entered S-phase over a two-week period.
Nevertheless, upon oncogene reactivation for as little as 72 h, residual tumor cells in each model
re-entered the cell cycle and entered S-phase at rates comparable to primary tumor cells. While
prior reports have demonstrated the presence of residual tumor cells that are non-proliferative
following oncogenic pathway inhibition, neither senescence nor angiogenic insufficiency have
been addressed as contributing factors. This, coupled with the absence of a lineage tracing
fluorescent marker to unambiguously label residual tumor cells, as well as the fact that tumors do
not recur in these models, has hampered definitive identification of the characteristics of residual
disease and the determination of whether cellular dormancy is a significant contributing factor to
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preventing tumor outgrowth [92, 93]. Nonetheless, the identification of non-proliferative residual
disease following oncogenic pathway inhibition in Myc-driven pancreatic cancers and in
Hedgehog-driven basal cell carcinomas highlights the possibility that dormancy is a conserved
response to targeted therapy independent of the oncogene or cell of origin.
Remarkably, despite the fact that prior studies investigating dormancy have been conducted in
disparate experimental models, including chicken chorioallantoic membrane assays and in vitro
cell culture, we find strong evidence for similarities between these previously identified pathways
and gene expression signatures and properties of dormant tumor cells that we have identified in
two separate genetically engineered mouse models for dormant residual disease capable of
giving rise to recurrent tumors. Indeed, the remarkable similarities between the gene expression
profiles of residual tumor cells from HER2/neu and Wnt1 mammary tumors, coupled with
significant overlap in dormancy-related gene expression profiles between these models and
previously described models of X and Y cancers, raises the intriguing possibility that dormancy
may be regulated by similar molecular mechanisms independent of the driving oncogene or
cancer type.
Importantly, though dormant disseminated tumor cells are often assumed to be the source from
which recurrent tumors arise, little preclinical or clinical evidence exists demonstrating a
precursor-product relationship between dormant isolated tumor cells and recurrence. In this
regard, it is possible that dormant MRD in the bone marrow is correlated with systemic disease
burden, but that these cells themselves do not give rise to recurrent tumors. In contrast, the
efficacy of adjuvant chemotherapy in delaying recurrence demonstrates that subclinical
proliferative metastases may underlie disease recurrence in some patients. As such, our
observation that primary tumor cells that survive oncogenic pathway inhibition exist in a dormant
state prior to recurrence provides new evidence that dormancy is a potential therapeutic target
with direct relevance to preventing tumor recurrence.
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Remarkable similarities in findings from Wnt1 and HER2 models and its implications for
generalizability
While inter-tumor heterogeneity, due to a plethora of oncogenic drivers within and across tissue
types, represents a major obstacle for cancer treatment, the remarkable similarity between gene
expression profiles of residual disease in the HER2/neu and Wnt1 models suggests that
therapeutic strategies useful for targeting dormant residual disease in tumors driven by one
oncogene may apply to dormant residual disease in tumors driven by other oncogenes.
Strikingly, in spite of our observation of EMT in only one of two residual disease models, the top
10 clusters of down-regulated genes, and the top 3 clusters of up-regulated genes, ranked by
DAVID enrichment score for either HER2/neu or Wnt1 residual disease were also found in the top
clusters from the other genotype. Therapeutic strategies suitable for targeting dormant tumor
cells may therefore be more productively focused on pathways regulated similarly across models
driven by different oncogenes, or arising from different cells of origin. For example, strategies to
eliminate dormant residual tumor cells might target secreted proteins or extracellular matrix
components that are up-regulated in dormant disease, thereby potentially disrupting pro-survival
tumor cell-microenvironment interactions.
Together, our observations indicate that residual cancer cells exhibit a unique phenotype that may
underlie resistance to therapy, as well as provide insights into more effective therapeutic
strategies.
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Figure 3.1. Kinetics of Tumor Recurrence Suggest a Latent Phase

(A-D) Kaplan-Meier curves showing recurrence-free survival (RFS) for (A) MTB;TetO-HER2/neu
intact, (B) HER2/neu-Prim1 orthotopic, (C) MTB;TetO-Wnt1 intact, and (D) Wnt1-Prim1 orthotopic
models. (E) Recurrent tumor growth curves from MTB;TetO-HER2/neu orthotopic tumors with
different recurrence latencies. (F) Tumor growth curves following doxycycline re-administration to
intact MTB;TetO-HER2/neu mice that previously harbored primary tumors that had not
spontaneously recurred.
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Figure 3.2. Identification of Residual Tumor Cells Following Oncogenic Pathway Inhibition

(A, B) Carmine staining of mammary glands following oncogenic pathway inhibition in
bitransgenic (A) MTB;TetO-HER2/neu and (B) MTB;TetO-Wnt1 models. Lymph nodes are
designated with an asterisk (*). (C, D) Hematoxylin and eosin-stained sections of intact (C)
MTB;TetO-HER2/neu and (D) MTB;TetO-Wnt1 MRLs. (E, F) Hematoxylin and eosin-stained
sections (left) and fluorescence microscopy of H2B-eGFP-labeled tumor cells (right) in orthotopic
(E) HER2/neu-Prim1 and (F) Wnt1-Prim1 MRLs. Scale bars (A, B): 750μm, (C-F): 250μm.
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Figure 3.3. Systemic Metastases with Intracardiac Injection of HER2/neu-Prim1 Tumor
Cells

(A, B) Bioluminescence imaging of a nu/nu mouse following intarcardiac injection of HER2/neuPrim1 tumor cells either (A) on doxycycline continuously for 30 days following injection or (B) 12
days after doxycycline withdrawal. (C) Brightfield (left) and GFP fluorescence (right) imaging of
liver (top), brain (center) or lungs (bottom) of a nu/nu mouse on doxycycline sacrificed 30 days
after intracardiac injection of HER2/neu-Prim1 tumor cells. Scale bar (C): 750μm
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Figure 3.4. Systemic Metastases in Cre-driven YFP and tdTomato Fluorescent Reporter
Mice

(A) Brightfield (left) and YFP fluorescence (right) images of lungs from an MTB/TAN/TTC/rYFP
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mouse on doxycycline with lung metastases. (B) Brightfield (top) and tdTomato fluorescence
(bottom) images of liver (left) and lung (right) bearing residual metastases 28d after doxycycline
withdrawal. (C) Fluorescence microscopy image of Hoechst and tdTomato fluorescence in a
tissue section showing residual DTCs 28d after doxycycline withdrawal. Scale bar (A-B): 750μm,
(C): 100μm

64

Figure 3.5. Peripheral Blood Leukocytes in MTB/TAN/TTC/rYFP Model Express YFP

(A) Flow cytometry of unstained FSC-Ahi peripheral blood leukocytes from MTB/TAN (left),
TAN/TTC/rYFP (middle), or MTB/TAN/TTC/rYFP (right) mice that are either never induced (top) or
induced for more than 1 month (bottom). (B) Flow cytometry of FSC-Ahi peripheral blood
leukocytes from MTB/TAN/TTC/rYFP that were never induced and were stained for CD45 and
CD11b.
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Figure 3.6. CTCs and DTCs in Orthotopic HER2/neu-Prim1 Model

(A) Flow cytometry of unstained peripheral blood from non-tumor bearing nu/nu mouse (left) and
H2B-eGFP-labeled HER2/neu-Prim1 tumor bearing nu/nu mouse (right) for GFP vs FSC-A. (B)
Quantification of the number of GFP+ CTCs recovered from intracardiac puncture of tumor
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bearing or non-tumor bearing mice. (C-F) Fluorescence microscopy imaging of Hoechst and
GFP fluorescence in tissue sections showing GFP+ DTCs in mouse femurs femur (DTCs are at
arrows in panel F). (G) Quantification of the average number of ostensible CTCs recovered per
ml of blood across mice bearing H2B-eGFP-labeled HER2/neu-Prim1 primary tumors, residual
disease, or recurrent tumors.
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Figure 3.7. Residual Tumor Cells are Quiescent

(A) Immunofluorescence (IF) staining for Ki67 on sections from H2B-eGFP-labeled orthotopic
HER2/neu-Prim1 primary tumors (PT, left) and residual lesions (RL) 28 d (middle) or 56 d (right)
after HER2/neu de-induction. (B, C) IF staining for BrdU on sections from H2B-eGFP-labeled
HER2/neu-Prim1 (B) or Wnt1-Prim1 (C) orthotopic primary tumors (left) or MRLs 28 d after
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oncogene deinduction (right) in mice labeled with BrdU for 2 wk prior to sacrifice. (D)
Quantification of the percent of H2B-eGFP-labeled tumor cells staining positive for Ki67 in (A).
(E, F) Quantification of the percent of H2B-eGFP-labeled tumor cells staining positive for BrdU in
(B, C), respectively. (G, H) IF staining for BrdU on sections from H2B-eGFP-labeled orthotopic
primary tumors (left), or MRLs 28 d after deinduction (middle) or 72 hr following reinduction
(right). Mice were labeled with BrdU for 2 hr prior to sacrifice. (I, J) Quantification of the percent
of H2B-eGFP-labeled tumor cells staining positive for BrdU in (G, H), respectively. (K) IF staining
for cleaved caspase-3 (CC-3) on sections from H2B-eGFP-labeled HER2neu-Prim1 orthotopic PT
(left), RL 28d (middle) or RL 56d (right) after HER2/neu de-induction. (L) Quantification of the
percent of H2B-eGFP-labeled tumor cells staining positive for CC-3 in (K). Scale bars (A-C, G, H,
K): 50μm, (K): 100μm. ***p-value vs. primary tumor (PT) <0.001.
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Figure 3.8. Minimal Residual Lesions are Well-Vascularized and Not Hypoxic

(A) H&E (left) and IF staining for CD31 (right) on sections of a representative HER2/neu-Prim1
orthotopic MRL. (B) IF staining for CD31 on sections of an intact MTB;TetO-Wnt1 primary tumor
(left) or MRL (right). (C) Fluorescence microscopy of liver (top) or orthotopic MRL (bottom) from
same mouse for H2B-eGFP, intravenously injected Hoechst 33342 and Lectin-AF647, and
immunofluorescence staining for pimonidazole. Arrowhead denotes area positive pimonidazole
staining surrounding hepatic vein; arrow denotes absence of pimonidazole staining surrounding
hepatic artery. Scale bars: 100μm for all images shown.
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Figure 3.9. CD31 Co-localizes with Intravenously Injected Lectin-AF647

(A-F) Fluorescence microscopy for Hoechst (blue, A), IF for CD31 (red, B), H2B-eGFP (Green,
D), lectin-AF647 (Yellow, E), merge of CD31 and Lectin-AF647 (C), or merge of all channels (F)
on H2B-eGFP-labeled orthotopic HER2/neu-Prim1 MRL. Scale bar 100μm for all images shown
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Figure 3.10. Residual Metastases Exhibit Cellular Dormancy

(A-D) Lung metastasis in MTB;TetO-HER2/neu;TTC;rYFP mouse on doxycycline (top) or residual
lung metastasis following doxycycline withdrawal (bottom). (A) Hematoxylin and eosin-stained
sections (left) or YFP fluorescence microscopy (right). (B) IF for Ki67 (left) or Ki67, YFP and
Hoechst (right). (C) IF for YFP, Hoechst, and CD31. Scale bars (A): 250μm, (B-C): 100μm.
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Figure 3.11. Human Breast Cancer Xenografts Develop Micrometastases in Lung

(A) IF staining for GFP, Hoechst, HER2, or a merge of these three channels, on BT474M1-GFP
orthotopic primary tumors. (B) Brightfield, (left) or fluorescence (middle) gross images of lung, or
fluorescence microscopy of lungs from mice with BT474M1-GFP tumors bearing
micrometastases. Scale bars (A): 100μm, (B left, middle): 750μm, (B right): 50μm.
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Figure 3.12. Human Breast Cancer Xenografts Exhibit Quiescence Following Targeted
Therapy

(A) Schematic of generation of xenograft primary tumors and MRLs following targeted therapy.
(B) Tumor volume for mice treated with vehicle control or with combination Lapatinib (L),
Trastuzumab (T), Pertuzumab (P), and estrogen deprivation (ED). (C) IF staining for Ki67, GFP
and Hoechst on sections of BT474M1-GFP primary tumor (left), or residual disease (right). (D) IF
staining for CD31, GFP, and Hoechst, on sections of BT474M1-GFP primary tumor (left) or
residual lesion (right), showing either CD31 alone (top), or CD31 in combination with GFP and
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Hoechst (bottom). (E) Quantification of the percent of GFP-labeled BT474M1 tumor cells staining
positive for Ki67 from (C), on sections from primary tumors (PT) or residual lesions (RL). ***pvalue vs. primary tumor cells < 0.001. Scale bars (C): 50µm, (D): 100μm
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Figure 3.13. Proliferative Residual Tumor Cells are Juxtaposed with Normal Mouse
Mammary Duct in HER2/neu-Prim1 model)

(A, B) IF staining for GFP (green), Pan-Cytokeratin (Pan-CK, white), or BrdU (red), following 2 wk
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BrdU exposure prior to sacrifice, 56d after doxycycline withdrawal, in tissue sections of H2BeGFP-labeled HER2/neu-Prim1 residual lesions in nu/nu mice. Yellow and orange colors show
overlap of BrdU with GFP. Scale bars: 250μm
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Figure 3.14. Proliferative Residual Tumor Cells are Juxtaposed with Normal Mouse
Mammary Duct in HER2/neu-Prim1 Model

(A-B) IF staining for GFP (green), Pan-Cytokeratin (Pan-CK, white), or BrdU (red), following 2 wk
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BrdU exposure prior to sacrifice in center of residual lesion (A) or tumor cells near BrdU+ normal
mammary ducts near residual lesion (B). IF staining for GFP (green), Hoechst (blue) and
PDGFR-β (red) of normal mammary duct near residual lesion (C). Experimental schematic (D)
and recurrence-free-survival results (E) for TAN monotransgenic mice bearing HER2/neu-Prim1
tumors following sham surgery or fat pad clearing surgery. (F-I) BT474M1-GFP residual disease
either scattered (F, H) or juxtaposed to normal mouse mammary gland cells encapsulated inside
ducts (G, I), stained for GFP (blue) and either CK8 (green) and CK14 (red, F, G), or Hoechst
(white) and Ki67 (Red, H, I). Scale bars: 100μm
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Figure 3.15. Analysis of RNA Isolated from MTB/TAN/TTC/rYFP No Culture Orthotopic
Residual Lesions

Agilent Bioanalyzer 2100 analysis of 2μl of RNA (of 12μl total isolated RNA) isolated from minimal
residual lesion tumor cells in MTB/TAN/TTC/rYFP no culture orthotopic residual lesions, showing
number of tumor cells isolated per residual lesion (x-axis) compared to RNA integrity number
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(RIN) (A, E), total RNA yield from 12μl (B, F), ribosomal RNA (rRNA) ratio (C, G), or RNA yield
per cell (D, H). Data shown either for all samples (A-D), or samples with RNA quality eligible for
WTA with rRNA ratio>0 and RIN>7 (E-H). Linear fit for total RNA yield vs number of tumor cells
(F).
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Figure 3.16. Residual Tumor Cells Express Genes Associated with Dormancy

(A) Schematic for isolation and analysis of primary tumor cells (green), dormant residual tumor
cells (red), recurrent tumor cells (blue), and stromal cells from recurrent tumors (yellow). (B) Dot
plot showing first (PC1) and second (PC2) principal components from principal component
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analysis of gene expressed in FACS-isolated primary tumor cells, dormant residual tumor cells,
and recurrent tumor cells from HER2/neu-Prim1 (left) and Wnt1-Prim1 (right) models. (C, F) Bar
graphs showing mean expression level and standard error of the mean (SEM) for genes
associated with cell cycle (C), or dormancy (F). (E, G) Dormancy score (E) and mTOR signature
score (G) for HER2/neu (left) and Wnt1 (right) models, with primary tumors (PT), residual lesions
(RL), recurrent tumors (RT), and recurrent tumor stroma (RS) absolute values (colored circles) or
mean values (black lines). (H) Heat map showing hierarchical clustering based upon expression
of ribosomal protein genes for primary tumor cells (PT), dormant residual tumor cells (RL),
recurrent tumor cells (RT), and recurrent tumor stromal cells (RS).
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Figure 3.17. Dormant Residual Disease Resides in Desmoplastic Stroma

IF staining for Fibronectin (A, D, G, J, M), collagen type-I (B, E, H, K, N), or collagen type-IB (C, F,
I, L, O), on tissue sections from HER2/neu-Prim1 residual lesions (A-C), normal mammary gland
(D-F), MTB/TAN/TTC/rYFP primary metastasis (G-I), MTB/TAN/TTC/rYFP residual metastasis (JL), or BT474M1-GFP residual lesion (M-O). Mammary gland (D-F) is labeled for duct (D) and
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lumen (Lu).
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Figure 3.18. Comparison of Intact Donors to No Culture Orthotopic Tumors with Array
Comparative Genomic Hybridization (aCGH) and Whole Exome Sequencing (WES) on Bulk
Tumor Tissue and RNA-Seq on FACS-isolated Tumor Cells
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(A) Copy Number Variation analysis of aCGH data showing copy number gains (orange) or copy
number losses (green) at loci in genomic DNA isolated from donor (D) or orthotopic (O1-O3)
tumors from the same donor tumor (Donor1-Donor3), or germline DNA from an FVB or Ts65Dn
control. (B) Quantification of number of genes with non-synonymous mutations in donor (blue, D)
or orthotopic (orange, O1-O3) tumors from the same donor (Donor1-Donor3). (C) Unsupervised
hierarchical clustering based on mutations from (B), showing either orthotopic or intact donor
tumors resulting from the same donor (see legend). (D) Principal component analysis (PCA) of
genome-wide expression data for FACS-isolated tumor cells from donor or orthotopic tumors from
the same donor (see legend). (E) Gene expression pathway activity measured for Stat5 (Stat5),
proliferation (Prolif), cMET (MET), Wnt, Notch, Myc, TGF-β1 and TGF-β3 (TGFB), EMT or mTOR.
(F) Statistical analysis of (E) comparing expression in orthotopic tumors to donor tumors for
donors 1-3 (D1-D3), showing down-regulation of pathways (-) or up-regulation of pathways (+) in
orthotopic tumors compared to intact donors. One symbol p-value <0.05, two symbols p-value
<0.01, three symbols p-value <0.001.
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Figure 3.19. Expression of HER2/neu and Epithelial Markers in Some No Culture
Orthotopic Recurrent Tumors

(A-C) IF staining on tissue sections of MTB/TAN/TTC/rYFP no culture orthotopic primary (top) or
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recurrent tumors (bottom) in nu/nu mice, showing Hoechst (blue) and (A) EpCAM, CK18, and
merge of EpCAM (red) and CK18 (green); (B) CK8, HER2, and merge of CK8 (green) and HER2
(red); or (C) E Cadherin, CK14, and marge of E Cadherin (green) and CK14 (red). (D)
Bioluminescence imaging of a 4x4 recurrent tumor that did not appear to reactivate HER2/neu
expression (left) or a 4x4 recurrent tumor that appeared to reactivate HER2/neu expression.
Scale bars 100μm for (A-C).
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Figure 3.20. Pathway Scores for No Culture Orthotopic MTB/TAN/TTC/rYFP Donor and
Orthotopic Primary Tumor, Residual Lesion, and Recurrent Tumor

(A-F) Pathway scores for intact MTB/TAN/TTC/rYFP donor primary tumor (black), orthotopic
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primary tumors (green), orthotopic residual lesions (red), or orthotopic recurrent tumors (blue) for
gene expression signatures associated with proliferation (A), c-Myc activity (B), TGF-β1 and TGFβ3 signaling (C), EMT (D), mTOR activity (E), or dormancy (F). (G) p-values for student’s t-test
comparing pathway scores of primary tumor (PT) or recurrent tumor (RT) to residual lesion (RL).
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Figure 3.21. Residual Tumor Cells from HER2/neu but not Wnt1 Models Express Genes
Associated with EMT

(A, B) Bar graphs showing mean expression level and standard error of the mean (SEM) for
genes associated with EMT in HER2/neu (A) or Wnt1 (B) models.
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Figure 3.22. HER2/neu-Prim1 but not Wnt1-Prim1 Residual Disease is Enriched for
Mesenchymal Tumor Cells

(A-C) IF staining for Hoechst (blue) and H2B-eGFP (green) along with luminal epithelial marker
CK8 (red, top) or myoepithelial marker CK14 (red, bottom), on sections of H2B-eGFP-labeled
orthotopic HER2/neu-Prim1 (A) or Wnt1-Prim1 (B) primary tumor (left), residual lesion 28 d after
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doxycycline withdrawal (right), or normal mammary gland (C). (D-G) IF staining for PDGFRβ
(red), Hoechst (blue) and GFP (green) on residual lesion 28d after doxycycline withdrawal. (E-T)
IF staining for Hoechst (blue) and H2B-eGFP (green) along with epithelial markers (red) CK5 (E,
M), CK18 (F, N), CK19 (G, O), Ep-CAM (I, Q), E-Cadherin (J, R), P-Cadherin (K, S), and p63 (L,
T), or with a Pan-CK antibody (H, P), on sections of MRLs from H2B-eGFP-labeled orthotopic
HER2/neu-Prim1 tumors (E-L)) or normal mammary ducts (M-T). Scale bars 200μm for (A-C),
50μm for D (left) and (E-T, scale bar shown in T), 20μm for D (right).
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Figure 3.23. Distribution of Mesenchymal Tumor Cells in HER2/neu-Prim1 Residual Lesion

IF staining for H2B-eGFP (blue), mesenchymal marker S100A4 (Fibroblast-specific Protein 1,
green), and CD24 (red). Scale bars 250μm
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Figure 3.24. Flow Cytometry Analysis of EMT in HER2/neu-Prim1 cells in vitro and in vivo

(A-D) Flow cytometry analysis of GFP+DAPI- tumor cells from H2B-eGFP-labeled HER2/neuPrim1 primary tumors (A, C) or residual lesions (B, D), staining for either CD49e vs CD24 (A, B)
or PDGFR-β vs CD24. (E) Flow cytometry staining of HER2/neu-Prim1 (54074), HER2neu-Prim2
(99142), or HER2/neu-Rec1 tumor cells in vitro for intracellular vimentin vs. extracellular EpCAM.
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Figure 3.25. Identification of Residual Tumor Cells Lacking Epithelial Markers in Intact
Mice

(A-C) IF staining on tissue sections of MTB/TAN/TTC/rYFP intact residual lesions for Hoechst
(blue), YFP (green), CK8 (red) or CK5 (white), showing spindle-shaped YFP+ tumor cells that
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lack expression of epithelial markers CK5 and CK8 (red arrows in panel C). (D-F) Images of H&E
staining of intact residual lesions show reproducible features, including a mesenchymal core
(green arrow), abnormal ductal morphology (blue arrows), and a corona of lymphocytes (red
arrows). Scale bars 100μm for (A-C, E, F), 300μm for (D).
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Figure 3.26. Residual Disease is Enriched for Rare Tumor Cell Subpopulations Present in
Primary Tumors

(A) Flow cytometry for EpCAM and CD49e on YFP+ CD45-DAPI- singlet tumor cells in
MTB/TAN/TTC/rYFP primary tumor cells (left) or dormant residual tumor cells (right). (B, C) Flow
cytometry on populations in (A) for CD24 and PDGFR-β expression on CD49e-EpCAM+ primary
tumor cells (B) or CD49e+EpCAM- residual tumor cells (C). (D) Quantification of percent CD49eEpCAM+ or CD49e+EpCAM- tumor cells in primary tumors or residual lesions, using gates from
(A), in MTB/TAN/TTC/rYFP mice. (E) Limiting dilution assay of CD24+Thy1+ tumor cells, or nonCD24+Thy1+ tumor cells, from MTB/TWNT/TTC/rYFP primary tumors. (F) Flow cytometry for
CD24 and Thy1 expression on YFP+CD45-DAPI- singlet tumor cells in MTB/TWNT/TTC/rYFP
primary tumor cells (left) or residual tumor cells (right). (G) Quantification of percent
CD24+Thy1+ or non-CD24+Thy1+ tumor cells in primary tumors or residual lesions, using gates
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from (G), in MTB/TWNT/TTC/rYFP mice. **p value vs. primary tumor (PT) <0.01, ***p value vs.
PT <0.001.
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Figure 3.27. Mesenchymal Markers Identified in HER2/neu Residual Disease are
Prognostic for Poor Recurrence-Free Survival in HER2+ Breast Cancer

(A) Gene expression data for CD49e (Itga5) or EpCAM prior to (Pre-tx) and following (Post-tx)
neoadjuvant therapy. (B) Change in expression of EpCAM (y-axis) and CD49e (x-axis) between
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Pre-Tx and Post-Tx time points in breast cancer patients. (C-F) 10 year recurrence-free survival
(RFS) meta-analysis of 12 data sets of HER2+ breast cancer, adjusted for tumor grade and size,
based on expression levels of Itga4 (CD49e, C), Pdgfrb (PDGFR-β, D), Cd24 (E), or Epcam (F).
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Figure 3.28. Genes Associated with Stem-like Cells are Up-regulated in Residual Lesion
Tumor Cells in HER2/neu and Wnt1 Models

(A-B) Gene expression in residual lesion tumor cells relative to primary and recurrent tumor cells
showing genes previously identified as up-regulated in normal mammary stem cells (left) or
neoplastic mammary stem-like cells (right) and differentially expressed in residual tumor cells
(FDR<0.1) for HER2/neu (A) or Wnt1 (B) models.
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Figure 3.29. Residual Tumor Cells from MTB/TWNT/TTC/rYFP No Culture Orthotopic
Tumors Give Rise to Mammary Epithelial Trees

(A-B) YFP+ residual disease showing branching mammary epithelial tree from
MTB/TWNT/TTC/rYFP residual disease 9 weeks after de-induction (A) but not in
MTB/TAN/TTC/rYFP residual disease more than 32 weeks after deinduction. (C) Carmine
stained mammary fat pad shows mammary duct arising in cleared fat pad injected with 1000
residual lesion tumor cells (left) but not in cleared fat pads injected with 1000 primary tumor donor
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cells (right). (D) Quantification of the number of cleared fat pads injected with residual lesion or
primary tumor cells that give rise to mammary epithelial trees.
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Figure 3.30. Immunohistochemistry (IHC) for Proteins Identified by Up-regulation of Genes
in Analysis of Residual Disease

(A) IHC for thrombospondin-1 (top) or Gjb2 (bottom), two proteins whose transcripts were upregulated in residual disease for which a commercially available antibody was also available,
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reveals expression of these proteins both in normal mammary gland epithelial cells (left) and in
HER2/neu-Prim1 residual lesions (right). (B) IHC for Dec2 in primary tumors (left) or residual
lesions (right) shows heterogeneous nuclear staining in primary tumors and residual lesions.
Scale bars 100μm for (A, B).
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Table 3.1. Agilent Bioanalyzer Analysis Results of RNA from FACS-isolated Tumor Cells
from Residual Lesions in vivo

Results for running Agilent Bioanalyzer 2100 with ‘Pico’ chips using RNA from FACS-isolated
tumor cells sorted out of fluorescently labeled residual lesions in vivo.
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Table 3.2. Gene Sets Down-regulated in Dormant Residual Tumor Cells in HER2/neu-Prim1
and Wnt1-Prim1 Models

Clusters of SP-PIR Keywords identified by DAVID functional ontology analysis of genes downregulated in dormant residual tumor cells compared to all other cell types (false discovery rate
(FDR)<0.1, fold-change (FC) >1.5-fold).
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Table 3.3. Gene Sets Up-regulated in Dormant Residual Tumor Cells in HER2/neu-Prim1
and Wnt1-Prim1 Models

Clusters of SP-PIR Keywords identified by DAVID functional ontology analysis of genes upregulated in dormant residual tumor cells compared to all other cell types (FDR<0.1, FC >1.5fold).
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Table 3.4. Copy Number Variation (CNV) Analysis of Gene Sets Up-regulated in Dormant
Residual Tumor Cells

CNV analysis of aCGH data showing copy number gains or copy number losses in genomic DNA
isolated from donor or orthotopic tumors from the same donor tumor, or germline DNA from an
FVB or Ts65Dn control.
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Table 3.5. Gene Sets Differentially Regulated in Dormant Residual Tumor Cells

Clusters of SP-PIR Keywords identified by DAVID functional ontology analysis of genes upregulated (left) or down-regulated (right) in dormant residual tumor cells compared to all other cell
types, in MTB/TAN/TTC/rYFP no culture orthotopic model (FDR<0.1, FC >1.5-fold).
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Table 3.6. TIC Frequency Calculation for All Tumor Cells in Intact MTB/TAN/TTC/rYFP
Primary Tumors or Residual Lesions

Calculation of TIC frequencies for all YFP+ CD45-DAPI- singlet tumor cells from either
MTB/TAN/TTC/rYFP primary tumors or residual lesions, injected into nu/nu mice on doxycycline.
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Table 3.7. TIC Frequency Calculation for All Tumor Cells in Syngeneic Orthotopic
MTB/TAN/TTC/rYFP Primary Tumors or Residual Lesions

Calculation of TIC frequencies for all YFP+ CD45-DAPI- singlet tumor cells from syngeneic
orthotopic primary tumors or residual lesions in nu/nu mice generated from the same
MTB/TAN/TTC/rYFP donor tumors, injected into nu/nu mice on doxycycline.
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Table 3.8. TIC Frequency Calculation for EpCAM+CD49e- Tumor Cells in Intact
MTB/TAN/TTC/rYFP Primary Tumors or Residual Lesions

Calculation of TIC frequencies for epithelial singlet tumor cells (EpCAM+CD49e-YFP+CD45DAPI- singlets) from either MTB/TAN/TTC/rYFP primary tumors or residual lesions, injected into
nu/nu mice on doxycycline.
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Table 3.9. TIC Frequency Calculation for All Tumor Cells in Intact MTB/TWNT/TTC/rYFP
Primary Tumors or Residual Lesions

Calculation of TIC frequencies for all YFP+ CD45-DAPI- singlet tumor cells from either
MTB/TWNT/TTC/rYFP primary tumors or residual lesions, injected into nu/nu mice on
doxycycline.
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Table 3.10. TIC Frequency Calculation for All Tumor Cells in Syngeneic Orthotopic
MTB/TWNT/TTC/rYFP Primary Tumors or Residual Lesions

Calculation of TIC frequencies for all YFP+ CD45-DAPI- singlet tumor cells from syngeneic
orthotopic primary tumors or residual lesions in nu/nu mice, generated from the same
MTB/TWNT/TTC/rYFP donor tumors, injected into nu/nu mice on doxycycline.
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Table 3.11. TIC Frequency Calculation for All Tumor Cells from H2B-eGFP-labeled
Orthotopic HER2/neu-Prim1 Primary Tumors or Residual Lesions

Calculation of TIC frequencies for all GFP+CD45-DAPI- singlet tumor cells from H2B-eGFPlabeled HER2/neu-Prim1 primary tumors or residual lesions, injected into nu/nu mice either on
doxycycline or not on doxycycline.
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Methods
Statistics
Unless otherwise noted, all statistical analyses providing a p-value were conducted using
student’s two-sided T-test assuming homoscedastic variance, performed in Excel (Microsoft).
Mice
Animal care and experiments were performed with the approval of, and in accordance with,
guidelines of the University of Pennsylvania IACUC. Bitransgenic and nude mice were generated
and tumors were induced, deinduced, monitored for tumor recurrence, and sacrificed as
described [108, 121, 126]. NSG mice were acquired from Jackson Laboratory (stock #005557).
For HER2 blockade, NSG mice were administered 100mg/kg Lapatinib by oral gavage 5
days/week and 20mg/kg Trastuzumab and 20mg/kg Pertuzumab three times per week.
Tissue Culture and Reagents
Primary tumor cells were cultured, and stable H2B-eGFP expression was achieved as described
[108, 126].
BT474-M1 tumor cells were a generous gift from Dr. Mien-Chie Hung. Cells were grown as
above, in media consisting of 10% fetal bovine serum (FBS, Gibco), 1% Penicillin/Streptomycin in
Dulbecco’s modified eagle’s medium (DMEM)/F12 (GIBCO 11330-032). Stable GFP expression
was achieved by transduction with GFP Bsd Lentiviral particles (Gentarget, LVP001) followed by
culture in media containing 10µg/ml blasticidin.
Orthotopic Recurrence Assay
Recurrence assays were performed as described [108]. Recurrence-free survival curves were
displayed as Kaplan-Meier survival curves using Prism 5.03 (Graph Pad Software, Inc).
Intravital Labeling
Intravital labeling was performed as a series of intravenous (i.v.) injections prior to sacrifice.
Pimonidazole HCl (HypoxyprobeTM-1, NPI Inc.) was resuspended in phosphate buffered saline
(PBS) at 20μg/μl, and injected i.v. at 60mg/kg 90 min prior to sacrifice. Hoechst 33342
(230001000, Thermo Fisher Scientific Inc.) was resuspended in PBS at 5μg/μl and injected i.v. at
20mg/kg 15 min prior to sacrifice. Lectin-AF647 was prepared by resuspending 1mg
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Lycopersicon Esculentum Lectin (B-1175, Vector Labs, Inc) in 425μl of PBS and mixing with 75μl
of Streptavidin, AlexaFluor® 647 Conjugate (S-32357, Life Technologies Corporation). LectinAF647 was centrifuged briefly to remove protein aggregates and was injected i.v. 10 min prior to
sacrifice. Mammary glands bearing MRLs 28d following oncogene deinduction, as well as livers
from same mice, were harvested at sacrifice and placed directly into Optimal Cutting Temperature
(OCT, Tissue-Tek, VWR).
Immunofluorescence and Direct Fluorescence
Normal mammary glands or mammary glands bearing MRLs were harvested, embedded in OCT
compound, and frozen. 8μm tissue sections were either fixed and permeabilized in dehydrated
acetone at -20°C for 10 min, or fixed in 4% paraformaldehyde for 10 min at room temperature
(RT) and permeabilized in 0.1% Triton-X-100 in PBS for 20 min. Following fixation and
permeabilization, sections were washed 2x5 min in PBS, blocked for 1 hr with 10% normal goat
serum with 3% BSA in PBS and incubated overnight (O/N) at 4°C with primary antibody diluted in
blocking buffer. Primary antibodies used to stain tissues fixed in paraformaldehyde were: CD31
(1:200, AB28364, AbCam), CK5 (1:1000, PRB-160P, Covance), CK14 (1:10,000, PRB-155P,
Covance), CK19 (1:50, AB15463, AbCam), Pan-CK Ab (1:100, SC-15367, Santa Cruz), ECadherin (1:100, 13-1900, Zymed), P-Cadherin (1:50, 13-200, Zymed), p63 (1:500, AB53039,
AbCam), Collagen Type-I (1:250, AB34710, AbCam), Ki67 (1:50, M7249, Dako), and BrdU
(1:200, OBT0030, AbD Serotec). Primary antibodies used to stain tissues fixed in acetone were:
Ep-CAM (1:100, 14-5791, eBioscience) and CK18 (1:100, NB110-56910, Novus Biologicals).
For BrdU staining, following fixation and permeabilization, sections were incubated with 2N HCl
for 10 min at 25°C and then 20 min at 37°C, followed by incubation in 0.1M sodium tetraborate for
15 min, and then blocked (as above) and stained with primary antibody. For staining of tissues
with primary antibodies raised in mice, specifically those against Fibronectin (1:200, 610077, BD
Transduction), the M.O.M.TM Immunodetection Kit (Vector Laboratories) was used with
Avidin/Biotin Blocking Kit (Vector Laboratories). Following O/N incubation with primary antibody,
tissues were washed 2x10 min in PBS, and incubated for 1 hr at RT with AlexaFluor-conjugated
secondary antibody (1:1000 dilution, Life Technologies Corporation). Sections were then washed
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10 min in PBS, 10 min in PBS with a 1:10,000 dilution of Hoechst 33258 (Sigma-Aldrich Co.), and
5 min in PBS. Sections were mounted in ProLong® Gold Antifade Reagent (Molecular Probes®,
Life Technologies Corporation), sealed with clear nail polish, and allowed to dry.
Slides were imaged with a Leica TCS SP5 (Leica Microsystems) confocal microscope using Leica
Application Suite Advanced Fluorescence (LAS AF, Leica Microsystems) software. Images
showing Ki67 or BrdU staining of H2B-eGFP-labeled HER2/neu-Prim1 tumor cells in Figure 3.7 is
presented as a masked image, wherein a binary mask is generated from the GFP channel and
applied to the Ki67 or BrdU channel, so that only Ki67 or BrdU co-staining with tumor cells is
shown. For all images used for quantification, either the entire MRL, or 1mm x 1mm of the
primary tumor, was imaged as a mosaic image.
Image Quantification
Images were quantified using CellProfiler (Broad Institute) software. Briefly, to quantify Ki67 or
BrdU, a mask was generated (as above) using H2B-eGFP nuclei from a mosaic image. The
number of nuclei that stained positive for Ki67 or BrdU was determined using this mask. The
fraction of tumor cells expressing BrdU or Ki67 was calculated as the total number of nuclei that
stained positive for Ki67 or BrdU divided by the total number of nuclei.
Flow Cytometry and Fluorescence-activated Cell Sorting (FACS)
Immediately following harvest, tissues from mice were digested enzymatically using
collagenase/hyaluronidase (Stemcell Technologies) for 90 min at 37ºC, followed by pipetting
vigorously in DNAse (Worthington Biochemical Corporation) and Dispase (Stemcell
Technologies) for 5 min at 37C. Tissue digests were strained through a 40μm filter (BD Falcon).
Single-cell suspensions were stained with fluorophore-conjugated antibodies for 30 min at 4ºC in
1%BSA and 5mM Ethylenediaminetetraacetic acid disodium salt (EDTA) in PBS. Antibodies used
were: CD45;AF700 (1:50, 560510, BD Biosciences), CD49e;PE (1:50, 557447, BD Pharmingen),
CD24;Pe-Cy7 (1:200, 560536, BD Biosciences), EpCAM;APC-Cy7 (1:50, 118218, BioLegend),
and PDGFR-β;APC (1:50, 17-1402, eBiosciences). Cells were washed twice in FACS diluent
(PBS with 1% bovine serum albumin (BSA, Sigma) and 5mM EDTA (Sigma)), and resuspended
in FACS diluent with 1µg/ml DAPI (Sigma-Aldrich Co.) for identifying viable cells. Compensation
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was performed using AbCTM anti-mouse bead kit (A10344, Life Technologies Corporation) and
anti-rat/hamster bead kit (A10389, Life Technologies Corporation), according to manufacturer’s
instructions. Flow cytometry was performed on a BD FACSCantoTM system using BD
FACSDivaTM software (BD Biosciences).
Data were analyzed using FlowJo. Dead cells, debris, and doublets were removed by
sequentially analyzing gates for DAPI, SSC-A vs. FSC-A, SSC-W vs. SSC-H and FSC-W vs.
FSC-H staining, respectively.
With the exception of enzymatic digest at 37ºC, all steps for flow cytometry, FACS, and limiting
dilution experiments were performed at 4ºC. For tumors harvested from mice bearing a YFPreporter, tumor cells were defined as YFP+CD45-DAPI- cells, excluding all dead cells, debris, and
doublets as above.
Expression Analysis of Purified Tumor and Stromal/Immune Cells
Tissue digestion was performed as above for flow cytometry, with the exceptions that digestion in
collagenase/hyaluronidase was limited to 20 min. Tissue/cells were maintained on ice or at 4ºC
for all other steps prior to resuspension in Trizol after sorting, in order to minimize transcriptional
changes. To further minimize transcriptional changes, antibody staining was omitted and sorting
was based on GFP expression and DAPI staining.
Removal of dead cells, debris, and doublets, was performed as above for flow cytometry. Cell
sorting was performed on a BD FACSVantage cell sorter. Cells were sorted into complete media
(including doxycycline for primary tumor cells), chilled to 4ºC, and maintained on ice.
Immediately following sorting, cells were pelleted and resuspended in TRIZOL.
Phenol/chloroform extraction was used in conjunction with the QIAGEN RNeasy kit to isolate
mRNA. Isolated RNA was analyzed on an Agilent Bioanalyzer, and only samples with an RNA
integrity number of at least 7.0 were selected for subsequent amplification and expression
analysis. 500pg of RNA was used as the input for whole transcriptome amplification (WTA) with
NuGEN Ovation Pico WTA V2.0 kits.
An expression heat map of ribosomal protein gene expression was generated using GENE-E
(www.broadinstitute.org/cancer/software/GENE-E/).
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CHAPTER 4
Modeling the Impact of Immune Modulation on Breast Cancer Recurrence
The immune system is a critical player in the development and progression of cancer. Whereas
the immune system may promote tumor growth through inflammatory signaling in some cancers,
it may alternatively serve a critical role in the elimination of cancer in other settings [13]. Recent
clinical trials with checkpoint blockade inhibitors have revealed a central role for therapies that
activate the immune system, however the impact of directly activating antigen presenting cells
with anti-CD40 stimulatory antibodies on breast cancer recurrence remains unknown.
Alternately, results from the Nurses’ Health Study indicate that daily intake of aspirin
(acetylsalicylic acid) is associated with a dramatic decrease in tumor recurrence, though the
biological basis for this observation is unclear. Anti-cancer therapies may also elicit different
immune responses, which can have a significant impact on subsequent treatment with immunebased therapies. Given the increasing importance of immune-oncology and the dramatic rise in
the use of targeted therapy in the clinic, we investigated the role of the immune system and
inflammation in residual disease following oncogenic pathway inhibition.
Characterization of leukocytes in residual disease
Prior observation of mesenchymal residual tumor cells revealed a complex inflammatory infiltrate
surrounding residual tumor cells (Figure 3.25). To identify the phenotype of these residual tumor
cells we performed IF for macrophage marker F4/80 and T-cell marker CD3 on tissue sections of
residual lesions in intact quadtransgenic MTB/TAN/TTC/rYFP mice. In regions previously
identified to harbor mesenchymal tumor cells (Figure 3.25), we identified large numbers of
macrophages juxtaposed with dormant residual tumor cells, as well as a corona of T cells (Figure
4.1A). This pattern was seen repeatedly in areas with mesenchymal residual tumor cells, and
could be discretized into sections with mesenchymal residual tumor cells and macrophages
(Figure 4.1B, region a), sections with abnormal ductal morphology and T-cell infiltration
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surrounding the macrophages (Figure 4.1B, region b), and areas with no apparent residual tumor
cells or recurrent pattern of inflammatory infiltrate (Figure 4.1B, region c).
Previous reports have indicated that macrophage invasion in primary tumors is associated with
poor prognosis [151-153]. These reports look at expression of either CD68 or CD163 in breast
cancer patients but did not explore alternate transcripts specific to macrophages, and did not
stratify patients to determine the prognostic impact of these markers on breast cancer subtypes.
Combining survival data from several publicly available datasets as before (Figure 3.27), we
asked whether expression of macrophage related markers was prognostic for poor RFS and
stratified our results by breast cancer subtype, as well as grade and lymph node status.
Consistent with prior reports, we identified increased expression of CD68 and CD163 as
correlated with poor 5- and 10-year RFS (Figure 4.2A, E). Interestingly, for both CD68 and
CD163, these markers were prognostic for poor RFS only in breast cancer patients with estrogen
receptor positive (ER+) breast cancer who had received treatment, whereas they associated with
improved outcome in patients with ER- breast cancer who had been treated with systemic
therapy, and did not hold the same prognostic value in patients who had not been treated with
systemic therapy (Figure 4.2A, E). Increased expression of alternate markers specific to
macrophages, including CSF1R and CD14, were not associated with poor RFS, and both were
instead associated with improved RFS in patients with ER- breast cancer (Figure 4.2 C, D).
Similarly, the myeloid marker CD11b and the M1 macrophage-associated marker CD11c – which
is also a marker for dendritic cells – were associated with improved RFS in patients with ERbreast cancer (Figure 4.2 B, F). These findings indicate that, while increased expression of the
macrophage markers CD68 and CD163 are prognostic for poor RFS in ER+ breast cancer,
macrophage-associated markers are associated with improved RFS in ER- breast cancer.
Interestingly, increased expression of CSF1R was associated with improved RFS even in patients
with ER+ breast cancer, a finding that is consonant with recent preclinical results suggesting
CSF1R inhibition may promote metastases in some models of breast cancer [154]. Differences in
survival when looking at alternate markers that should be specific to macrophages, such as
CD68, CSF1R, and CD14, suggest that while the proteins associated with these transcripts are
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used as markers specific to all macrophages, different transcripts may be associated with
heterogeneous macrophage subpopulations.
While these data suggested a complex role for macrophage biology in primary tumors, they did
not inform whether macrophages present in residual disease are critical for tumor recurrence. To
determine whether macrophages are involved in tumor recurrence, we looked at transcript levels
of macrophage-related markers in recurrent tumors compared to primary tumors in mouse
models. We identified 8 different macrophage markers as significantly up-regulated in recurrent
tumors compared to primary tumors, in tumors driven by three different oncogenes: HER2/neu,
Wnt1, and c-Myc (Figure 4.3A). These data suggested that macrophages were associated with
tumor recurrence in breast cancer models driven by different oncogenes.
To better phenotype and study macrophages, we used an orthotopic model of HER2/neu-Prim1
tumor cells labeled with H2B-eGFP, and this model facilitates both easier identification of residual
disease, and studies in larger cohorts of mice in a shorter time frame than is possible with intact
animals. IF staining revealed that residual lesions in HER2/neu-Prim1 tumors in nu/nu mice
harbored a large number of F4/80+ macrophages, similar to the intact system (Figure 4.3B). To
determine the relative proportion of different myeloid populations in residual lesions, we used flow
cytometry to phenotype CD45+CD11b+ leukocytes in residual lesions. The majority of myeloid
cells were Ly6C-Ly6G-, and expressed F4/80 and CD115 (CSF1R), consistent with a
macrophage phenotype (Figure 4.3C), suggesting that macrophages were the primary myeloid
cell population in residual disease.
We previously observed that residual lesions exposed to BrdU for 2 weeks contained a large
number of BrdU-positive non-tumor cells. If these cells were macrophages, it would raise the
possibility that the residual lesion macrophages were either locally proliferative, or were newly
generated myeloid cells recruited from a distant site. If either of these was the case, they would
open the opportunity to inhibit macrophage proliferation in, or recruitment to, the residual lesion.
Thus, we used flow cytometry to investigate the uptake of BrdU over 2 weeks by myeloid cells in
the residual lesion. CD45+CD11b+Ly6C-Ly6G-F4/80+CD115+ macrophages and
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CD45+CD11b+Ly6C-Ly6G-F4/80+CD115+ resident monocytes incorporated BrdU at a more than
3-fold higher rate than dormant residual tumor cells or than CD45+CD11b+Gr1+ myeloid-derived
suppressor cells (MDSCs) (Figure 4.3D), supporting the idea that macrophages either proliferated
in, or were recruited to, dormant residual lesions.
Finally, to further characterize macrophages in residual lesions, we performed IF for CD163,
CD206, Ym1, and RELMα (Fizz1). These markers are generally associated with ‘alternatively
activated’ macrophages, a phenotype that has been associated tumor associated macrophages
(TAMs) in previous reports [155]. Macrophages inside the residual lesion expressed CD206, but
only macrophages around the border of the residual lesion expressed CD163, and no
macrophages near the residual lesion expressed Ym1 or RELMα (Figure 4.3 E-I). We also
observed CD206 expression in red pulp macrophages, which are not alternatively activated
macrophages, and thus it was unclear that expression of CD206 alone was sufficient to indicate
that residual lesion macrophages were alternatively activated (Figure 4.3E).
Together, these results provide a picture of residual lesion macrophages as a dynamic population
that do not express markers of alternatively activated macrophages sometimes associated with
TAMs.
Activating macrophages with anti-CD40 antibodies does not inhibit tumor recurrence
Our results indicated that macrophages comprised the major leukocyte population in residual
disease. Recent reports indicate that antibodies stimulating CD40 on macrophages can activate
them in a manner that inhibits tumor progression in desmoplastic pancreatic tumors [156]. As
residual lesions are highly desmoplastic (Figure 3.17), we hypothesized that activation of
macrophages with the anti-CD40 antibody FGK45 might inhibit tumor recurrence in mice following
oncogenic pathway inhibition.
Prior to administering FGK45, we wanted to know whether tumor cells expressed CD40, and thus
whether FGK45 might bind directly to the tumor cells, as this would complicate our subsequent
interpretation of results. Using both flow cytometry and IF, we found that while leukocytes in
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primary tumors and residual lesion-juxtaposed lymph nodes expressed CD40, primary tumor cells
and residual lesion tumor cells did not express CD40 (Figure 4.4). As leukocytes expressed
CD40, we next asked whether macrophages would express an activated phenotype upon
treatment with anti-CD40 antibodies. To test this, we administered FGK45 or isotype control to
mice bearing regressing tumors 72 hours after doxycycline withdrawal, and harvested tumors
from these mice 60 hours after FGK45 administration. Macrophages in regressing tumors
showed increased expression of activation markers CD86 and CD40, but not MHC-II, after
stimulation with FGK45 (Figure 4.5).
As FGK45 administration inhibits pancreatic tumor progression concurrent with a depletion of
pancreatic tumor stroma, we examined tumor stroma in mice treated with FGK45, at the same
time point where macrophages had also shown increased expression of activation markers CD40
and CD86. Collagen type-I and Masson’s trichrome staining did not reveal any differences in
ECM density between treated and untreated mice (Figure 4.6A, B). These results, as well as the
lack of increased MHC-II activation on FGK45-stimulated macrophages, were inconsistent with
results observed in the previous study in pancreatic cancer [156]. However, as FGK45-treated
macrophages increased their expression of activation markers CD40 and CD86, this suggested
that the macrophages may have been sufficiently activated to have an impact on tumor
progression, and we thus asked whether FGK45 administration impacted tumor recurrence.
We administered a single dose of FGK45 or isotype control to either intact MTB/TAN mice, or
orthotopic HER2/neu-Prim1 tumors in syngeneic TAN mice, either 72 hours after doxycycline
withdrawal, or 4 weeks after doxycycline withdrawal, and monitored mice for recurrence (Figure
4.6C). Intact MTB/TAN mice treated with FGK45 72 hours after doxycycline administration
showed a decreased recurrence latency, while no other cohort demonstrated a change in time to
recurrence (Figure 4.6D, E). These results were surprising, as we had originally hypothesized
that administration of a stimulatory anti-CD40 antibody would inhibit tumor recurrence, consistent
with its role for inhibiting pancreatic cancer in mice and humans.
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To follow up on these results, we wanted to know whether the increased rate of recurrence was
due to the presence of macrophages or T-cells. We repeated the previous experiment in
MTB/TAN mice with administration of FGK45 72 hours after doxycycline withdrawal, and mice
were either ablated for macrophages with clodrolip, or ablated for T-cells with a combination of
anti-CD4 and anti-CD8 antibodies (Figure 4.6F). Strikingly, none of the mice recapitulated the
decreased recurrence latency that was seen in the first study (Figure 4.6G).
Given the relatively small number of animals used in the intact MTB/TAN studies (n=10 per
cohort), the most likely explanation for our observation in Figure 4.6D is that the result was a
random event. In this cohort, all mice recurred by 130 days, which is approximately the mean
recurrence latency for MTB/TAN mice as a population (Figure 3.1), thus it is not implausible that
all mice would develop recurrent tumors by that time in a cohort of 10 mice. Additionally,
including both MTB/TAN and syngeneic orthotopic models, we followed recurrence in four cohorts
of mice, thereby increasing our chance of seeing a false positive result.
Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on tumor recurrence
Recent analysis of data from the Nurses’ Health Study indicates that daily NSAID intake may
significantly delay the time to tumor recurrence in breast cancer patients [157]. Previous studies
investigating a link between aspirin intake and primary breast cancer incidence identified
decreased rates of ER+ breast cancer in women regularly using NSAIDs [158]. This connection
was attributed to the impact of blocking COX activity with aspirin or other NSAIDs on estrogen
production from aromatase [159], and no impact was seen on ER- breast cancer. The findings
from the Nurse’s Health Study were especially interesting because they suggested that daily
aspirin intake inhibited breast cancer recurrence in both ER+ and ER- breast cancer, thus
suggesting that NSAID intake inhibited breast cancer recurrence through an as-of-yet unidentified
mechanism.
We considered the possibility that administration of NSAIDs might inhibit cancer recurrence in
HER2/neu-Prim1 orthotopic tumors, and that these models may be useful to identify the
mechanism underlying aspirin’s protective effect in women with breast cancer. As macrophages
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can exhibit an inflammatory phenotype, and macrophages constitute the major leukocyte
population of residual lesion in our model, it is possible that if macrophages impact recurrence,
they could do so through promoting inflammation near residual tumor cells. In support of a role
for COX inhibitors, such as NSAIDs, in abrogating tumor recurrence in our models, we observed
that COX2 staining on blood vessels and leukocytes by IF in H2B-eGFP-labeled HER2/neu-Prim1
residual lesions in nu/nu mice (Figure 4.7A). As NSAIDs inhibit prostaglandin synthesis, we also
examined gene expression of prostaglandin synthesis-related genes in primary and recurrent
tumors, in models driven by either HER2/neu, Wnt1, or c-Myc oncogenes. We found an increase
in transcripts associated with prostaglandin synthesis, including COX1, COX2, and PTGES, as
well as transcripts associated with prostaglandin signaling, PTGER2 and PTGER4 (Figure 4.7B),
supporting the possibility that NSAIDs may impact tumor recurrence in these models through its
effect on prostaglandin signaling.
To test whether NSAIDs might have an impact on tumor recurrence, we performed a recurrence
assay on nu/nu mice bearing orthotopic H2B-eGFP-labeled HER2/neu-Prim1 tumors, given
drinking water that either did or did not contain high-dose aspirin (60mg/kg/day). There was not a
significant difference between times to recurrence in the two cohorts (Figure 4.7C). We
subsequently found prior reports indicating that mice metabolize aspirin at a significantly higher
rate than rats or humans, raising the possibility that aspirin was not an effective NSAID in mice
[160]. It was also possible that an intact immune system was required in order to see an impact
of COX inhibition on tumor recurrence. To address both of these possibilities, we performed
recurrence studies in both nu/nu mice bearing HER2/neu-Prim1 orthotopic tumors, and also
MTB/TAN mice, where mice in both studies were randomized to receive either indomethacin in
drinking water, or drinking water alone. While both studies showed a trend towards an increase
in RFS, only the study in HER2/neu-Prim1 orthotopic tumors in nu/nu mice was statistically
significant (Figure 4.7 D, E).
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The magnitude of the delay in time to recurrence is significantly smaller than was seen in the
results from the Nurses’ Health Study, thus it was unclear that these models were ideally suited to
identify a role for NSAIDs in breast cancer recurrence.
Dexamethasone inhibits cancer recurrence at doses that also ablate macrophages
As macrophages are the primary myeloid population in residual disease in our models, and
macrophage-related transcripts were increased in recurrent tumors relative to primary tumors, we
hypothesized that ablation of macrophages might inhibit tumor recurrence. A previous report
used dexamethasone to eliminate macrophages [161], consistent with dexamethasone’s role as a
broadly immunosuppressive corticosteroid.
To determine whether macrophage ablation with dexamethasone inhibited tumor recurrence, we
performed a recurrence assay in both intact MTB/TAN and HER2/neu-Prim2 orthotopic tumors in
nu/nu mice, treated either with 80mg/kg (mpk) dexamethasone or vehicle control. In both studies,
we observed a dramatic decrease in recurrence in cohorts treated with dexamethasone (Figure
4.8A, B). Given the high dose used in these studies, we wanted to know whether lower doses of
dexamethasone also inhibited recurrence, and whether doses that inhibited recurrence tracked
with doses that also ablated macrophages. To answer these questions, we performed a
recurrence assay using HER2/neu-Prim1 orthotopic tumors in nu/nu mice enrolled into one of 5
cohorts, either a control cohort, or a cohort administered one of four doses of dexamethasone:
80mpk, 10mpk, 1mpk or 0.1mpk. Mice treated with 80mpk or 10mpk dexamethasone exhibited
statistically significant delays in time to recurrence compared to control cohorts, but the same
effect was not seen at lower doses of dexamethasone (Figure 4.8C). Consistent with our
hypothesis that macrophages in the minimal residual lesion promote recurrence, we observed
that only doses of dexamethasone that also led to a significant decrease in the number of
macrophages, determined by quantification of IF staining on tissue sections of residual lesions,
had an impact on tumor recurrence (Figure 4.8D). Orthotopic residual lesions that never
recurred, in mice treated with 80mpk dexamethasone for more than 200d, displayed a
significantly lower number of cells than residual lesions observed 28d after doxycycline
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withdrawal in untreated mice (Figure 4.8E). Consistent with broad immunosuppression, lymph
nodes in these mammary glands displayed significant signs of atrophy, lacking germinal centers
(Figure 4.8F).
Our findings supported the possibility that ablating macrophages inhibits tumor recurrence,
however as dexamethasone is a broadly immunosuppressive drug, it remained unclear whether
the delay in recurrence we observed was due to the impact of dexamethasone on macrophages.
Macrophage-specific ablation and tumor recurrence
As a first step to determine whether macrophage-specific ablation delayed tumor recurrence, we
sought methods that could ablate macrophages in residual lesions with greater specificity than
dexamethasone. Towards this end, we considered the use of liposome-encapsulated clodronate
(clodrolip), a well-established method to systemically ablate macrophages [162]. While this
method robustly ablated splenic macrophages, it did not ablate macrophages within the residual
lesion (Figure 4.9 A). Next, we considered the possibility that residual lesion macrophage
precursors were GR1+ monocytes. Administration of RB6-8C5, an antibody against GR1,
ablated over 99% of peripheral blood monocytes (Figure 4.9 C, D). We performed a recurrence
study with HER2/neu-Prim1 orthotopic tumors in nu/nu mice treated either with RB6-8C5 or an
isotype control antibody. Ablation of GR1 expressing cells did not inhibit tumor recurrence
(Figure 4.9E) and did not ablate F4/80 macrophages in the residual lesion (data not shown).
Interestingly, we observed that mice treated with chronic RB6-8C5 developed massive
splenomegaly (Figure 4.10A). In general, the size of recurrent HER2/neu-Prim1 orthotopic tumor
in an untreated nu/nu mouse at time of sacrifice is directly proportional to the size of the mouse’s
spleen (Figure 4.10B). In spite of this correlation, we found that mice treated with chronic RB68C5 developed massive splenomegaly prior to the development of recurrent tumors (Figure
4.10C). In contrast, mice treated with 80mpk or 10mpk dexamethasone had small spleens at
time of recurrence, however mice treated with 1mpk or 0.1mpk dexamethasone did not have
significantly smaller spleens upon tumor recurrence (Figures 4.10C-E). These data suggest that,
while RB6-8C5 may have depleted a population of peripheral blood cells that can act as
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macrophage precursors, chronic administration of the antibody may also lead to splenomegaly,
possibly due to increased production of leukocyte populations.
As a next step to specifically ablate macrophages, we identified methods that ablate
macrophages in a c-fms-dependent manner. c-fms is the gene encoding CSF1R, an
indispensable receptor for the maturation and development of macrophages, and strategies
targeting c-fms through antibodies or genetic-based ablation methods can be used to selectively
eliminate macrophages. Thus, we tested the efficacy of the anti-c-fms antibody M279 compared
to an isotype control for ablating F4/80+ macrophages in HER2/neu-Prim1 orthotopic residual
lesions, and found that the vast majority of macrophages were ablated, with some residual
lesions showing practically no macrophages following M279 treatment (Figure 4.11A). We also
used a second approach for ablating macrophages in a c-fms-dependent manner in intact
MTB/TAN mice, by crossing these mice to transgenic ‘Macrophage ablation through fas-induced
apoptosis,’ or Mafia, mice. The Mafia transgene contains a fusion protein product and GFP
reporter both downstream of a c-fms-dependent promoter [163]. Upon administration of a small
molecule dimerizing agent, AP20187, the cell membrane-localized protein product from the Mafia
transgene dimerizes and initiates apoptotic signaling through the cell’s Fas-induced apoptosis
pathway. The GFP reporter allows easy identification of c-fms+ macrophages. Upon
administration of AP20187, more than 80% of CD45+CD11b+c-fms-GFP+ macrophages in
residual disease-bearing mammary glands from MTB/TAN/Mafia mice were ablated (Figure
4.11B).
Using these two c-fms-dependent macrophage ablation methods, we performed a recurrence
assay in HER2/neu-Prim1 orthotopic tumors in nu/nu mice with the anti-c-fms antibody M279
(Figure 4.11C), and in MTB/TAN/Mafia mice with AP20187 (Figure 4.11D). Both studies showed
a trend towards a delay in recurrence in mice treated with macrophage ablating methods
compared to controls, however only the result from the anti-c-fms antibody ablation study was
statistically significant (Figure 4.11E-F).

132

The delay in recurrence with c-fms-dependent macrophage ablation was modest compared to the
impact of dexamethasone-induced macrophage ablation. To better understand this discrepancy
we investigated the phenotype of residual lesion macrophages in residual lesions 28 days after
doxycycline withdrawal from these two models. As the anti-c-fms antibody has been reported to
be ineffective against inflammatory macrophages [164], we stained for the inflammatory
macrophage marker CD11c in parallel with F4/80. Residual lesions from control residual lesions
28d after doxycycline withdrawal showed a dense infiltrate of macrophages, many of which were
CD11c+ (Figure 4.11G, left). In dexamethasone-treated residual lesions, almost no F4/80+
macrophages were present, and none of these macrophages expressed CD11c (Figure 4.11G,
middle). In contrast, while few macrophages were also present in residual lesions from M279treated mice, these macrophages uniformly displayed a CD11c+ phenotype (Figure 4.11G, right).
Taken together, these findings suggest that the presence of CD11c+F4/80+ inflammatory
macrophages in M279-treated mice may account for the relatively modest results seen with antic-fms therapy relative to dexamethasone, and thereby suggest that elimination of proinflammatory CD11c+F4/80+ macrophages may allow for more complete inhibition of tumor
recurrence.
Inflammation and tumor recurrence
Our aforementioned results begin to suggest that CD11c+F4/80+ macrophages may promote
recurrence. To test whether inflammation may generally promote recurrence, we performed a
recurrence assay with HER2/neu-Prim1 orthotopic tumors in nu/nu mice, in which mice were
randomly assigned to a cohort that would have local inflammation induced within the residual
lesion, or a cohort that would simply remain under observation with no other intervention. To
induce inflammation, we injected 50ul of sterile saline using a fresh sterile syringe directly into the
residual lesion of the nu/nu mouse every third day. To ensure that the needle tip was inside the
residual lesion, the needle was inserted and removed from the mammary gland several times in
order to identify a region that resisted insertion of the needle. Presumably, the relatively high
levels of ECM in the residual lesion make it more difficult to insert a needle into the residual lesion
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than into other parts of the mammary gland, therefore this method allowed accurate localization
of residual disease inside of a mammary gland without surgical intervention.
Using HER2/neu-Prim1 orthotopic tumors in nu/nu mice, we began saline injection 3 days after
doxycycline withdrawal, and repeated every three days (q3d). Residual lesions harvested 28d
after doxycycline withdrawal from mice chronically injected with saline produced higher levels of
the pro-inflammatory cytokine IL6 than residual lesions from uninjected mice (Figure 4.12A). We
then performed a recurrence assay using orthotopic HER2/neu-Prim1 tumors in nu/nu mice, and
upon doxycycline withdrawal, randomly enrolled mice into cohorts to either be injected chronically
with saline q3d, or to remain uninjected (Figure 4.12B). Mice chronically injected with saline
demonstrated a faster rate of recurrence than mice that were uninjected (Figure 4.12C),
suggesting that inflammation promotes recurrence in this model.
Discussion
Together, our results portray a complex phenotype of leukocytes present in residual disease
following oncogenic pathway inhibition. Across multiple studies, treatments that promote
inflammation or activate macrophages promote recurrence, whereas studies that inhibit
inflammation or deplete macrophages protect mice against recurrence. These results are
generally consistent with clinical observations that anti-inflammatory drugs inhibit tumor
recurrence in breast cancer patients, although they do not address the specific pharmacological
mechanism by which NSAIDs might inhibit tumor recurrence in breast cancer patients.
Our observation that macrophages are recruited to residual lesions is consistent with reports that
demonstrate recruitment of macrophages in a c-fms-dependent manner to breast cancer
following treatment with cytotoxic chemotherapy [151]. In this study, c-fms-dependent ablation
improved overall survival when given in combination with cytotoxic chemotherapy, paclitaxel.
Alternately, a study showing that anti-CD40 macrophage activation following cytotoxic
chemotherapy with gemcitabine can dramatically inhibit tumor growth [156]. We did not observe
a dramatic decrease in time to recurrence using either c-fms-dependent macrophage ablation or
macrophage stimulation with an anti-CD40 antibody. One possible explanation for the
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differences between our findings and previous reports is that doxycycline withdrawal in our
models most closely represents oncogenic pathway inhibition with targeted therapy, but may not
have the immunological impact as chemotherapy. As various chemotherapies may have either
immune stimulatory or immunosuppressive effects [165], this may account for a proportion of the
differences we see between our results and results in systems using chemotherapy.
Indeed, the use of macrophage-ablating therapies in combination with antibody-based targeted
therapies may inhibit the efficacy of these targeted therapies, given that macrophage-stimulatory
agents can promote the activity of drugs such as trastuzumab and rituximab [166].
Nonetheless, our observations with dexamethasone-based macrophage ablation provide the
exciting possibility that appropriately ablating inflammatory macrophages may dramatically inhibit
tumor recurrence in some settings.

135

Figure 4.1. Distribution of Leukocyte Populations Relative to Mesenchymal Residual
Tumor Cells

(A, B) IF imaging for Hoechst, tumor cell marker YFP, macrophage marker F4/80, or T-cell marker
CD3, in a tissue section of a residual lesion from an intact MTB/TAN/TTC/rYFP mouse. (B)
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Labels for different regions repeatedly identified across multiple residual lesions, including a
region with mesenchymal tumor cells and macrophages (a), a region with abnormal ducts and Tcells (b), and a region with disorganized mammary fat pad morphology showing extensive
autofluorescence and inflammatory infiltrate (c). Scale bars 100μm for all images.
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Figure 4.2. Association Between Macrophage-related Transcripts and Recurrence-free
Survival (RFS) for Breast Cancer Patients

Association between increased expression of macrophage-related transcripts and 5 year (left) or
10 year (right) recurrence-free survival, showing prognostic impact for overexpression of either
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CD68 (A), CD11b (B), CSF1R (C), CD14 (D), CD163 (E), or CD11c (F) on either all patients (All);
patients stratified by high estrogen receptor (ER) expression (ER+) or low ER expression (ER-);
high HER2 expression (HER2+) or low HER2 expression (HER2-); a combination of ER and
HER2 expression status; presence (Node+) or absence (Node-) of disseminated tumor cells in
lymph nodes; grade 3 (G3), or grades 1-2 (G1+G2) disease; or molecular subtype.
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Figure 4.3. Evidence Supporting a Role for Macrophages in Tumor Progression in
Transgenic Mouse Models of Breast Cancer

(A) Expression of macrophage-related transcripts in primary or recurrent tumors in HER2/neu, c-
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Myc, and Wnt1;p53+/- models of breast cancer. (B) IF on tissue section of an H2B-eGFP-labeled
HER2/neu-Prim1 orthotopic residual lesion in a nu/nu mouse for Hoechst (blue), H2B-eGFP
(green), or macrophage marker F4/80 (red). (C) Flow cytometry to identify different myeloid cell
(CD45+CD11b+) populations in a HER2/neu-Prim1 orthotopic residual lesion in a nu/nu mouse.
(D) Flow cytometry on different myeloid populations or tumor cells to quantify 2 week uptake of
BrdU. (E-H) IF to phenotype residual lesion macrophage populations. (I) Quantification of
different macrophage populations. Scale bars 100μm for (B), 50μm for (E), 25μm for (F), 10μm
for (G, H).
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Figure 4.4. Residual Lesion Leukocytes but not Tumor Cells Express CD40

(A, B) Flow cytometry for either fluorescence-minus one (FMO) control staining or CD40
expression on CD45+GFP- leukocytes (A) or CD45-GFP+ tumor cells (B) in MTB/TAN recurrent
tumors. (C) IF showing CD40 staining in non-germinal center regions of lymph nodes. (D) IF
showing CD40 staining in lymph node, but not in adjacent residual lesion tumor cells. Scale bars
300μm for (C), 100μm for (D).
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Figure 4.5. Macrophages are Activated by anti-CD40 Antibody FGK45

(A) Flow cytometry for macrophage activation markers CD86 or CD40, or IgG2a isotype control,
on DAPI-CD45+CD11b+Ly6c-Ly6g- macrophages in tumors from MTB/TAN mice 72 hours after
deinduction, either treated with an anti-CD40 antibody FGK45 (orange and red lines) or treated
with an isotype control antibody (blue and green). (B) Quantification of expression of
macrophage activation markers on IgG2a control antibody treated or FGK45-treated mice, from
(A).
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Figure 4.6. Impact of Treatment with FGK45 on ECM Protein Expression and Recurrence
Latency

(A, B) IF for CK8 (green) and collagen-type I (red) (A) or brightfield images of Masson’s
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Trichrome (B) images tumors 60 hours after treatment with FGK45 or isotype control,
administered 72 hours after doxycycline withdrawal in MTB/TAN mice. (C) Experimental
schematic showing timing of administration of either FGK45 or isotype control antibody; 72 hours
or 4 weeks after doxycycline withdrawal. (D, E) Kaplan-Meier curves displaying RFS in either
MTB/TAN mice (D) or HER2/neu-Prim1 syngeneic tumors in TAN monotransgenic mice (E),
according to experimental schematic in (C). (F) Schematic for follow-up experiment including
systemic ablation of either macrophages or T-cells, prior to and following administration of FGK45
antibody. (G) Kaplan-Meier curves displaying RFS of MTB/TAN mice treated according to (F).
Scale bars 100μm for (A, B).
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Figure 4.7. Evidence Supporting a Role for COX Signaling in Tumor Progression in
Transgenic Mouse Models of Breast Cancer

(A) IF on tissue section of an H2B-eGFP-labeled HER2/neu-Prim1 orthotopic residual lesion in a
nu/nu mouse for Hoechst (blue), H2B-eGFP (green), or COX2 (red). (B) Expression of
macrophage-related transcripts in recurrent tumors relative to primary tumors (p-values in
parenthesis), in HER2/neu, c-Myc (MTB/TOM), and Wnt1;p53+/- models of breast cancer. (C)
Kaplan-Meier curves displaying RFS for nu/nu mice bearing HER2/neu-Prim1 orthotopic tumors

146

treated with chronic high dose aspirin starting at time of doxycycline withdrawal. (D, E) KaplanMeier curves displaying RFS in either HER2/neu-Prim1 tumors in nu/nu mice (D) or MTB/TAN
mice (E) treated with chronic indomethacin starting at time of doxycycline withdrawal.
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Figure 4.8. Dexamethasone Inhibits Tumor Recurrence at Doses that Ablate Macrophages
within Residual Lesions

(A, B) Kaplan-Meier curves displaying RFS in either MTB/TAN mice (A) or HER2/neu-Prim2
tumors in nu/nu mice (B) treated with chronic 80 mg/kg dexamethasone starting at time of
doxycycline withdrawal. (C) Kaplan-Meier curves displaying RFS in HER2/neu-Prim1 tumors in
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nu/nu mice treated with different doses of dexamethasone or vehicle control. (D) Quantification
of the number of macrophages present in residual lesions from mice treated with different doses
of dexamethasone, as measured by intensity of F4/80 staining on tissue sections. (E, F) H&E
staining of residual lesion (E) or lymph node (F) displaying atrophic morphology in mice treated
with 80mg/kg dexamethasone. Scale bars 500μm for (E, F).
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Figure 4.9. Impact of Clodronate Liposomes or anti-GR1 antibody on RFS

(A) IF on tissue section of an H2B-eGFP-labeled HER2/neu-Prim1 orthotopic residual lesion in a
nu/nu mouse for Hoechst (blue), H2B-eGFP (green), or F4/80 (red). (B) Flow cytometry of GR1
and CD11b on CD45+DAPI- leukocytes peripheral blood from nu/nu mice following retreatment
with anti-GR1 antibody after a previous treatment one month earlier. (C) Quantification of
depletion of GR1+ monocytes from (B). (D) Kaplan-Meier curves displaying RFS in HER2/neuPrim1 tumors in nu/nu mice treated with chronic anti-GR1 antibody or isotype control, starting at
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deinduction. Scale bars 100μm for (A).
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Figure 4.10. Spleen Size is Increased by anti-GR1 Treatment and Decreased by
Dexamethasone

(A) Images showing representative spleens from mice treated with either isotype control antibody
or anti-GR1 antibody RB6-8C5. (B) Dot plot showing correlation between spleen weight (g) and
tumor volume (mm3). (C) Dot plot showing spleen weight vs tumor volume for mice treated with
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anti-GR1 antibody, dexamethasone, clodrolip, or untreated control mice data from (A). (D) Bar
plot showing spleen weight for mice treated with different doses of dexamethasone, control IP
injections of saline, or indomethacin in drinking water. (E) p-values for bar graphs in (D), vs
control. Scale bars 1cm for (A).
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Figure 4.11. c-fms-dependent Macrophage Ablation Results in a Small Delay in Tumor
Recurrence

(A) IF for Hoechst (blue), H2B-eGFP (green), or F4/80 (red) on tissue sections of H2B-eGFPlabeled HER2/neu-Prim1 orthotopic residual lesions in nu/nu mice treated either with isotype
control antibody or with anti-c-fms antibody. (B) Flow cytometry on residual disease-bearing
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mammary glands 4 weeks after doxycycline withdrawal in MTB/TAN/Mafia mice after 4 weeks of
treatment with either vehicle or AP20187. (C) Experimental schematic showing timing of anti-cfms antibody administration to nu/nu mice bearing HER2/neu-Prim1 tumors following doxycycline
withdrawal. (D) Experimental schematic showing timing of administration of AP20187 dimerizing
agent to MTB/TAN/Mafia mice following doxycycline withdrawal. (E) Kaplan-Meier curves
displaying RFS for (C). (F) Kaplan-Meier curves displaying RFS for (D). (G) IF for Hoechst
(blue), H2BeGFP (blue), F4/80 (red), or CD11c (green). Scale bars 100μm for (A, G).
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Figure 4.12. Chronic Intramammary Saline Injections Increase Residual Lesion IL6 and
Promote Recurrence

(A) Bar graph showing quantification of ELISA for IL6 from residual lesions either injected every 3
days (q3d) with saline or uninjected, 28 days after doxycycline withdrawal. (B) Experimental
schematic showing timing of chronic saline injection. (C) Kaplan-Meier curves displaying RFS in
HER2/neu-Prim1 tumors in nu/nu mice either injected into residual lesion with q3d saline or
uninjected. * = p-value<0.05
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Methods
Statistics
Unless otherwise noted, all statistical analyses providing a p-value were conducted using
student’s two-sided T-test assuming homoscedastic variance, performed in Excel (Microsoft). pvalues for survival analyses of Kaplan-Meier curves were analyzed attained with Wilcoxon ranksum test, performed in Prism 5 (Graphpad).
Mice
Animal care and experiments were performed with the approval of, and in accordance with,
guidelines of the University of Pennsylvania IACUC. Bitransgenic and nude mice were generated
and tumors were induced, deinduced, monitored for tumor recurrence, and sacrificed as
described [108, 121, 126]. Mafia mice were previously described [163].
Tissue Culture and Reagents
Primary tumor cells were cultured, and stable H2B-eGFP expression was achieved as described
[108, 126].
Orthotopic Recurrence Assay
Recurrence assays were performed as described [108]. Recurrence-free survival curves were
displayed as Kaplan-Meier survival curves using Prism 5.03 (Graph Pad Software, Inc).
Immunofluorescence and Direct Fluorescence
Normal mammary glands or mammary glands bearing MRLs were harvested, embedded in OCT
compound, and frozen. 8μm tissue sections were either fixed and permeabilized in dehydrated
acetone at -20°C for 10 min, or fixed in 4% paraformaldehyde for 10 min at room temperature
(RT) and permeabilized in 0.1% Triton-X-100 in PBS for 20 min. Following fixation and
permeabilization, sections were washed 2x5 min in PBS, blocked for 1 hr with 10% normal goat
serum with 3% BSA in PBS and incubated overnight (O/N) at 4°C with primary antibody diluted in
blocking buffer. Primary antibodies used to stain tissues fixed in paraformaldehyde were: F4/80
(1:50, AB6640, Abcam), GFP (1:1000, NB100-1770, Novus Biologicals), CD3 (1:100, ab5690,
Abcam). Primary antibodies used to stain tissues fixed in acetone were: F4/80 (1:500, AB6640,
Abcam), GFP (1:1000, NB100-1770, Novus Biologicals), CD3 (1:100, ab5690, Abcam), CD163
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(1:50, SC-33560, Santa Cruz), CD206 (1:500, MCA2235, AbD Serotec), RELMa (1:20, ab39626,
Abcam), Ym1 (1:20, 1404, StemCell Technologies), CD40 (1:50, sc-16933, Santa Cruz),
Collagen-I (1:250, AB34710, Abcam), CK8 (1:50, , Developmental Studies Hybridoma Bank
Uuniversity of Iowa), COX2 (1:500, ab15191, Abcam), CD11c (1:10, 550283, BD Pharmingen).
Slides were imaged with a Leica TCS SP5 (Leica Microsystems) confocal microscope using Leica
Application Suite Advanced Fluorescence (LAS AF, Leica Microsystems) software.
Flow Cytometry
Immediately following harvest, tissues from mice were digested enzymatically using
collagenase/hyaluronidase (Stemcell Technologies) for 90 min at 37ºC, followed by pipetting
vigorously in DNAse (Worthington Biochemical Corporation) and Dispase (Stemcell
Technologies) for 5 min at 37C. Tissue digests were strained through a 40μm filter (BD Falcon).
Single-cell suspensions were stained with fluorophore-conjugated antibodies for 30 min at 4ºC in
1%BSA and 5mM Ethylenediaminetetraacetic acid disodium salt (EDTA) in PBS. Antibodies used
were: CD45 (1:200, 560510, BD Biosciences), CD11b (1:500, 101241, BioLegend), Ly6C (1:100,
128029, BioLegend), Ly6G (1:250, 562700, BD Biosciences), CD115 (1:50, 46-1152,
eBioscience), F4/80 (1:50, 25-4801, eBioscience), CD40 (1:50, 553791, BD Biosciences), IgG
Isotype control (1:50, 553989, BD Biosciences), CD86 (1:50, 553692, BD Biosciences), MHC-II
(1:1000, 558593, BD Biosciences). Cells were washed twice in FACS diluent (PBS with 1%
bovine serum albumin (BSA, Sigma) and 5mM EDTA (Sigma)), and resuspended in FACS diluent
with 1µg/ml DAPI (Sigma-Aldrich Co.) for identifying viable cells. Compensation was performed
using AbCTM anti-mouse bead kit (A10344, Life Technologies Corporation) and anti-rat/hamster
bead kit (A10389, Life Technologies Corporation), according to manufacturer’s instructions. Flow
cytometry was performed on a BD FACSCantoTM system using BD FACSDivaTM software (BD
Biosciences).
Data were analyzed using FlowJo. Dead cells, debris, and doublets were removed by
sequentially analyzing gates for DAPI, SSC-A vs. FSC-A, SSC-W vs. SSC-H and FSC-W vs.
FSC-H staining, respectively.
With the exception of enzymatic digest at 37ºC, all steps for flow cytometry, FACS, and limiting
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dilution experiments were performed at 4ºC.
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CHAPTER 5
Summary and Future Directions
Summary
Breast cancer is the second leading cause of cancer-related mortality among women worldwide,
and breast cancer recurrence represents the final step in breast cancer progression for the
majority of breast cancer patients. In spite of the paramount importance of preventing breast
cancer recurrence, little is known about the biology of residual disease that gives rise to
recurrence. Due to the increasingly widespread use of targeted therapies in the clinic, the need
to define the phenotype of residual disease that gives rise to recurrence following targeted
therapy is increasingly urgent. Simultaneously, the advent of immuno-oncology therapies in the
clinic has had a major impact across multiple cancer types, however the relationship between the
immune system and residual disease following targeted therapy remains poorly understood. In
this thesis, we identify novel biological aspects of tumor cells that survive targeted therapy, and
identify possible roles for targeted macrophage ablation in preventing tumor recurrence. The
advances presented here represent a step towards a more complete understanding of residual
disease that survives oncogenic pathway inhibition, however significant work remains before
these findings can be said to be of importance to human breast cancer
Future directions for characterizing residual disease
While our finding of dormancy in residual disease argues that dormant residual disease may be
an attractive therapeutic target because it is a conserved response across multiple models of
oncogenic inhibition in GEMMs, several key questions remain. These can be divided into two
main areas: clinical validation and functional validation.
Clinical validation
Replicating our finding – that residual tumor cells surviving oncogenic pathway inhibition exhibit
cellular dormancy – in humans, is a critical step that if successful, would justify the investment of
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greater time and resources into the use of these models to study dormancy with the goals of
developing methods to identify and eliminate dormant residual disease in humans. Validation
would consist of both determining the proportion of residual disease in a typical patient that is
dormant, and evaluating these dormant tumor cells in order to determine whether dormant tumor
cells in humans have similar biological qualities to dormant residual disease in out mouse
models.
What tumor tissue would be used for clinical validation? Ideally, this should be performed on the
residual tumor cells that give rise to recurrence in patients, though as it is unclear how to
prospectively identify this population of tumor cells in a patient, it should then be accomplished in
a manner that systematically evaluates all residual disease in a given patient. Again, it is unclear
how to do this, as the only residual disease that can be identified in patients with no evidence of
disease is typically DTCs in bone marrow or CTCs in blood. While these tumor cell populations
are correlated with poor outcomes, it is unclear that they give rise to recurrent tumors in patients,
or that they generally represent all residual disease in a patient. Nonetheless, as they represent
an identifiable manifestation of MRD in patients, DTCs or CTCs are one of the best available
options for clinical validation of our findings. An alternative tissue source for residual disease to
validate findings is residual disease, local or metastatic, that shows complete and sustained
regression upon neoadjuvant or adjuvant systemic targeted therapy. Given that residual tumor
cells at local or metastatic sites show cellular dormancy in our models, it would be useful to
identify patients receiving combination targeted therapy to maximally inhibit an oncogenic
pathway, who also have surgically resectable residual disease following systemic therapy. Any
source of residual disease would need to be compared to control tumor tissue, preferably both
primary disease and any available metastases. Following identification of sources of tumor cells
for analysis, tumor cells should be isolated to ensure that stromal cells do not contaminate the
tumor cell samples.
Residual disease would subsequently need to be evaluated for whether it was dormant, and if it
was dormant, whether it shared qualities of dormant residual disease with the mouse models
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discussed here. Some approaches that were taken to conclusively demonstrate dormancy in
these mouse models would not be feasible in human disease, such as 2 week BrdU uptake.
However, gene expression profiling of dormant tumor cells in our models conclusively
demonstrated dormancy through broad down-regulation of families of genes associated with
mitosis and biosynthesis. Thus, an attractive approach would be to perform gene expression
profiling on residual tumor cells to both determine whether they were dormant and, if dormant,
provide a basis for comparison of dormancy in human to mouse models. Unfortunately this would
only work well if the population of tumor cells analyzed is predominantly dormant prior to
performing gene expression profiling, which would be difficult to evaluate due to the lack of
markers available to identify dormant tumor cells in humans.
Identification of reproducible protein markers for dormant tumor cells in these mouse models
could facilitate development of immunohistochemical or flow cytometric approaches to evaluate
dormancy of human tumor cells on a per-cell basis in a high-throughput manner, thus permitting
comparison between dormancy in human tumor cells and dormant in mouse tumor cells. Genes
that are repeatedly up-regulated in residual tumor cells across models would be suitable
candidates to evaluate for protein expression in residual tumor cells compared to other tumor
cells.
To begin making progress towards these ends, we have developed partnerships with clinical
collaborators to evaluate isolated residual tumor cells from breast cancer patients, and compare
these cells to primary or metastatic tumor cells from the same patients.
Functional validation
Functional validation is also crucial in order to identify keystone genes and pathways that regulate
both dormancy and survival of dormant tumor cells, and ultimately to provide conclusive evidence
for the functional relevance of dormancy. While we observe that the vast majority of residual
tumor cells are dormant, it remains possible that a small subpopulation of residual tumor cells
have biological properties distinct from the majority dormant population, and that it is this small
subpopulation that is responsible for recurrence, and not the dormant tumor cells. Thus, methods
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that specifically eliminate dormant tumor cells are necessary to definitively demonstrate that
dormant tumor cells contribute to recurrence.
Knockdown of genes recurrently up-regulated in dormant tumor cells, such as Dec2, and
subsequent evaluation of the impact of knockdown on recurrence latency, should provide a
reproducible approach to evaluating the role of particular genes in dormancy and recurrence.
Beyond Dec2, transcription factors or kinases that are associated with families of up-regulated
genes identified in residual tumor cells compared to proliferative tumor cells will also be key
targets to investigate through evaluation of the impact of knockdown of a gene of interest on
tumor recurrence latency.
High-throughput screening with an in vitro model of dormancy could help identify strategies to
eliminate dormant tumor cells. To facilitate in vitro work, we are currently evaluating the similarity
between an in vitro dormancy model developed in our lab, and in vivo dormancy in residual tumor
cells.
Following both clinical and functional validation, therapies targeting dormant tumor cells that also
have an impact on tumor recurrence in these preclinical mouse models could serve as candidates
to be used to target dormant tumor cells in the clinic.
Future directions for studying immune response associated with dormant residual disease
Our findings surrounding the role of inflammation and macrophages in dormant residual disease
similarly require clinical and functional validation. However, the first step to take is to determine
whether CD11c+F4/80+ macrophages promote tumor recurrence.
Role for CD11c+F4/80+ macrophages in recurrence
To evaluate whether these leukocytes are necessary for tumor recurrence, we plan to perform
bone marrow transplant from CD11c-DTR mice into nu/nu mice. The resulting nu/nu;CD11c-DTR
chimeras will be able to be ablated of all CD11c+ cells upon administration of diphtheria toxin,
thus permitting functional evaluation of the role of CD11c+F4/80+ macrophages in tumor
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dormancy and recurrence. This study should involve four arms: a control treatment arm, an antic-fms antibody alone arm, a diphtheria toxin (to ablate CD11c+F4/80+ macrophages) alone arm,
and a combined anti-c-fms plus diphtheria toxin arm, to ablate both non-inflammatory
macrophages and inflammatory macrophages in the residual lesion.
Beyond this study, it would be useful to identify pharmacological targets that could be used to
eliminate CD11c+F4/80+ macrophages from residual disease, which would also spare CD11c+
dendritic cells. Presumably the presence of dendritic cells near tumor cells has a positive impact
on tumor progression due to the role of dendritic cells as antigen presenting cells, and this
possibility is supported by the positive prognostic impact of increased CD11c expression levels in
primary breast cancers (Figure 4.2). A possible approach to specifically therapeutically target
inflammatory macrophages would be to inhibit cytokine receptors necessary to recruit these
leukocytes to residual lesions, or to eliminate cells using antibodies targeting as-yet-unidentified
specific markers for these immune cells.
Clinical validation
If we functionally demonstrate that CD11c+F4/80+ leukocytes potentiate tumor recurrence,
validating this finding in samples from breast cancer patients would be an important next step.
Due to the small spatial scale of residual disease, and the potential for leukocyte populations
surrounding, but not juxtaposed with, residual tumor cells (such as CD163+ macrophages in the
HER2/neu-Prim1 orthotopic residual lesion or CD3+ T-cells in the intact MTB/TAN/TTC/rYFP
residual lesion), it would be necessary to use tissue sections to determine the organization of
leukocyte populations relative to tumor cells. This may best be achieved by analysis of local
residual disease following neoadjuvant therapy, as it is not feasible to acquire tissue sections
containing CTCs or DTCs from living patients. Evaluation of this tissue for the presence of
CD11c+F4/80+ leukocytes would be an important first step, however it is possible that the
functional role that these inflammatory leukocytes play in murine residual disease is filled in by
alternate pro-inflammatory actors. Given the clinical evidence from the Nurses’ Health Study
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suggesting a role for inflammation in breast cancer recurrence, further evaluation of leukocyte
populations present in residual disease should remain a priority for breast cancer research.
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